BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH;  American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283. [PMID: 26566064 DOI: 10.1002/hep.28156] [Cited by in Crossref: 1159] [Cited by in F6Publishing: 1005] [Article Influence: 193.2] [Reference Citation Analysis]
Number Citing Articles
1 Cheung KW, Seto MTY, Wong D, Mak ASL, So PL, Lau WL, Wang W, Kan ASY, Lee CP, Ng EHY. Pattern and predictors of medical care received by hepatitis B carriers during pregnancy and after delivery. Public Health 2019;168:36-42. [PMID: 30685596 DOI: 10.1016/j.puhe.2018.12.008] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wei XL, Luo HY, Li CF, Jin Y, Zeng ZL, Ju HQ, Wu QN, Wang Y, Mao MJ, Liu WL, Jia WH, Zhang HZ, Li YH, Wang F, Xu RH. Hepatitis B virus infection is associated with younger median age at diagnosis and death in cancers. Int J Cancer 2017;141:152-9. [PMID: 28369849 DOI: 10.1002/ijc.30719] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
3 Liu F, Liu ZR, Li T, Liu Y, Zhang M, Xue Y, Zhang LX, Ye Q, Fan XP, Wang L. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status. J Dig Dis. 2018;19:561-571. [PMID: 30098114 DOI: 10.1111/1751-2980.12654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
4 Wong GL, Chan HL, Tse YK, Yip TC, Lam KL, Lui GC, Szeto CC, Wong VW. Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment. Aliment Pharmacol Ther. 2018;48:984-992. [PMID: 30125952 DOI: 10.1111/apt.14945] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 11.3] [Reference Citation Analysis]
5 Boglione L, Caccia C, Civra A, Cusato J, D'Avolio A, Biasi F, Lembo D, Di Perri G, Poli G, Leoni V. Trend of 25-hydroxycholesterol and 27-hydroxycholesterol plasma levels in patients affected by active chronic hepatitis B virus infection and inactive carriers. J Steroid Biochem Mol Biol 2021;210:105854. [PMID: 33631373 DOI: 10.1016/j.jsbmb.2021.105854] [Reference Citation Analysis]
6 Yu Y, Ai J, Zhang W. Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2017;11:925-37. [PMID: 28661190 DOI: 10.1080/17474124.2017.1343665] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Li X, Zhou L, Gu L, Gu Y, Chen L, Lian Y, Huang Y. Veritable antiviral capacity of natural killer cells in chronic HBV infection: an argument for an earlier anti-virus treatment. J Transl Med 2017;15:220. [PMID: 29089040 DOI: 10.1186/s12967-017-1318-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
8 Suárez E, Buti M, Rodríguez M, Prieto M, Pascasio-Acevedo JM, Casanovas T, Crespo J, Tapiador JAR, Gómez-Rodríguez R, Figueruela B, Diago M, Morillas RM, Zozaya JM, Calleja JL, Casado M, Molina E, Fuentes J, Simón MA. Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients. Eur J Gastroenterol Hepatol 2019;31:267-71. [PMID: 30576297 DOI: 10.1097/MEG.0000000000001289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Tillmann HL, Samuel G. Current state-of-the-art pharmacotherapy for the management of hepatitis B infection. Expert Opin Pharmacother 2019;20:873-85. [PMID: 30857443 DOI: 10.1080/14656566.2019.1583744] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
10 Freeland C, Racho R, Kamischke M, Moraras K, Wang E, Cohen C. Cure everyone and vaccinate the rest: The patient perspective on future hepatitis B treatment. J Viral Hepat 2021. [PMID: 34363715 DOI: 10.1111/jvh.13592] [Reference Citation Analysis]
11 Zhao P, Qian X, Su C, Yang X, Bai X. Lamivudine vs placebo or no treatment in preventing the transmission of hepatitis B virus during pregnancy: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg 2020;114:121-30. [PMID: 31703121 DOI: 10.1093/trstmh/trz078] [Reference Citation Analysis]
12 Debarry J, Cornberg M, Manns MP. Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection. Liver Int 2017;37 Suppl 1:67-72. [PMID: 28052625 DOI: 10.1111/liv.13320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Update on the management and treatment of viral hepatitis. World J Gastroenterol 2021;27:3249-61. [PMID: 34163109 DOI: 10.3748/wjg.v27.i23.3249] [Reference Citation Analysis]
14 Goyal A, Liao LE, Perelson AS. Within-host mathematical models of hepatitis B virus infection: Past, present, and future. Curr Opin Syst Biol 2019;18:27-35. [PMID: 31930181 DOI: 10.1016/j.coisb.2019.10.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
15 Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019;133:137-146. [PMID: 30341058 DOI: 10.1182/blood-2018-04-848044] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 15.7] [Reference Citation Analysis]
16 Lee M, Chung GE, Lee JH, Oh S, Nam JY, Chang Y, Cho H, Ahn H, Cho YY, Yoo JJ, Cho Y, Lee DH, Cho EJ, Yu SJ, Lee DH, Lee JM, Kim YJ, Yoon JH. Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. Hepatology 2017;66:1556-69. [PMID: 28617992 DOI: 10.1002/hep.29318] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
17 Hwang JP, Feld JJ, Hammond SP, Wang SH, Alston-Johnson DE, Cryer DR, Hershman DL, Loehrer AP, Sabichi AL, Symington BE, Terrault N, Wong ML, Somerfield MR, Artz AS. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.J Clin Oncol. 2020;38:3698-3715. [PMID: 32716741 DOI: 10.1200/JCO.20.01757] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 17.0] [Reference Citation Analysis]
18 Dey D, Banerjee M. Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis. J Clin Transl Hepatol 2016;4:248-57. [PMID: 27777893 DOI: 10.14218/JCTH.2016.00025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
19 Auzin AM, Slavenburg S, Peters C, Boland G, Rahamat-Langendoen J, Melchers WJG, Schuurman R. Rapid, random-access, and quantification of hepatitis B virus using the Cepheid Xpert HBV viral load assay. J Med Virol 2021;93:3999-4003. [PMID: 32761911 DOI: 10.1002/jmv.26392] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Mani SKK, Andrisani O. Interferon signaling during Hepatitis B Virus (HBV) infection and HBV-associated hepatocellular carcinoma. Cytokine 2019;124:154518. [PMID: 30126685 DOI: 10.1016/j.cyto.2018.08.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
21 Levrero M, Subic M, Villeret F, Zoulim F. Perspectives and limitations for nucleo(t)side analogs in future HBV therapies. Current Opinion in Virology 2018;30:80-9. [DOI: 10.1016/j.coviro.2018.04.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
22 Li T, Liu F, Zhang L, Ye Q, Fan X, Xue Y, Wang L. Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs. Saudi J Gastroenterol 2018;24:30-6. [PMID: 29451182 DOI: 10.4103/sjg.SJG_228_17] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Feng G, He N, Zhou YF, Li XP, Niu C, Liu ML, Zhang KL, Li Y, Li YM, Zheng MH, Mi M. A simpler diagnostic formula for screening nonalcoholic fatty liver disease. Clin Biochem 2019;64:18-23. [PMID: 30503530 DOI: 10.1016/j.clinbiochem.2018.11.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Sylvester-Armstrong KR, Duff P. Evidence for Use of Tenofovir in Pregnancy to Prevent Perinatal Transmission of Hepatitis B Infection. Clin Obstet Gynecol 2019;62:835-45. [PMID: 30921004 DOI: 10.1097/GRF.0000000000000438] [Reference Citation Analysis]
25 Lingala S, Lau DT, Koh C, Auh S, Ghany MG, Hoofnagle JH. Long-term lamivudine therapy in chronic hepatitis B. Aliment Pharmacol Ther 2016;44:380-9. [PMID: 27375283 DOI: 10.1111/apt.13707] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
26 Gu Y, Lian Y, Gu L, Chen L, Li X, Zhou L, Huang Y, Wang J, Huang Y. Correlations between cytokines produced by T cells and clinical-virological characteristics in untreated chronic hepatitis B patients. BMC Infect Dis 2019;19:216. [PMID: 30832595 DOI: 10.1186/s12879-019-3853-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
27 Matsumoto A, Nishiguchi S, Enomoto H, Tanaka Y, Shinkai N, Okuse C, Kang JH, Matsui T, Miyase S, Yatsuhashi H, Nagaoka S, Kanda T, Enomoto M, Yamada R, Hiramatsu N, Saito S, Takaguchi K, Ito K, Masaki T, Morihara D, Tsuge M, Chayama K, Ikeda F, Kagawa T, Kondo Y, Murata K, Tanaka E. Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B. J Gastroenterol 2020;55:977-89. [PMID: 32666202 DOI: 10.1007/s00535-020-01707-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Piaserico S, Messina F, Russo FP. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. Am J Clin Dermatol 2019;20:829-45. [PMID: 31222626 DOI: 10.1007/s40257-019-00457-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
29 Hadziyannis SJ. Letter: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther 2016;44:537-8. [PMID: 27484938 DOI: 10.1111/apt.13715] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Liu J, Li T, Zhang L, Xu A. The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review. Hepatology. 2019;70:1045-1055. [PMID: 30561829 DOI: 10.1002/hep.30474] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 50.0] [Reference Citation Analysis]
31 Li Q, Lu C, Li W, Huang Y, Chen L. Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B. Oncotarget. 2017;8:45768-45776. [PMID: 28514753 DOI: 10.18632/oncotarget.17470] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
32 Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. J Hepatol 2020;73:1037-45. [PMID: 32553667 DOI: 10.1016/j.jhep.2020.06.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
33 Cheung KW, Seto MTY, So PL, Wong D, Mak ASL, Lau WL, Wang W, Kan ASY, Lee CP, Ng EHY. Optimal timing of hepatitis B virus DNA quantification and clinical predictors for higher viral load during pregnancy. Acta Obstet Gynecol Scand 2019;98:1301-6. [PMID: 31021394 DOI: 10.1111/aogs.13631] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Querido S, Weigert A, Adragão T, Rodrigues L, Jorge C, Bruges M, Machado D. Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients. Transpl Infect Dis 2019;21:e13009. [PMID: 30295412 DOI: 10.1111/tid.13009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
35 Hsu CW, Su WW, Lee CM, Peng CY, Chuang WL, Kao JH, Chu HC, Huang YH, Chien RN, Liaw YF. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. J Formos Med Assoc. 2018;117:588-597. [PMID: 29456079 DOI: 10.1016/j.jfma.2017.12.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
36 Chen HJ, Huang N, Chen LS, Chou YJ, Li CP, Wu CY, Chang YC. Does Pay-For-Performance Program Increase Providers Adherence to Guidelines for Managing Hepatitis B and Hepatitis C Virus Infection in Taiwan? PLoS One 2016;11:e0161002. [PMID: 27517172 DOI: 10.1371/journal.pone.0161002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Jeng WJ, Chen YC, Sheen IS, Lin CL, Hu TH, Chien RN, Liaw YF. Clinical relapse after cessation of tenofovir therapy in HBeAg-negative patients. Clin Gastroenterol Hepatol. 2016; Jul 9. [Epub ahead of print]. [PMID: 27404969 DOI: 10.1016/j.cgh.2016.07.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
38 Shen S, Wong GL, Kuang Z, van Campenhout MJH, Fan R, Wong VW, Yip TC, Chi H, Liang X, Hu X, Lin W, Wu Y, Liu X, Boonstra A, Hou J, Sun J, Chan HL. Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B. J Med Virol 2020;92:1206-13. [PMID: 31724212 DOI: 10.1002/jmv.25628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Lee HW, Chan HL. Unresolved issues of immune tolerance in chronic hepatitis B. J Gastroenterol 2020;55:383-9. [PMID: 32016713 DOI: 10.1007/s00535-020-01665-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
40 Chon YE, Park JY, Myoung S, Jung KS, Kim BK, Kim SU, Kim DY, Ahn SH, Han K. Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis. American Journal of Gastroenterology 2017;112:882-91. [DOI: 10.1038/ajg.2017.93] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
41 Kong Z, Liang N, Yang GL, Zhang Z, Liu Y, Li J, Liu X, Liang S, Nikolova D, Jakobsen JC, Gluud C, Liu JP. Xiao Chai Hu Tang, a herbal medicine, for chronic hepatitis B. Cochrane Database Syst Rev 2019;2019. [PMID: 31697415 DOI: 10.1002/14651858.CD013090.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
42 Wang J, Xia J, Yan X, Yang Y, Wei J, Xiong Y, Wu W, Liu Y, Chen Y, Jia B, Chen Z, Zhang Z, Ding W, Huang R, Wu C. Plateletcrit as a potential index for predicting liver fibrosis in chronic hepatitis B. J Viral Hepat 2020;27:602-9. [PMID: 31981279 DOI: 10.1111/jvh.13264] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
43 Chen YC, Jeng WJ, Chien RN, Chu CM, Liaw YF. Clinical outcomes after spontaneous and nucleos(t)ide analogue-treated HBsAg seroclearance in chronic HBV infection. Aliment Pharmacol Ther 2016;43:1311-8. [PMID: 27072504 DOI: 10.1111/apt.13630] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
44 Wang D, Zhang P, Zhang M. Predictors for advanced liver fibrosis in chronic hepatitis B virus infection with persistently normal or mildly elevated alanine aminotransferase. Exp Ther Med 2017;14:5363-70. [PMID: 29285064 DOI: 10.3892/etm.2017.5219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
45 Kim MN, Lee JH, Chon YE, Ha Y, Hwang SG. Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy. European Journal of Gastroenterology & Hepatology 2020;32:433-9. [DOI: 10.1097/meg.0000000000001520] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
46 Gao X, Duan X, Cai H, Hu Y, Liu M, Kang K, Zhou M, Fu D, Yi W. The safety and efficacy of tenofovir disoproxil fumarate used throughout pregnancy for mothers with chronic hepatitis B. Eur J Gastroenterol Hepatol 2020;32:1533-7. [PMID: 31895914 DOI: 10.1097/MEG.0000000000001662] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Yi W, Cao X, Zeng Z, Cao W, Zhang Y, Sun F, Wang Y, Wan G, Li M, Xie Y. Developmental consequences of children born from mothers with telbivudine treatment during late pregnancy: A prospective study with 3-year follow-up. Virulence 2021;12:1527-37. [PMID: 34120564 DOI: 10.1080/21505594.2021.1936769] [Reference Citation Analysis]
48 Zhou T, Block T, Liu F, Kondratowicz AS, Sun L, Rawat S, Branson J, Guo F, Steuer HM, Liang H, Bailey L, Moore C, Wang X, Cuconatti A, Gao M, Lee ACH, Harasym T, Chiu T, Gotchev D, Dorsey B, Rijnbrand R, Sofia MJ. HBsAg mRNA degradation induced by a dihydroquinolizinone compound depends on the HBV posttranscriptional regulatory element. Antiviral Res. 2018;149:191-201. [PMID: 29133129 DOI: 10.1016/j.antiviral.2017.11.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
49 Han H, Yang J, Zhuge Y, Zhang M, Wu M. Point Shear Wave Elastography to Evaluate and Monitor Changing Portal Venous Pressure in Patients with Decompensated Cirrhosis. Ultrasound in Medicine & Biology 2017;43:1134-40. [DOI: 10.1016/j.ultrasmedbio.2017.01.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Méndez-Sánchez N, Yuen MF, Hwang JP. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book 2018;38:262-79. [PMID: 30231359 DOI: 10.1200/EDBK_200939] [Cited by in Crossref: 62] [Cited by in F6Publishing: 37] [Article Influence: 20.7] [Reference Citation Analysis]
51 Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2019;118:7-38. [PMID: 30527436 DOI: 10.1016/j.jfma.2018.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
52 Wang J, Wang Y, Zhang X, Liu J, Zhang Q, Zhao Y, Peng J, Feng Q, Dai J, Sun S. Gut Microbial Dysbiosis Is Associated with Altered Hepatic Functions and Serum Metabolites in Chronic Hepatitis B Patients. Front Microbiol. 2017;8:2222. [PMID: 29180991 DOI: 10.3389/fmicb.2017.02222] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 16.8] [Reference Citation Analysis]
53 Voulgaris T, Papatheodoridi M, Lampertico P, Papatheodoridis GV. Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. Liver Int 2020;40:484-95. [PMID: 31884726 DOI: 10.1111/liv.14334] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 19.0] [Reference Citation Analysis]
54 Tufon KA, Anong DN, Meriki HD, Georges TD, Maurice M, Kouanou YS, Bolimo AF, Tony NJ, Kwenti TE, Wung NH, Nkuo-Akenji T. Characterization and assessment of HBV chronically infected patients: Identification of those eligible for treatment in the South West region of Cameroon. PLoS One 2018;13:e0203312. [PMID: 30183765 DOI: 10.1371/journal.pone.0203312] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
55 Yang HC, Shih YF, Liu CJ. Viral Factors Affecting the Clinical Outcomes of Chronic Hepatitis B. J Infect Dis 2017;216:S757-64. [PMID: 29156050 DOI: 10.1093/infdis/jix461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
56 Dzobo K. The Role of Viruses in Carcinogenesis and Molecular Targeting: From Infection to Being a Component of the Tumor Microenvironment. OMICS 2021;25:358-71. [PMID: 34037476 DOI: 10.1089/omi.2021.0052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Harris AM, Isenhour C, Schillie S, Vellozzi C. Hepatitis B Virus Testing and Care among Pregnant Women Using Commercial Claims Data, United States, 2011-2014. Infect Dis Obstet Gynecol. 2018;2018:4107329. [PMID: 29805248 DOI: 10.1155/2018/4107329] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
58 Bloom K, Kaldine H, Cathomen T, Mussolino C, Ely A, Arbuthnot P. Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA. BMC Infect Dis. 2019;19:802. [PMID: 31510934 DOI: 10.1186/s12879-019-4436-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
59 Thongprayoon C, Kaewput W, Sharma K, Wijarnpreecha K, Leeaphorn N, Ungprasert P, Sakhuja A, Cabeza Rivera FH, Cheungpasitporn W. Outcomes of kidney transplantation in patients with hepatitis B virus infection: A systematic review and meta-analysis. World J Hepatol 2018;10:337-46. [PMID: 29527269 DOI: 10.4254/wjh.v10.i2.337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
60 Wong GL, Seto WK, Wong VW, Yuen MF, Chan HL. Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. Aliment Pharmacol Ther. 2018;47:730-737. [PMID: 29359487 DOI: 10.1111/apt.14497] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
61 Ababneh NA, Sallam M, Kaddomi D, Attili AM, Bsisu I, Khamees N, Khatib A, Mahafzah A. Patterns of hepatitis B virus S gene escape mutants and reverse transcriptase mutations among genotype D isolates in Jordan. PeerJ 2019;7:e6583. [PMID: 30867996 DOI: 10.7717/peerj.6583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
62 Jeng WJ, Lok AS. Should Treatment Indications for Chronic Hepatitis B Be Expanded? Clin Gastroenterol Hepatol. 2020;. [PMID: 32434068 DOI: 10.1016/j.cgh.2020.04.091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
63 Wirden M, Larrouy L, Mahjoub N, Todesco E, Damond F, Delagreverie H, Akhavan S, Charpentier C, Chaix M, Descamps D, Calvez V, Marcelin A. Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load. Journal of Clinical Virology 2017;96:49-53. [DOI: 10.1016/j.jcv.2017.09.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
64 Hamida ME, Raja SM, Seyoum Y, Elkhidir IM, Tekle F. Prevalence of chronic hepatitis B phases in Eritrean patients: a laboratory-based cross-sectional study. BMC Gastroenterol 2021;21:198. [PMID: 33933017 DOI: 10.1186/s12876-021-01789-3] [Reference Citation Analysis]
65 Aberra H, Desalegn H, Berhe N, Mekasha B, Medhin G, Gundersen SG, Johannessen A. The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia. Journal of Hepatology 2019;70:1065-71. [DOI: 10.1016/j.jhep.2019.01.037] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
66 Peiffer KH, Spengler C, Basic M, Jiang B, Kuhnhenn L, Obermann W, Zahn T, Glitscher M, Loglio A, Facchetti F, Carra G, Kubesch A, Vermehren J, Knop V, Graf C, Dietz J, Finkelmeier F, Herrmann E, Trebicka J, Grünweller A, Zeuzem S, Sarrazin C, Lampertico P, Hildt E. Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers. JCI Insight 2020;5:135833. [PMID: 33055418 DOI: 10.1172/jci.insight.135833] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Sonneveld MJ, Brouwer WP, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Liaw YF, Hansen BE, Choi H, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Knegt RJ, Janssen HLA. Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. Lancet Gastroenterol Hepatol 2019;4:538-44. [PMID: 30975477 DOI: 10.1016/S2468-1253(19)30087-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
68 Coppola N, Alessio L, Gualdieri L, Pisaturo M, Sagnelli C, Minichini C, Di Caprio G, Starace M, Onorato L, Signoriello G, Macera M, Angelillo IF, Pasquale G, Sagnelli E. Hepatitis B virus infection in undocumented immigrants and refugees in Southern Italy: demographic, virological, and clinical features. Infect Dis Poverty. 2017;6:33. [PMID: 28179020 DOI: 10.1186/s40249-016-0228-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 8.5] [Reference Citation Analysis]
69 Li X, Xie T, Gao L, Ma C, Yang X, Liang X. Prostaglandin E2 facilitates Hepatitis B virus replication by impairing CTL function. Molecular Immunology 2018;103:243-50. [DOI: 10.1016/j.molimm.2018.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
70 Al Mahtab M, Mf Akbar S, Begum M, Islam MA, Rahim MA, M Noor-E-Alam S, Alam MA, A Khondaker F, L Moben A, Mohsena M, Khan MSI, Huq MZ, Munshi S, Hoque A, Haque SA. Stem Cell Therapy for Cirrhosis of Liver in Bangladesh: Specific Design Compatible for Developing Country. Euroasian J Hepatogastroenterol 2018;8:121-5. [PMID: 30828553 DOI: 10.5005/jp-journals-10018-1277] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
71 Wongjarupong N, Yonli AT, Nagalo BM, Djigma FW, Somda SK, Hassan MA, Mohamed EA, Sorgho AP, Compaore TR, Soubeiga ST, Kiendrebeogo I, Sanou M, Diarra B, Yang HI, Chen CJ, Ouattara AK, Zohoncon TM, Martinson JJ, Buetow K, Chamcheu JC, Antwi SO, Borad MJ, Simpore J, Roberts LR. Characteristics of Patients With Chronic Hepatitis B Virus Infection With Genotype E Predominance in Burkina Faso. Hepatol Commun 2020;4:1781-92. [PMID: 33305149 DOI: 10.1002/hep4.1595] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Viganò M, Loglio A, Labanca S, Zaltron S, Castelli F, Andreone P, Messina V, Ganga R, Coppola N, Marrone A, Russello M, Marzano A, Tucci A, Taliani G, Fasano M, Fagiuoli S, Villa E, Bronte F, Santantonio T, Brancaccio G, Occhipinti V, Facchetti F, Grossi G, Rumi M, Lampertico P. Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. Liver Int 2019;39:484-93. [PMID: 30525275 DOI: 10.1111/liv.14017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
73 Jourdain G, Ngo-Giang-Huong N, Cressey TR, Hua L, Harrison L, Tierney C, Salvadori N, Decker L, Traisathit P, Sirirungsi W, Khamduang W, Bowonwatanuwong C, Puthanakit T, Siberry GK, Watts DH, Murphy TV, Achalapong J, Hongsiriwon S, Klinbuayaem V, Thongsawat S, Chung RT, Pol S, Chotivanich N. Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen. BMC Infect Dis 2016;16:393. [PMID: 27506549 DOI: 10.1186/s12879-016-1734-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
74 Grossi G, Viganò M, Loglio A, Lampertico P. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). Liver Int 2017;37:45-51. [DOI: 10.1111/liv.13291] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
75 Xing T, Xu H, Cao L, Ye M. HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis. PLoS One 2017;12:e0169444. [PMID: 28107377 DOI: 10.1371/journal.pone.0169444] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
76 Allard NL, MacLachlan JH, Dev A, Dwyer J, Srivatsa G, Spelman T, Thompson AJ, Cowie BC. Adherence in chronic hepatitis B: associations between medication possession ratio and adverse viral outcomes. BMC Gastroenterol 2020;20:140. [PMID: 32381025 DOI: 10.1186/s12876-020-01219-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
77 Lee IC, Chau GY, Yeh YC, Chao Y, Huo TI, Su CW, Lin HC, Hou MC, Huang YH. Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure. PLoS One 2017;12:e0188552. [PMID: 29176777 DOI: 10.1371/journal.pone.0188552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035. [PMID: 29877316 DOI: 10.1038/nrdp.2018.35] [Cited by in Crossref: 172] [Cited by in F6Publishing: 139] [Article Influence: 57.3] [Reference Citation Analysis]
79 Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, Acharya SK, Flaherty JF, Massetto B, Cathcart AL, Kim K, Gaggar A, Subramanian GM, McHutchison JG, Pan CQ, Brunetto M, Izumi N, Marcellin P; GS-US-320-0108 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196-206. [PMID: 28404092 DOI: 10.1016/s2468-1253(16)30107-8] [Cited by in Crossref: 218] [Cited by in F6Publishing: 67] [Article Influence: 43.6] [Reference Citation Analysis]
80 Fagan O, Amstrong P, Merwe KVD, Crosnoi D, Steele C, Sopena-falco J, Parihar V. Viral hepatitis: A brief introduction, review of management, advances and challenges. WJMA 2021;9:139-51. [DOI: 10.13105/wjma.v9.i2.139] [Reference Citation Analysis]
81 Kim JH, Kim YD, Lee M, Jun BG, Kim TS, Suk KT, Kang SH, Kim MY, Cheon GJ, Kim DJ, Baik SK, Choi DH. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. J Hepatol. 2018;69:1066-1073. [PMID: 30075230 DOI: 10.1016/j.jhep.2018.07.018] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 21.3] [Reference Citation Analysis]
82 Peiffer KH, Kuhnhenn L, Jiang B, Mondorf A, Vermehren J, Knop V, Susser S, Walter D, Dietz J, Carra G, Finkelmeier F, Zeuzem S, Sarrazin C, Hildt E. Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients. J Infect Dis 2018;218:114-23. [PMID: 29528436 DOI: 10.1093/infdis/jiy119] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
83 Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66:1444-1453. [PMID: 28622419 DOI: 10.1002/hep.29320] [Cited by in Crossref: 151] [Cited by in F6Publishing: 135] [Article Influence: 37.8] [Reference Citation Analysis]
84 Tada T, Kumada T, Toyoda H, Kobayashi N, Akita T, Tanaka J. Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers. J Gastroenterol Hepatol. 2018;33:918-925. [PMID: 28914957 DOI: 10.1111/jgh.13989] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
85 Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021;27:1497-506. [PMID: 33911470 DOI: 10.3748/wjg.v27.i14.1497] [Reference Citation Analysis]
86 Sripongpun P, Tangkijvanich P, Chotiyaputta W, Charatcharoenwitthaya P, Chaiteerakij R, Treeprasertsuk S, Bunchorntavakul C, Sobhonslidsuk A, Leerapun A, Khemnark S, Poovorawan K, Siramolpiwat S, Chirapongsathorn S, Pan-Ngum W, Soonthornworasiri N, Sukeepaisarnjaroen W; THASL study group. Evaluation of aspartate aminotransferase to platelet ratio index and fibrosis 4 scores for hepatic fibrosis assessment compared with transient elastography in chronic hepatitis C patients. JGH Open 2020;4:69-74. [PMID: 32055700 DOI: 10.1002/jgh3.12219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
87 Aberra H, Desalegn H, Berhe N, Medhin G, Stene-Johansen K, Gundersen SG, Johannessen A. Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa. BMC Infect Dis. 2017;17:438. [PMID: 28629395 DOI: 10.1186/s12879-017-2549-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
88 Cho YY, Lee JH, Chang Y, Nam JY, Cho H, Lee DH, Cho EJ, Lee DH, Yu SJ, Lee JM, Kim YJ, Yoon JH. Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients. J Viral Hepat 2018;25:1161-71. [PMID: 29741286 DOI: 10.1111/jvh.12927] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
89 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 32.0] [Reference Citation Analysis]
90 Ségéral O, N'Diaye DS, Prak S, Nouhin J, Chhun S, Khamduang W, Chim K, Roque-Afonso AM, Piola P, Borand L, Ngo-Giang-Huong N, Rouet F; ANRS 12328 12345 Study Group. Usefulness of a serial algorithm of HBsAg and HBeAg rapid diagnosis tests to detect pregnant women at risk of HBV mother-to-child transmission in Cambodia, the ANRS 12328 pilot study. J Clin Virol 2018;109:29-34. [PMID: 30388664 DOI: 10.1016/j.jcv.2018.10.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
91 Sun Z, Liu X, Jiang J, Huang H, Wang J, Wu D, Li L. Toward Biomarker Development in Large Clinical Cohorts: An Integrated High-Throughput 96-Well-Plate-Based Sample Preparation Workflow for Versatile Downstream Proteomic Analyses. Anal Chem 2016;88:8518-25. [PMID: 27471874 DOI: 10.1021/acs.analchem.6b01333] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
92 Wilson P, Parr JB, Jhaveri R, Meshnick SR. Call to Action: Prevention of Mother-to-Child Transmission of Hepatitis B in Africa. J Infect Dis 2018;217:1180-3. [PMID: 29351639 DOI: 10.1093/infdis/jiy028] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
93 Xie Y, Yi W, Zhang L, Lu Y, Hao HX, Gao YJ, Ran CP, Lu HH, Chen QQ, Shen G, Wu SL, Chang M, Ping-Hu L, Liu RY, Sun L, Wan G, Li MH. Evaluation of a logistic regression model for predicting liver necroinflammation in hepatitis B e antigen-negative chronic hepatitis B patients with normal and minimally increased alanine aminotransferase levels. J Viral Hepat 2019;26 Suppl 1:42-9. [PMID: 31380591 DOI: 10.1111/jvh.13163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
94 Ivanov AV, Valuev-Elliston VT, Tyurina DA, Ivanova ON, Kochetkov SN, Bartosch B, Isaguliants MG. Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis. Oncotarget. 2017;8:3895-3932. [PMID: 27965466 DOI: 10.18632/oncotarget.13904] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 22.3] [Reference Citation Analysis]
95 Lechner S, Yee M, Limketkai BN, Pham EA. Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction. Dig Dis Sci 2020;65:897-905. [PMID: 32020359 DOI: 10.1007/s10620-020-06100-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
96 Wang J, Yu Y, Li G, Shen C, Meng Z, Zheng J, Jia Y, Chen S, Zhang X, Zhu M, Song Z, Wu J, Shao L, Qian P, Mao X, Wang X, Huang Y, Zhao C, Zhang J, Qiu C, Zhang W. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. J Hepatol. 2017;. [PMID: 28870671 DOI: 10.1016/j.jhep.2017.08.021] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 9.8] [Reference Citation Analysis]
97 Tepper JL, Puopolo KM. Update on Prenatal Laboratory Screening: Joint Commission Required Elements. Neoreviews 2019;20:e584-91. [PMID: 31575780 DOI: 10.1542/neo.20-10-e584] [Reference Citation Analysis]
98 Toy M, Hutton D, McCulloch K, Romero N, Revill PA, Penicaud MC, So S, Cowie BC. The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia. Liver Int 2021. [PMID: 34328697 DOI: 10.1111/liv.15027] [Reference Citation Analysis]
99 Cao JM, Yang JQ, Ming ZQ, Wu JL, Yang LQ, Chen TW, Li R, Ou J, Zhang XM, Mu QW, Li HJ, Hu J. A radiomics model of liver CT to predict risk of hepatic encephalopathy secondary to hepatitis B related cirrhosis.Eur J Radiol. 2020;130:109201. [PMID: 32738462 DOI: 10.1016/j.ejrad.2020.109201] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 He L, Xia Z, Shen J, Zhang X, Peng W, Li C, Wen T. The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection. Medicine (Baltimore) 2019;98:e14386. [PMID: 30732177 DOI: 10.1097/MD.0000000000014386] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
101 Thilakanathan C, Wark G, Maley M, Davison S, Lawler J, Lee A, Shackel N, Nguyen V, Jackson K, Glass A, Locarnini SA, Levy MT. Mother-to-child transmission of hepatitis B: Examining viral cut-offs, maternal HBsAg serology and infant testing. Liver Int 2018;38:1212-9. [PMID: 29532580 DOI: 10.1111/liv.13736] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
102 Lee SW, Kwon JH, Lee HL, Yoo SH, Nam HC, Sung PS, Nam SW, Bae SH, Choi JY, Yoon SK, Han NI, Jang JW. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut 2020;69:1301-8. [PMID: 31672838 DOI: 10.1136/gutjnl-2019-318947] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
103 Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26:411-429. [PMID: 32854458 DOI: 10.3350/cmh.2020.0049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
104 Sobhonslidsuk A, Numthavaj P, Wanichanuwat J, Sophonsritsuk A, Petraksa S, Pugasub A, Jittorntam P, Kongsomgan A, Roytrakul S, Phakdeekitcharoen B. Reversal of Proximal Renal Tubular Dysfunction after Nucleotide Analogue Withdrawal in Chronic Hepatitis B. Biomed Res Int. 2017;2017:4327385. [PMID: 29214169 DOI: 10.1155/2017/4327385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
105 Wang J, Xia J, Yan X, Yang Y, Wei J, Xiong Y, Wu W, Liu Y, Chen Y, Jia B, Chen Z, Zhang Z, Ding W, Huang R, Wu C. The gamma-glutamyl transpeptidase to platelet ratio predicts liver inflammation in chronic hepatitis B with normal or mildly elevated alanine transaminase. Clin Res Hepatol Gastroenterol 2020;44:913-22. [PMID: 32147439 DOI: 10.1016/j.clinre.2020.01.011] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
106 Johansson ED, Nunez M. Acute Hepatitis B Surge: Opioid Epidemic Implication and Management Challenges. Open Forum Infect Dis 2020;7:ofaa190. [PMID: 32550238 DOI: 10.1093/ofid/ofaa190] [Reference Citation Analysis]
107 Lim N, Jackson S, Engler C, Lake JR. The Impact of Tenofovir Disoproxil Fumarate on Reduced Bone Mineral Density and Fractures in Liver Transplant Recipients. Transplant Proc 2021;53:215-20. [PMID: 33139039 DOI: 10.1016/j.transproceed.2020.09.009] [Reference Citation Analysis]
108 Zhang Y, Zhang WL, Pang XW, Wang LX, Wei X, Huang CX, Bai XF, Han S, Liu LN, Lian JQ. Effect of 48-week pegylated interferon α-2a or nucleos(t)ide analogue therapy on renal function in Chinese patients with chronic hepatitis B. Virol J 2017;14:49. [PMID: 28274240 DOI: 10.1186/s12985-017-0712-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
109 Tada T, Kumada T, Toyoda H, Ohisa M, Akita T, Tanaka J. Long-term natural history of liver disease in patients with chronic hepatitis B virus infection: an analysis using the Markov chain model. J Gastroenterol 2018;53:1196-205. [PMID: 29675604 DOI: 10.1007/s00535-018-1467-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
110 Brown SA, Axenfeld E, Stonesifer EG, Hutson W, Hanish S, Raufman J, Urrunaga NH. Current and prospective therapies for acute liver failure. Disease-a-Month 2018;64:493-522. [DOI: 10.1016/j.disamonth.2018.04.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
111 Liu Y, Luo Y, Zhu T, Jiang M, Tian Z, Tang G, Liang X. Regulatory B Cells Dysregulated T Cell Function in an IL-35-Dependent Way in Patients With Chronic Hepatitis B. Front Immunol 2021;12:653198. [PMID: 33912178 DOI: 10.3389/fimmu.2021.653198] [Reference Citation Analysis]
112 Pan X, Chen J, Zhou L, Ou X, He F, Liu Y, Zheng S, Wang H, Cao B, Wang Z, Liu H, Liu G, Huang Z, Shen G, Liu S, Chen D. Efficacy and safety of continuous antiviral therapy from preconception to prevent perinatal transmission of hepatitis B virus. Sci Rep 2020;10:13631. [PMID: 32788743 DOI: 10.1038/s41598-020-70644-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, Gutiérrez ML, Suárez E, Gómez Rubio M, López J, Castillo P, Rodríguez M, Zozaya JM, Simón MA, Morano LE, Calleja JL, Yébenes M, Esteban R. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS One 2017;12:e0184550. [PMID: 28898281 DOI: 10.1371/journal.pone.0184550] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
114 Guo YF, Pan JX, Zhuang WH. Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome. Infect Agent Cancer 2018;13:40. [PMID: 30559832 DOI: 10.1186/s13027-018-0215-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
115 Demirtaş CÖ, Özdoğan OC. Convenient chronic hepatitis B candidates for antiviral cessation and retreatment after relapse: When and who? Turk J Gastroenterol 2018;29:720-1. [PMID: 30381278 DOI: 10.5152/tjg.2018.290918] [Reference Citation Analysis]
116 Sinn DH, Lee JH, Kim K, Ahn JH, Kim JH, Lee DH, Yoon JH, Kang W, Gwak GY, Paik YH, Choi MS, Koh KC, Paik SW. A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels. Gut Liver. 2017;11:528-534. [PMID: 27980231 DOI: 10.5009/gnl16403] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
117 Liu WP, Xiao XB, Xue M, Wang GQ, Wang XP, Song YQ, Zhu J. Prophylactic Use of Entecavir for Lymphoma Patients With Past Hepatitis B Virus Infection: A Randomized Controlled Trial. Clinical Lymphoma Myeloma and Leukemia 2019;19:103-8. [DOI: 10.1016/j.clml.2018.11.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
118 Sohn W, Cho JY, Kim JH, Lee JI, Kim HJ, Woo MA, Jung SH, Paik YH. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B. Clin Mol Hepatol 2017;23:170-8. [PMID: 28506056 DOI: 10.3350/cmh.2016.0086] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
119 Cannizzaro MV, Franceschini C, Esposito M, Bianchi L, Giunta A. Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management. Psoriasis (Auckl) 2017;7:35-40. [PMID: 29387606 DOI: 10.2147/PTT.S108209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Song DS, Kim W, Ahn SH, Yim HJ, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Jung YK, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Lee KS, Lim YS, Lee WS, Yang JM, Kim KH, Han KH, Um SH. Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial. Clin Mol Hepatol 2021;27:346-59. [PMID: 33493393 DOI: 10.3350/cmh.2020.0307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
121 Coller KE, Butler EK, Luk KC, Rodgers MA, Cassidy M, Gersch J, McNamara AL, Kuhns MC, Dawson GJ, Kaptue L, Bremer B, Wedemeyer H, Cloherty GA. Development and performance of prototype serologic and molecular tests for hepatitis delta infection. Sci Rep 2018;8:2095. [PMID: 29391553 DOI: 10.1038/s41598-018-20455-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
122 Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, Hui AJ, Janssen HL, Chowdhury A, Tsang TY, Mehta R, Gane E, Flaherty JF, Massetto B, Gaggar A, Kitrinos KM, Lin L, Subramanian GM, McHutchison JG, Lim YS, Acharya SK, Agarwal K;  GS-US-320-0110 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185-195. [PMID: 28404091 DOI: 10.1016/s2468-1253(16)30024-3] [Cited by in Crossref: 196] [Cited by in F6Publishing: 59] [Article Influence: 39.2] [Reference Citation Analysis]
123 Jeon MY, Kim BK, Lee JS, Lee HW, Park JY, Kim DY, Ahn SH, Han KH, Kim SU. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. Clin Mol Hepatol 2021;27:295-304. [PMID: 33317247 DOI: 10.3350/cmh.2020.0216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
124 Chen Z, Gu G, Bian Z, Cai W, Shen Y, Hao Y, Zhang S, Shao J, Qin G. Clinical course and perinatal transmission of chronic hepatitis B during pregnancy: A real-world prospective cohort study. Journal of Infection 2017;75:146-54. [DOI: 10.1016/j.jinf.2017.05.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
125 Verna EC. Updated Hepatitis B Guidance: Implications for liver transplant patients. Liver Transpl 2018;24:465-9. [PMID: 29466838 DOI: 10.1002/lt.25037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
126 Ren P, Li H, Huang Y, Jiang J, Guo S, Cao Z, Zhang C, Zhou T, Gan Q, Zhao S, Chen L, Guo Q, Cai W, Wang H, Hu P, Xie Q. A simple-to-use tool for predicting response to peginterferon in HBV DNA suppressed chronic hepatitis B patients in China. Antiviral Res 2021;194:105163. [PMID: 34389410 DOI: 10.1016/j.antiviral.2021.105163] [Reference Citation Analysis]
127 Yeh ML, Huang CF, Huang CI, Dai CY, Lin IH, Liang PC, Hsieh MH, Lin ZY, Chen SC, Huang JF, Chen JJ, Yu ML, Chuang WL. Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. PLoS One 2019;14:e0220663. [PMID: 31393964 DOI: 10.1371/journal.pone.0220663] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
128 Huang D, Sansas B, Jiang JH, Gong QM, Jin GD, Calais V, Yu DM, Zhu MY, Wei D, Zhang DH, Inchauspé G, Zhang XX, Zhu R. Recognition of Core- and Polymerase-derived immunogenic peptides included in novel therapeutic vaccine by T cells from Chinese chronic hepatitis B patients. J Viral Hepat 2017;24 Suppl 1:66-74. [PMID: 29082648 DOI: 10.1111/jvh.12791] [Reference Citation Analysis]
129 Sawinski D, Blumberg EA. Infection in Renal Transplant Recipients. Chronic Kidney Disease, Dialysis, and Transplantation. Elsevier; 2019. pp. 621-638.e6. [DOI: 10.1016/b978-0-323-52978-5.00040-9] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
130 Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov 2018;17:35-56. [PMID: 28935918 DOI: 10.1038/nrd.2017.162] [Cited by in Crossref: 239] [Cited by in F6Publishing: 183] [Article Influence: 59.8] [Reference Citation Analysis]
131 Chan HLY, Messinger D, Papatheodoridis GV, Cornberg M, Xie Q, Piratvisuth T, Ren H, Kennedy PT, Thompson A, Caputo A, Bakalos G, Pavlovic V, Lampertico P. A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B. Aliment Pharmacol Ther. 2018;48:547-555. [PMID: 29956827 DOI: 10.1111/apt.14862] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
132 Li J, Chang MS, Tran TT, Nguyen MH. Management of Chronic Hepatitis B in Pregnancy. J Clin Gastroenterol 2017;51:789-95. [PMID: 28816860 DOI: 10.1097/MCG.0000000000000908] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
133 Alkhouri N, Reddy GK, Lawitz E. Oligonucleotide-Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases. Hepatology 2021;73:1581-93. [PMID: 32978989 DOI: 10.1002/hep.31569] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
134 Osiowy C, Coffin C, Andonov A. Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy. Curr Treat Options Infect Dis 2016;8:177-93. [PMID: 27547127 DOI: 10.1007/s40506-016-0080-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
135 Cobb BR, Valsamakis A. Chronic Hepatitis B, C, and D. Microbiol Spectr 2016;4. [PMID: 27726758 DOI: 10.1128/microbiolspec.DMIH2-0025-2015] [Reference Citation Analysis]
136 Graf C, Mondorf A, Knop V, Peiffer KH, Dietz J, Friess J, Wedemeyer H, Buggisch P, Mauss S, Berg T, Rausch M, Sprinzl M, Klinker H, Hinrichsen H, Bronowicki JP, Haag S, Hüppe D, Lutz T, Poynard T, Zeuzem S, Friedrich-Rust M, Sarrazin C, Vermehren J. Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection. J Clin Med 2019;8:E2101. [PMID: 31810183 DOI: 10.3390/jcm8122101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
137 Mixson-Hayden T, Purdy MA, Ganova-Raeva L, McGovern D, Forbi JC, Kamili S. Evaluation of performance characteristics of hepatitis B e antigen serologic assays. J Clin Virol 2018;109:22-8. [PMID: 30388663 DOI: 10.1016/j.jcv.2018.10.005] [Reference Citation Analysis]
138 Pan CQ, Dai E, Duan Z, Han G, Zhao W, Wang Y, Zhang H, Zhu B, Jiang H, Zhang S, Zhang X, Zou H, Chen X, Chen Y. Long-term safety of infants from mothers with chronic hepatitis B treated with tenofovir disoproxil in China. Gut 2021:gutjnl-2020-322719. [PMID: 33789963 DOI: 10.1136/gutjnl-2020-322719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Jeong S, Cho Y, Park SM, Kim W. Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2021;55:e77-86. [PMID: 33883516 DOI: 10.1097/MCG.0000000000001548] [Reference Citation Analysis]
140 Yu HC, Lin KH, Tsay FW, Tsai TJ, Wu PC, Chen YH, Chen YH. Kinetics of hepatitis B surface antigen and estimated glomerular filtration rate in telbivudine-treated hepatitis B patients with different rescue strategies. PLoS One 2020;15:e0237586. [PMID: 32785260 DOI: 10.1371/journal.pone.0237586] [Reference Citation Analysis]
141 Han LF, Zheng JM, Zheng LQ, Gao HB, Chen LX, Xu QL, Chai YH, Zhang X, Pan C, Yao LF. Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation. BMC Infect Dis 2019;19:614. [PMID: 31299917 DOI: 10.1186/s12879-019-4250-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
142 Li S, Li H, Xiong Y, Liu F, Peng M, Zhang D, Ren H, Hu P. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study. J Viral Hepat 2017;24:12-20. [DOI: 10.1111/jvh.12755] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
143 Cheng R, Xu J, Tan N, Luo H, Pan J, Xu X. Predictive Nomograms for Clinical Outcomes in Hepatitis B-Related Cirrhosis Patients Receiving Antiviral Therapy. Infect Drug Resist 2021;14:2707-19. [PMID: 34290509 DOI: 10.2147/IDR.S316026] [Reference Citation Analysis]
144 Tian Y, James Ou JH. Hepatitis B Virus-Specific T Cells as a Biomarker for Discontinuation of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Hepatology 2019;69:1342-4. [PMID: 30168616 DOI: 10.1002/hep.30243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Paccoud O, Surgers L, Lacombe K. [Hepatitis B virus infection: Natural history, clinical manifestations and therapeutic approach]. Rev Med Interne 2019;40:590-8. [PMID: 30982550 DOI: 10.1016/j.revmed.2019.03.333] [Reference Citation Analysis]
146 Cornberg M, Lok AS, Terrault NA, Zoulim F;  2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Hepatology. 2019;. [PMID: 31713892 DOI: 10.1002/hep.31030] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
147 Zhang X, An X, Shi L, Yang X, Chen Y, Liu X, Li J, Ye F, Lin S. Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years. Sci Rep 2021;11:13389. [PMID: 34183689 DOI: 10.1038/s41598-021-92757-0] [Reference Citation Analysis]
148 Indolfi G, Abdel-Hady M, Bansal S, Debray D, Smets F, Czubkowski P, van der Woerd W, Samyn M, Jahnel J, Gupte G, Zellos A, Mozer-Glassberg Y, Verkade HJ, Sokal E, Fischler B. Management of Hepatitis B Virus Infection and Prevention of Hepatitis B Virus Reactivation in Children With Acquired Immunodeficiencies or Undergoing Immune Suppressive, Cytotoxic, or Biological Modifier Therapies. J Pediatr Gastroenterol Nutr. 2020;70:527-538. [PMID: 31977956 DOI: 10.1097/mpg.0000000000002628] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
149 Geng J, Bao H, Chen Y, Shi L, Geng J, Wang Q, Yu H. Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis. Expert Rev Anti Infect Ther 2020;18:823-34. [PMID: 32329638 DOI: 10.1080/14787210.2020.1760843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
150 Bannister EG, Yuen L, Littlejohn M, Edwards R, Sozzi V, Colledge D, Li X, Locarnini S, Hardikar W, Revill PA. Molecular characterization of hepatitis B virus (HBV) in African children living in Australia identifies genotypes and variants associated with poor clinical outcome. J Gen Virol 2018;99:1103-14. [PMID: 29932395 DOI: 10.1099/jgv.0.001086] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
151 Hung CH, Kee KM, Chen CH, Tseng PL, Tsai MC, Chen CH, Wang JH, Chang KC, Kuo YH, Yen YH, Hu TH, Lu SN. A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute Exacerbation. Clin Transl Gastroenterol 2017;8:e104. [PMID: 28662023 DOI: 10.1038/ctg.2017.29] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
152 El-Raziky ME, Fouad HM, Abd Elkhalak NS, Ghobrial CM, El-Karaksy HM. Paediatric chronic hepatitis B virus infection: are children too tolerant to treat? Acta Paediatr. 2019;108:1144-1150. [PMID: 30362178 DOI: 10.1111/apa.14626] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
153 Toy M, Wei B, Virdi TS, Le A, Trinh H, Li J, Zhang J, Hsing AW, So SK, Nguyen MH. Racial/ethnic- and county-specific prevalence of chronic hepatitis B and its burden in California. Hepatol Med Policy 2018;3:6. [PMID: 30288329 DOI: 10.1186/s41124-018-0034-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
154 Liang RY, Xu JH, Si CW, Wang S, Shang J, Yu ZJ, Mao Q, Xie Q, Zhao W, Li J, Gao ZL, Wu SM, Tang H, Cheng J, Chen XY, Zhang WH, Wang H, Xu ZN, Wang L, Dai J, Yu YY. A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) vs Viread for the treatment of chronic hepatitis B: First-stage results at week 48. Medicine (Baltimore). 2019;98:e16778. [PMID: 31415381 DOI: 10.1097/md.0000000000016778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
155 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex 2021:S0375-0906(21)00061-6. [PMID: 34384668 DOI: 10.1016/j.rgmx.2021.04.002] [Reference Citation Analysis]
156 Braun P, Delgado R, Drago M, Fanti D, Fleury H, Izopet J, Lombardi A, Mancon A, Marcos MA, Sauné K, O Shea S, Pérez-Rivilla A, Ramble J, Trimoulet P, Vila J, Whittaker D, Artus A, Rhodes D. A European multicenter study on the analytical performance of the VERIS HBV assay. J Clin Virol 2018;99-100:50-6. [PMID: 29328964 DOI: 10.1016/j.jcv.2017.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
157 Ozaras R, Uraz S, Demirel A, Mete B, Tabak F. Does resolved HBV or anti-HBc-only carry the same risk of HBV reactivation? J Oncol Pharm Pract 2018;24:477-9. [PMID: 29925293 DOI: 10.1177/1078155218782593] [Reference Citation Analysis]
158 Wang Y, Xiang X, Chen L, Cao Z, Bao R, Zhou H, Tang W, Lu J, Lin L, Xie Q, Bao S, Wang H. Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy. Oncotarget 2016;7:58553-62. [PMID: 27329718 DOI: 10.18632/oncotarget.10155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
159 Wang L, Wang B, You H, Wu X, Zhou J, Ou X, Jia J. Platelets' increase is associated with improvement of liver fibrosis in entecavir-treated chronic hepatitis B patients with significant liver fibrosis. Hepatol Int 2018;12:237-43. [PMID: 29700765 DOI: 10.1007/s12072-018-9864-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
160 Tang LSY, Covert E, Wilson E, Kottilil S. Chronic Hepatitis B Infection: A Review. JAMA 2018;319:1802. [DOI: 10.1001/jama.2018.3795] [Cited by in Crossref: 194] [Cited by in F6Publishing: 169] [Article Influence: 64.7] [Reference Citation Analysis]
161 Stournaras E, Neokosmidis G, Stogiannou D, Protopapas A, Tziomalos K. Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis. Eur J Gastroenterol Hepatol 2018;30:1277-82. [PMID: 30179906 DOI: 10.1097/MEG.0000000000001254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Reference Citation Analysis]
163 Li N, Ma WT, Pang M, Fan QL, Hua JL. The Commensal Microbiota and Viral Infection: A Comprehensive Review. Front Immunol. 2019;10:1551. [PMID: 31333675 DOI: 10.3389/fimmu.2019.01551] [Cited by in Crossref: 80] [Cited by in F6Publishing: 60] [Article Influence: 40.0] [Reference Citation Analysis]
164 Cuenca-Gómez JÁ, Lozano-Serrano AB, Cabezas-Fernández MT, Soriano-Pérez MJ, Vázquez-Villegas J, Estévez-Escobar M, Cabeza-Barrera I, Salas-Coronas J. Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice. BMC Infect Dis 2018;18:568. [PMID: 30428845 DOI: 10.1186/s12879-018-3469-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
165 Su T, Yang H, Tseng T, Liou J, Liu C, Chen C, Chen P, Chen D, Liu C, Kao J. Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. The Journal of Infectious Diseases 2018;217:1193-201. [DOI: 10.1093/infdis/jix690] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 11.3] [Reference Citation Analysis]
166 Lee J, Cho S, Kim HJ, Lee H, Ko MJ, Lim YS. High level of medication adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir: A nationwide cohort study. J Viral Hepat 2021;28:353-63. [PMID: 33051945 DOI: 10.1111/jvh.13418] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
167 Wang J, Xia J, Zhang R, Yan X, Yang Y, Zhao X, Chang H, Wang G, Chen G, Liu Y, Chen Y, Jia B, Zhang Z, Ding W, Huang R, Wu C. A novel index using routine clinical parameters for predicting significant liver inflammation in chronic hepatitis B. J Viral Hepat 2018;25:1151-60. [PMID: 29741221 DOI: 10.1111/jvh.12925] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
168 Komatsu H, Inui A, Yoshio S, Fujisawa T. Pharmacotherapy options for managing hepatitis B in children. Expert Opin Pharmacother 2021;22:449-67. [PMID: 33090882 DOI: 10.1080/14656566.2020.1841165] [Reference Citation Analysis]
169 Koukoulioti E, Brodzinski A, Mihm U, Sarrazin C, Jung M, Schott E, Fülöp B, Schlosser B, Berg T, van Bömmel F. Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections. European Journal of Gastroenterology & Hepatology 2019;31:845-52. [DOI: 10.1097/meg.0000000000001351] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 Wu IC, Liu WC, Chang TT. Applications of next-generation sequencing analysis for the detection of hepatocellular carcinoma-associated hepatitis B virus mutations. J Biomed Sci 2018;25:51. [PMID: 29859540 DOI: 10.1186/s12929-018-0442-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
171 Jinato T, Chuaypen N, Poomipak W, Praianantathavorn K, Makkoch J, Kiatbumrung R, Jampoka K, Tangkijvanich P, Payungporn S. Original Research: Analysis of hepatic microRNA alterations in response to hepatitis B virus infection and pegylated interferon alpha-2a treatment. Exp Biol Med (Maywood) 2016;241:1803-10. [PMID: 27190255 DOI: 10.1177/1535370216647184] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
172 Wong D, Littlejohn M, Yuen L, Jackson K, Mason H, Bayliss J, Rosenberg G, Gaggar A, Kitrinos K, Subramanian M, Marcellin P, Buti M, Janssen HLA, Gane E, Locarnini S, Thompson A, Revill PA. HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients. Aliment Pharmacol Ther 2018;47:114-22. [PMID: 29023803 DOI: 10.1111/apt.14362] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
173 Arends JE, Lieveld FI, Ahmad S, Ustianowski A. New Viral and Immunological Targets for Hepatitis B Treatment and Cure: A Review. Infect Dis Ther 2017;6:461-76. [PMID: 29071665 DOI: 10.1007/s40121-017-0173-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
174 Chak EW, Sarkar S, Bowlus C. Improving Healthcare Systems to Reduce Healthcare Disparities in Viral Hepatitis. Dig Dis Sci 2016;61:2776-83. [PMID: 27234269 DOI: 10.1007/s10620-016-4205-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
175 Lee KS, Kweon YO, Um SH, Kim BH, Lim YS, Paik SW, Heo J, Lee HJ, Kim DJ, Kim TH, Lee YS, Byun KS, Kim D, Lee MS, Yu K, Suh DJ. Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. Clin Mol Hepatol 2017;23:331-9. [PMID: 28946736 DOI: 10.3350/cmh.2016.0040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
176 Wong GL. Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. Clin Mol Hepatol. 2018;24:108-113. [PMID: 29353469 DOI: 10.3350/cmh.2017.0068] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
177 Bzowej NH, Tran TT, Li R, Belle SH, Smith CI, Khalili M, Chung R, Tsai N, Terrault N; Hepatitis B Research Network (HBRN). Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study. Am J Gastroenterol 2019;114:1283-91. [PMID: 31082876 DOI: 10.14309/ajg.0000000000000221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
178 Wong RJ, Le A, Nguyen MT, Trinh HN, Huynh A, Ly MT, Nguyen HA, Nguyen KK, Yang J, Garcia RT, Levitt B, da Silveira E, Gish RG. Significant Hepatic Fibrosis Among Treatment-Naive Chronic Hepatitis B Virus With Increased Hepatitis B Virus DNA and Normal Alanine Aminotransferase. Clin Gastroenterol Hepatol 2018;16:146-8. [PMID: 28733260 DOI: 10.1016/j.cgh.2017.07.012] [Reference Citation Analysis]
179 Goyal A, Romero-Severson EO. Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil. PLoS One 2018;13:e0203831. [PMID: 30192887 DOI: 10.1371/journal.pone.0203831] [Reference Citation Analysis]
180 Fujii T, Kawasoe K, Ohta A, Nitta K. A case of entecavir-induced Fanconi syndrome. CEN Case Rep 2019;8:256-60. [PMID: 31154657 DOI: 10.1007/s13730-019-00404-5] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
181 Sato K, Kobayashi T, Yamazaki Y, Takakusagi S, Horiguchi N, Kakizaki S, Kusano M, Yamada M. Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C: HBV reactivation during DAA-based therapy. Hepatol Res 2017;47:1346-53. [DOI: 10.1111/hepr.12905] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
182 Gu S, Fu X, Ye G, Chen C, Li X, Zhong S, Tang L, Chen H, Jiang D, Hou J, Li Y. High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection. Front Immunol 2021;12:649197. [PMID: 34234772 DOI: 10.3389/fimmu.2021.649197] [Reference Citation Analysis]
183 Wang J, Shen T, Wang Q, Zhang T, Li L, Wang Y, Fang Y. The long-term efficacy of cytokine-induced killer cellular therapy for hepatocellular carcinoma: a meta-analysis. Immunotherapy 2019;11:1325-35. [PMID: 31578914 DOI: 10.2217/imt-2019-0079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
184 Tseng TC, Liu CJ, Su TH, Yang WT, Chen CL, Yang HC, Wang CC, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. Am J Gastroenterol. 2017;112:1564-1574. [PMID: 28853728 DOI: 10.1038/ajg.2017.254] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
185 Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yang Z. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver. 2019;. [PMID: 31158948 DOI: 10.5009/gnl18546.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
186 Woldemedihn GM, Rueegg CS, Desalegn H, Aberra H, Berhe N, Johannessen A. Validity of a point-of-care viral load test for hepatitis B in a low-income setting. J Virol Methods 2021;289:114057. [PMID: 33359613 DOI: 10.1016/j.jviromet.2020.114057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
187 Soriano V, Aguilera A, Gonzalez R, Gomez-Gallego F, Barea L, Treviño M, Corral O. Occult hepatitis B and HIV infection. Eur J Gastroenterol Hepatol 2019;31:1403-7. [PMID: 30969194 DOI: 10.1097/MEG.0000000000001417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
188 Kaewdech A, Tangkijvanich P, Sripongpun P, Witeerungrot T, Jandee S, Tanaka Y, Piratvisuth T. Hepatitis B surface antigen, core‐related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation. Liver Int 2020;40:2961-71. [DOI: 10.1111/liv.14606] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
189 Lakoh S, García-Tardón N, Adekanmbi O, van der Valk M, Smith SJ, Grobusch MP. Prevalence of viral hepatitis B and C in Sierra Leone-current knowledge and knowledge gaps: a narrative review. Trans R Soc Trop Med Hyg 2021:trab054. [PMID: 33772308 DOI: 10.1093/trstmh/trab054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
190 Dave S, Park S, Murad MH, Barnard A, Prokop L, Adams LA, Singh S, Loomba R. Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Hepatology 2021;73:68-78. [PMID: 32277491 DOI: 10.1002/hep.31267] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
191 Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yan Z. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver 2020;14:232-47. [PMID: 31158948 DOI: 10.5009/gnl18546] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
192 Zhao J, Fan YC, Chen LY, Gao S, Li F, Wang K. Alteration of methyl-CpG binding domain family in patients with chronic hepatitis B. Clin Res Hepatol Gastroenterol 2017;41:272-83. [PMID: 28065745 DOI: 10.1016/j.clinre.2016.11.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
193 Xu K, Liu LM, Farazi PA, Wang H, Rochling FA, Watanabe-Galloway S, Zhang JJ. Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B. Glob Health Action 2018;11:1433987. [PMID: 29447614 DOI: 10.1080/16549716.2018.1433987] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
194 Chuang WL, Jia J, Chan HLY, Han KH, Tanwandee T, Tan D, Chen X, Gane E, Piratvisuth T, Chen L, Xie Q, Sung JJ, Messinger D, Wat C, Bakalos G, Liaw YF. Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients. Aliment Pharmacol Ther 2018;47:1306-16. [PMID: 29520872 DOI: 10.1111/apt.14595] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
195 Liang J, Liang X, Ma H, Nie L, Tian Y, Chen G, Wang Y. Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR. J Clin Transl Hepatol 2021;9:143-8. [PMID: 34007795 DOI: 10.14218/JCTH.2020.00118] [Reference Citation Analysis]
196 Li J, Gordon SC, Rupp LB, Zhang T, Trudeau S, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Daida YG, Schmidt MA, Lu M; CHeCS Investigators. Long-term progression of viral load and serum markers of fibrosis among treated and untreated patients with chronic hepatitis B. J Gastroenterol Hepatol 2017;32:1250-7. [PMID: 27888529 DOI: 10.1111/jgh.13667] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
197 Vinikoor MJ, Sinkala E, Kanunga A, Muchimba M, Nsokolo B, Chilengi R, Wandeler G, Mulenga J, Chisenga T, Bhattacharya D, Saag MS, Foster G, Fried MW, Kelly P. Chronic hepatitis B virus monoinfection at a university hospital in Zambia. World J Hepatol 2018;10:622-8. [PMID: 30310540 DOI: 10.4254/wjh.v10.i9.622] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
198 Hsu LI, Wang YH, Hsieh FI, Yang TY, Wen-Juei Jeng R, Liu CT, Chen CL, Hsu KH, Chiou HY, Wu MM, Chen CJ. Effects of Arsenic in Drinking Water on Risk of Hepatitis or Cirrhosis in Persons With and Without Chronic Viral Hepatitis. Clin Gastroenterol Hepatol 2016;14:1347-1355.e4. [PMID: 27060428 DOI: 10.1016/j.cgh.2016.03.043] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
199 Chang KM, Liu M. Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics. Curr Opin Pharmacol 2016;30:93-105. [PMID: 27570126 DOI: 10.1016/j.coph.2016.07.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
200 Ayoub WS, Cohen E. Hepatitis B Management in the Pregnant Patient: An Update. J Clin Transl Hepatol 2016;4:241-7. [PMID: 27777892 DOI: 10.14218/JCTH.2016.00014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
201 Liu Y, Xue J, Liao W, Yan H, Liang X. Serum HBV RNA Dynamic and Drug Withdrawal Predictor Value in Patients With Chronic HBV Infection on Long-term Nucleos(t)ide Analogue (NA) Therapy. J Clin Gastroenterol 2020;54:e73-82. [PMID: 32604147 DOI: 10.1097/MCG.0000000000001376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
202 Fan Y, Zhou S, Li C, Ma B, Fan L, Jing H. The use of tenofovir and telbivudine combination therapy for immune-tolerant chronic hepatitis B patients awaiting assisted reproduction. Eur J Gastroenterol Hepatol 2019;31:1167-8. [PMID: 31385874 DOI: 10.1097/MEG.0000000000001444] [Reference Citation Analysis]
203 Hao Z, Biqing Z, Ling Y, Wenting Z. The Effectiveness of Antiviral Treatments for Patients with HBeAg-Positive Chronic Hepatitis B: A Bayesian Network Analysis. Can J Gastroenterol Hepatol 2018;2018:3576265. [PMID: 30276197 DOI: 10.1155/2018/3576265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
204 Fan H, Lin L, Jia S, Xie M, Luo C, Tan X, Ying R, Guan Y, Li F. Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B. J Viral Hepat 2019;26:77-84. [DOI: 10.1111/jvh.13165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
205 Aslam A, Susheela A, Iriana S, Chan SS, Lau D. Acute hepatitis E superinfection leading to chronic hepatitis B reactivation. BMJ Case Rep 2018;2018:bcr-2017-223616. [PMID: 29891510 DOI: 10.1136/bcr-2017-223616] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
206 Ho CH, Chen SH, Tsai HW, Wu IC, Chang TT. Fully galactosyl-fucosyl-bisected IgG1 reduces anti-HBV efficacy and liver histological improvement. Antiviral Res 2019;163:1-10. [PMID: 30611775 DOI: 10.1016/j.antiviral.2018.12.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
207 Huang DQ, Yeo YH, Tan E, Takahashi H, Yasuda S, Saruwatari J, Tanaka K, Oniki K, Kam LY, Muthiah MD, Hyogo H, Ono M, Barnett SD, Li J, Zou B, Fung J, Lee TY, Wong VW, Yuen MF, Dan YY, Lim SG, Cheung R, Toyoda H, Eguchi Y, Nguyen MH. ALT Levels for Asians With Metabolic Diseases: A Meta-analysis of 86 Studies With Individual Patient Data Validation. Hepatol Commun 2020;4:1624-36. [PMID: 33163833 DOI: 10.1002/hep4.1593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
208 Barut S, Gemici Ü, Güneş F, Demir O, Duygu F. Predictors of histological indication for treatment in HBeAg negative chronic HBV infection. J Med Virol 2017;89:1952-7. [PMID: 28618019 DOI: 10.1002/jmv.24879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
209 Lam AM, Espiritu C, Vogel R, Ren S, Lau V, Kelly M, Kuduk SD, Hartman GD, Flores OA, Klumpp K. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus. Antimicrob Agents Chemother 2019;63:e01734-18. [PMID: 30373799 DOI: 10.1128/AAC.01734-18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
210 Wang J, Huang R, Yan X, Li M, Chen Y, Xia J, Liu Y, Jia B, Zhu L, Zhang Z, Zhu C, Wu C. Red blood cell distribution width: A promising index for evaluating the severity and long-term prognosis of hepatitis B virus-related diseases. Dig Liver Dis 2020;52:440-6. [PMID: 32008975 DOI: 10.1016/j.dld.2019.12.144] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
211 Lakoh S, Firima E, Jiba DF, Kamara MN, Gashau W, Deen GF, Adekanmbi O, Yendewa GA. Prevalence of sero-markers and non-invasive assessment of liver cirrhosis in patients with Hepatitis B virus infection in Freetown, Sierra Leone: a cross-sectional study. BMC Gastroenterol 2021;21:320. [PMID: 34372775 DOI: 10.1186/s12876-021-01892-5] [Reference Citation Analysis]
212 Zhang W, Gong H, Su Z, Zhang X, Cao S. Risk factors associated with hepatic osteopathy in HBV related cirrhosis measured by liver stiffness: An Observational study. Medicine (Baltimore). 2019;98:e16628. [PMID: 31374030 DOI: 10.1097/md.0000000000016628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
213 Choe WH, Kim K, Lee SY, Choi YM, Kwon SY, Kim JH, Kim BJ. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations. World J Gastroenterol 2019;25:4985-98. [PMID: 31543688 DOI: 10.3748/wjg.v25.i33.4985] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
214 O'Brien TR, Yang HI, Groover S, Jeng WJ. Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. Gastroenterology 2019;156:400-17. [PMID: 30287169 DOI: 10.1053/j.gastro.2018.09.052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
215 Chen Y, Yang S, Chen D. Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review. Journal of Microbiology, Immunology and Infection 2019;52:1-8. [DOI: 10.1016/j.jmii.2017.10.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
216 Ward JW, Hinman AR. What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats. Gastroenterology. 2019;156:297-310. [PMID: 30391470 DOI: 10.1053/j.gastro.2018.10.048] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
217 Lim SG, Phyo WW, Ling JZJ, Cloherty G, Butler EK, Kuhns MC, McNamara AL, Holzmayer V, Gersch J, Yang WL, Ngu JH, Chang J, Tan J, Ahmed T, Dan YY, Lee YM, Lee GH, Tan PS, Huang DQ, Khine HTW, Lee C, Tay A, Chan E. Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg). Aliment Pharmacol Ther 2021;53:172-82. [PMID: 33159496 DOI: 10.1111/apt.16149] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
218 Abara WE, Cha S, Malik T, DeSimone MS, Schillie S, Collier M, Schumann B, Klemme M, Kamb M. Prenatal Screening for and Prevalence of Hepatitis B Surface Antigen in Pregnant Women and Prevention of Transmission to Infants Born to Infected Mothers-Guam, 2014. J Pediatric Infect Dis Soc 2018;7:290-5. [PMID: 28992071 DOI: 10.1093/jpids/pix062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
219 Nováková L, Pavlík J, Chrenková L, Martinec O, Červený L. Current antiviral drugs and their analysis in biological materials - Part II: Antivirals against hepatitis and HIV viruses. J Pharm Biomed Anal 2018;147:378-99. [PMID: 29031512 DOI: 10.1016/j.jpba.2017.07.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
220 Triantos C, Kalafateli M, Aggeletopoulou I, Mandellou M, Assimakopoulos S, Tselekouni P, Taprantzi D, Tsiaoussis G, Vourli G, Anastassiou ED, Gogos C, Labropoulou-Karatza C, Thomopoulos K. Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis. Eur J Gastroenterol Hepatol 2017;29:998-1003. [PMID: 28746158 DOI: 10.1097/MEG.0000000000000924] [Reference Citation Analysis]
221 Arandjelovic P, Doerflinger M, Pellegrini M. Current and emerging therapies to combat persistent intracellular pathogens. Curr Opin Pharmacol 2019;48:33-9. [PMID: 31051429 DOI: 10.1016/j.coph.2019.03.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
222 Agarwal K, Brunetto M, Seto WK, Lim Y, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang W, Bae H, Sharma M, Janssen HL, Pan CQ, Çelen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HL. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. Journal of Hepatology 2018;68:672-81. [DOI: 10.1016/j.jhep.2017.11.039] [Cited by in Crossref: 137] [Cited by in F6Publishing: 115] [Article Influence: 45.7] [Reference Citation Analysis]
223 Chotun N, Preiser W, van Rensburg CJ, Fernandez P, Theron GB, Glebe D, Andersson MI. Point-of-care screening for hepatitis B virus infection in pregnant women at an antenatal clinic: A South African experience. PLoS One 2017;12:e0181267. [PMID: 28732085 DOI: 10.1371/journal.pone.0181267] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
224 Tran S, Jeong D, Henry L, Cheung RC, Nguyen MH. Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study. Am J Gastroenterol 2021;116:1885-95. [PMID: 33927125 DOI: 10.14309/ajg.0000000000001271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
225 Xu J, Zhan Q, Fan Y, Yu Y, Zeng Z. Human genetic susceptibility to hepatitis B virus infection. Infect Genet Evol 2021;87:104663. [PMID: 33278635 DOI: 10.1016/j.meegid.2020.104663] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
226 Jeon MY, Lee HW, Kim SU, Kim BK, Park JY, Kim DY, Han K, Ahn SH. Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B. Liver Int 2018;38:676-86. [DOI: 10.1111/liv.13583] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
227 Ren H. The experience of management of chronic hepatitis B in China. J Viral Hepat 2017;24 Suppl 1:4-5. [PMID: 29082643 DOI: 10.1111/jvh.12793] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
228 Kim SS, Ahn EK, Cho SY, Park RW, Cho HJ, Kim JH, Kim HG, Lee GR, Hwang SH, Yang MJ, Cheong JY, Cho SW. Impact of nucleos(t)ide analog treatment on the development of malignancy in patients with chronic hepatitis B. Medicine (Baltimore) 2018;97:e11087. [PMID: 29901622 DOI: 10.1097/MD.0000000000011087] [Reference Citation Analysis]
229 Suh YS, Chun DI, Choi SW, Lee HW, Nho JH, Kwon SH, Cho JH, Won SH. Pathologic femoral fracture due to tenofovir-induced Fanconi syndrome in patient with chronic hepatitis B: A case report. Medicine (Baltimore) 2017;96:e8760. [PMID: 29145330 DOI: 10.1097/MD.0000000000008760] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Li H, Yan L, Shi Y, Lv D, Shang J, Bai L, Tang H. Hepatitis B Virus Infection: Overview. Adv Exp Med Biol 2020;1179:1-16. [PMID: 31741331 DOI: 10.1007/978-981-13-9151-4_1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
231 Li MH, Lu Y, Zhang L, Wang XY, Ran CP, Hao HX, Zhang D, Qu XJ, Shen G, Wu SL, Cao WH, Qi TL, Liu RY, Hu LP, Chang M, Hua WH, Liu SA, Wan G, Xie Y. Association of Cytokines with Alanine Aminotransferase, Hepatitis B Virus Surface Antigen and Hepatitis B Envelope Antigen Levels in Chronic Hepatitis B. Chin Med J (Engl) 2018;131:1813-8. [PMID: 30058578 DOI: 10.4103/0366-6999.237394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
232 Oropeza CE, Tarnow G, Sridhar A, Taha TY, Shalaby RE, McLachlan A. The Regulation of HBV Transcription and Replication. Adv Exp Med Biol 2020;1179:39-69. [PMID: 31741333 DOI: 10.1007/978-981-13-9151-4_3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
233 Lee HA, Lee HW, Kim IH, Park SY, Sinn DH, Yu JH, Seo YS, Um SH, Lee JI, Lee KS, Lee CH, Tak WY, Kweon YO, Kang W, Paik YH, Lee JW, Suh SJ, Jung YK, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Yim HJ, Kim SU. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther 2020;52:196-204. [PMID: 32452564 DOI: 10.1111/apt.15741] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
234 Kinoshita W, Ogura N, Watashi K, Wakita T. Host factor PRPF31 is involved in cccDNA production in HBV-replicating cells. Biochem Biophys Res Commun 2017;482:638-44. [PMID: 27864147 DOI: 10.1016/j.bbrc.2016.11.085] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
235 Cheng JY, Wong VW, Tse Y, Chim AM, Chan HL, Wong GL. Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B: Cheng et al. Hepatology 2016;64:1507-17. [DOI: 10.1002/hep.28778] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
236 Lei JH, Peng F, Chen Z, Xiao XQ. Is HBV viral load at admission associated with development of acute-on-chronic liver failure in patients with acute decompensation of chronic hepatitis B related cirrhosis? BMC Infect Dis 2019;19:363. [PMID: 31039732 DOI: 10.1186/s12879-019-3988-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
237 Fontaine H, Alric L, Labreuche J, Legendre B, Louvet A, Antoine C, Legendre CM, Hazzan M, Kamar N, Dharancy S, Pol S, Duhamel A, Mathurin P. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation. J Hepatol 2019;70:831-8. [PMID: 30879789 DOI: 10.1016/j.jhep.2018.12.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
238 Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2:100067. [PMID: 32118201 DOI: 10.1016/j.jhepr.2020.100067] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 47.0] [Reference Citation Analysis]
239 Andriamandimby SF, Olive MM, Shimakawa Y, Rakotomanana F, Razanajatovo IM, Andrianinarivomanana TM, Ravalohery JP, Andriamamonjy S, Rogier C, Héraud JM. Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: implication for the WHO's elimination strategy. BMC Public Health 2017;17:636. [PMID: 28778194 DOI: 10.1186/s12889-017-4630-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
240 Li MH, Zhang D, Zhang L, Qu XJ, Lu Y, Shen G, Wu SL, Chang M, Liu RY, Hu LP, Hao HX, Hua WH, Song SJ, Wan G, Liu SA, Xie Y. Ratios of T-helper 2 Cells to T-helper 1 Cells and Cytokine Levels in Patients with Hepatitis B. Chin Med J (Engl) 2017;130:1810-5. [PMID: 28748854 DOI: 10.4103/0366-6999.211541] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
241 Zeng DW, Dong J, Liu YR, Jiang JJ, Zhu YY. Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol 2016;22:6663-72. [PMID: 27547009 DOI: 10.3748/wjg.v22.i29.6663] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
242 Alavian SM, Imanieh MH, Imanieh MH. Predictive Factors in the Incidence of Cirrhosis in Chronic Hepatitis B Virus Infections. Hepat Mon. 2016;16:e34790. [PMID: 27330536 DOI: 10.5812/hepatmon.34790] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
243 Liaw Y. Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients. Journal of Hepatology 2018;68:1102-4. [DOI: 10.1016/j.jhep.2017.12.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
244 Nguyen MH, Yang HI, Le A, Henry L, Nguyen N, Lee MH, Zhang J, Wong C, Wong C, Trinh H. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study. J Infect Dis 2019;219:10-8. [PMID: 29982737 DOI: 10.1093/infdis/jiy391] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
245 Bahrami M, Cheraghpour M, Jafarirad S, Alavinejad P, Asadi F, Hekmatdoost A, Mohammadi M, Yari Z. The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial. Complement Ther Med 2020;52:102452. [PMID: 32951715 DOI: 10.1016/j.ctim.2020.102452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
246 Zeng J, Cai S, Liu J, Xue X, Wu X, Zheng C. Dynamic Changes in Liver Stiffness Measured by Transient Elastography Predict Clinical Outcomes Among Patients With Chronic Hepatitis B. J Ultrasound Med 2017;36:261-8. [PMID: 27914175 DOI: 10.7863/ultra.15.12054] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
247 Mani N, Cole AG, Phelps JR, Ardzinski A, Cobarrubias KD, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Guo H, Guo JT, Harasym TO, Kadhim S, Kultgen SG, Lee ACH, Li AHL, Long Q, Majeski SA, Mao R, McClintock KD, Reid SP, Rijnbrand R, Snead NM, Micolochick Steuer HM, Stever K, Tang S, Wang X, Zhao Q, Sofia MJ. Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation. Antimicrob Agents Chemother. 2018;62:e00082-18. [PMID: 29555628 DOI: 10.1128/aac.00082-18] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 9.3] [Reference Citation Analysis]
248 Li G, Zhou Y, Sze DM, Liu C, Zhang Q, Wang Z, Yu H, Chan G, Wu Z, Su S, Hu Y. Active Ingredients and Action Mechanisms of Yi Guan Jian Decoction in Chronic Hepatitis B Patients with Liver Fibrosis. Evid Based Complement Alternat Med 2019;2019:2408126. [PMID: 31565062 DOI: 10.1155/2019/2408126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
249 Yang S, Shen Z, Kang Y, Sun L, Viswanathan U, Guo H, Zhou T, Dai X, Chang J, Zhang J, Guo JT. A putative amphipathic alpha helix in hepatitis B virus small envelope protein plays a critical role in the morphogenesis of subviral particles. J Virol 2021:JVI. [PMID: 33536177 DOI: 10.1128/JVI.02399-20] [Reference Citation Analysis]
250 Lu Y, Zhu FC, Liu JX, Zhai XJ, Chang ZJ, Yan L, Wei KP, Zhang X, Zhuang H, Li J. The maternal viral threshold for antiviral prophylaxis of perinatal hepatitis B virus transmission in settings with limited resources: A large prospective cohort study in China. Vaccine 2017;35:6627-33. [PMID: 29079104 DOI: 10.1016/j.vaccine.2017.10.032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
251 Wu X, Cai B, Lu W, Fu Y, Wei B, Niu Q, Su Z, Li Y, Wang L. HBV upregulated triggering receptor expressed on myeloid cells-1 (TREM-1) expression on monocytes participated in disease progression through NF-Kb pathway. Clin Immunol 2021;223:108650. [PMID: 33316373 DOI: 10.1016/j.clim.2020.108650] [Reference Citation Analysis]
252 Cornberg M, Lok AS, Terrault NA, Zoulim F, Berg T, Brunetto MR, Buchholz S, Buti M, Chan HL, Chang K, Dandri M, Dusheiko G, Feld JJ, Ferrari C, Ghany M, Janssen HL, Kennedy P, Lampertico P, Liang J, Locarnini S, Maini MK, Mishra P, Papatheodoridis G, Petersen J, Schlottmann S, Wang S, Wedemeyer H. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡. Journal of Hepatology 2020;72:539-57. [DOI: 10.1016/j.jhep.2019.11.003] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 60.0] [Reference Citation Analysis]
253 Chen VL, Du X, Chen Y, Kuppa A, Handelman SK, Vohnoutka RB, Peyser PA, Palmer ND, Bielak LF, Halligan B, Speliotes EK. Genome-wide association study of serum liver enzymes implicates diverse metabolic and liver pathology. Nat Commun 2021;12:816. [PMID: 33547301 DOI: 10.1038/s41467-020-20870-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
254 Lai K, Zhang C, Ke W, Gao Y, Zhou S, Liu L, Yang Y. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China. Clin Drug Investig 2017;37:233-47. [PMID: 27928739 DOI: 10.1007/s40261-016-0486-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
255 Hadziyannis E, Laras A. Viral Biomarkers in Chronic HBeAg Negative HBV Infection. Genes (Basel) 2018;9:E469. [PMID: 30262738 DOI: 10.3390/genes9100469] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
256 Su F, Berry K, Ioannou GN. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. Gut. [DOI: 10.1136/gutjnl-2019-319867] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
257 Bloom K, Maepa MB, Ely A, Arbuthnot P. Gene Therapy for Chronic HBV-Can We Eliminate cccDNA? Genes (Basel) 2018;9:E207. [PMID: 29649127 DOI: 10.3390/genes9040207] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
258 Kilonzo SB, Gunda DW, Mpondo BCT, Bakshi FA, Jaka H. Hepatitis B Virus Infection in Tanzania: Current Status and Challenges. J Trop Med 2018;2018:4239646. [PMID: 29666656 DOI: 10.1155/2018/4239646] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
259 Kuhnhenn L, Jiang B, Kubesch A, Vermehren J, Knop V, Susser S, Dietz J, Carra G, Finkelmeier F, Grammatikos G, Zeuzem S, Sarrazin C, Hildt E, Peiffer K. Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg-negative chronic HBV infection. Aliment Pharmacol Ther 2018;47:1523-35. [DOI: 10.1111/apt.14636] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
260 Ho CH, Tsai HW, Lee CY, Huang LJ, Chien RN, Wu IC, Chiu YC, Liu WC, Cheng PN, Chang TT, Chen SH. Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG. Sci Rep 2017;7:1957. [PMID: 28512353 DOI: 10.1038/s41598-017-02158-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
261 Chi H, Wong D, Peng J, Cao J, Van Hees S, Vanwolleghem T, Qi X, Chen L, Feld JJ, de Knegt RJ, Hansen BE, Janssen HLA. Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation. Clinical Infectious Diseases 2017;65:680-3. [DOI: 10.1093/cid/cix353] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
262 Min IS, Lee CH, Shin IS, Lee NE, Son HS, Kim SB, Seo SY, Kim SH, Kim SW, Lee SO, Lee ST, Kim IH. Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate. Gut Liver 2019;13:93-103. [PMID: 30400723 DOI: 10.5009/gnl18183] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
263 Sonneveld MJ, Hansen BE, Brouwer WP, Chan HL, Piratvisuth T, Jia JD, Zeuzem S, Chien RN, de Knegt RJ, Wat C, Pavlovic V, Gaggar A, Xie Q, Buti M, de Man RA, Janssen HLA; SONIC-B Study group. hbsag levels can be used to rule out cirrhosis in hbeag positive chronic hepatitis b: results from the sonic-b study. J Infect Dis 2020:jiaa192. [PMID: 32318704 DOI: 10.1093/infdis/jiaa192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
264 Ning L, Lin W, Hu X, Fan R, Liang X, Wu Y, Shen S, Yu R, Sun J, Hou J. Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross-sectional survey. J Viral Hepat 2017;24:1043-51. [PMID: 28581186 DOI: 10.1111/jvh.12733] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
265 Faure-Bardon V, Ville Y. Maternal infections: revisiting the need for screening in pregnancy. BJOG 2021;128:304-15. [PMID: 32937015 DOI: 10.1111/1471-0528.16509] [Reference Citation Analysis]
266 Kong LN, Yao Y, Li L, Zhao QH, Wang T, Li YL. Psychological distress and self-management behaviours among patients with chronic hepatitis B receiving oral antiviral therapy. J Adv Nurs 2021;77:266-74. [PMID: 33074555 DOI: 10.1111/jan.14610] [Reference Citation Analysis]
267 Li M, Lv T, Wu S, Wei W, Wu X, Ou X, Ma H, Chow SC, Kong Y, You H, Jia J. Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. Hepatol Int. 2020;14:105-114. [PMID: 31898210 DOI: 10.1007/s12072-019-10005-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
268 Liu Y, Liu H, Hu Z, Ding Y, Pan XB, Zou J, Xi J, Yu G, Huang H, Luo MT, Guo F, Liu S, Sheng Q, Jia J, Zheng YT, Wang J, Chen X, Guo JT, Wei L, Lu F. Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination. Hepatology 2020;71:463-76. [PMID: 31278760 DOI: 10.1002/hep.30844] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
269 Duan WJ, Wang XZ, Ma AL, Shang J, Nan YM, Gao ZL, Tang H, Fu QC, Xie Q, Mao Q, Niu JQ, Han T, Li J, Han Y, Cao JB, Kong YY, Shi XY, Lv FD, Wang TL, Ma H, You H, Ou XJ, Jia JD. Multicenter prospective study to validate a new transient elastography device for staging liver fibrosis in patients with chronic hepatitis B. J Dig Dis 2020;21:519-25. [PMID: 32700794 DOI: 10.1111/1751-2980.12924] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
270 Wu Y, Wen J, Xiao W, Zhang B. Pregenomic RNA: How to assist the management of chronic hepatitis B? Rev Med Virol 2019;29:e2051. [PMID: 31074177 DOI: 10.1002/rmv.2051] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
271 Wang Y, Li XY, Wu LL, Zheng XY, Deng Y, Li MJ, You X, Chong YT, Hao YT. Dynamic prediction of liver cirrhosis risk in chronic hepatitis B patients using longitudinal clinical data. Eur J Gastroenterol Hepatol 2020;32:120-6. [PMID: 31688313 DOI: 10.1097/MEG.0000000000001592] [Reference Citation Analysis]
272 Hu Y, Ye Y, Ye L, Wang X, Yu H. Efficacy and safety of interferon alpha therapy in children with chronic hepatitis B: A long-term follow-up cohort study from China. Medicine (Baltimore) 2019;98:e16683. [PMID: 31393369 DOI: 10.1097/MD.0000000000016683] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
273 Waziry R, Grebely J, Amin J, Alavi M, Hajarizadeh B, George J, Matthews GV, Law M, Dore GJ. Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014). J Hepatol 2016;65:1086-93. [PMID: 27569777 DOI: 10.1016/j.jhep.2016.08.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
274 Konerman MA, Lok AS. Interferon Treatment for Hepatitis B. Clin Liver Dis. 2016;20:645-665. [PMID: 27742005 DOI: 10.1016/j.cld.2016.06.002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 8.2] [Reference Citation Analysis]
275 Lv LL, Yang YX, Shi TD. Effect of haptoglobin on the treatment of chronic hepatitis B with interferon. Exp Ther Med 2019;18:1417-25. [PMID: 31316628 DOI: 10.3892/etm.2019.7661] [Reference Citation Analysis]
276 Chen G, Wang C, Lau G. Treatment of chronic hepatitis B infection-2017. Liver Int 2017;37:59-66. [DOI: 10.1111/liv.13309] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
277 Wang Y, Liang J, Sheng W, Tien F, Chen C, Tien H. Hepatitis B reactivation during treatment of tyrosine kinase inhibitors—Experience in 142 adult patients with chronic myeloid leukemia. Leukemia Research 2019;81:95-7. [DOI: 10.1016/j.leukres.2019.05.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
278 Li J, Verhaar AP, Pan Q, de Knegt RJ, Peppelenbosch MP. Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B. Clin Exp Gastroenterol. 2017;10:203-209. [PMID: 28860836 DOI: 10.2147/ceg.s135526] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
279 Inoue T, Tanaka Y. The Role of Hepatitis B Core-Related Antigen. Genes (Basel) 2019;10:E357. [PMID: 31075974 DOI: 10.3390/genes10050357] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
280 Huang M, Zhong J, Lu C, Deng F, Li L, Nong Y, Liang L, Qin H, Deng Y. Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy. Pharmgenomics Pers Med 2019;12:297-303. [PMID: 31695474 DOI: 10.2147/PGPM.S224256] [Reference Citation Analysis]
281 Wu X, Shi Y, Zhou J, Sun Y, Piao H, Jiang W, Ma A, Chen Y, Xu M, Xie W, Cheng J, Xie S, Shang J, Cheng J, Xie Q, Ding H, Zhang X, Bai L, Zhang M, Wang B, Chen S, Ma H, Ou X, Jia J, You H. Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. Expert Opin Biol Ther 2018;18:61-9. [PMID: 30063860 DOI: 10.1080/14712598.2018.1451511] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
282 Howell J, Chan HL, Feld JJ, Hellard ME, Thompson AJ. Closing the Stable Door After the Horse Has Bolted: Should We Be Treating People With Immune-Tolerant Chronic Hepatitis B to Prevent Hepatocellular Carcinoma? Gastroenterology 2020;158:2028-32. [DOI: 10.1053/j.gastro.2020.02.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
283 Walker TY, Smith EA, Fenlon N, Lazaroff JE, Dusek C, Fineis P, Crowley SA, Benson R, Veselsky SL, Murphy TV. Characteristics of Pregnant Women With Hepatitis B Virus Infection in 5 US Public Health Jurisdictions, 2008-2012. Public Health Rep 2016;131:685-94. [PMID: 28123209 DOI: 10.1177/0033354916663183] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
284 Yao M, Wang L, Leung PSC, Li Y, Liu S, Wang L, Guo X, Zhou G, Yan Y, Guan G, Chen X, Bowlus CL, Liu T, Jia J, Gershwin ME, Ma X, Zhao J, Lu F. The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. Clin Rev Allergy Immunol. 2018;54:282-294. [PMID: 29256057 DOI: 10.1007/s12016-017-8655-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
285 Soriano V, Barreiro P, Benitez L, Peña JM, de Mendoza C. New antivirals for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs 2017;26:843-51. [DOI: 10.1080/13543784.2017.1333105] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
286 Zhang PF, Xie D, Li Q. Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects. Immunotherapy 2020;12:1021-34. [PMID: 32727249 DOI: 10.2217/imt-2020-0009] [Reference Citation Analysis]
287 Espinosa CM, Jhaveri R. Update on the management of hepatitis B and C infections in the neonatal period. Semin Perinatol 2018;42:185-90. [PMID: 29526383 DOI: 10.1053/j.semperi.2018.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
288 Yanny BT, Latt NL, Saab S, Han S, Choi G, Kramer J, Sahota AK. Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection. J Clin Gastroenterol 2018;52:908-12. [PMID: 29334502 DOI: 10.1097/MCG.0000000000000986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
289 Truong J, Shadbolt B, Ooi M, Chitturi S, Kaye G, Farrell GC, Teoh NC. Week 4 viral load predicts long-term suppression of hepatitis B virus DNA during antiviral therapy: improving hepatitis B treatment in the real world. Intern Med J 2017;47:50-6. [PMID: 27571991 DOI: 10.1111/imj.13244] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
290 Raad II, Chaftari AM, Torres HA, Ayoub EM, Narouz LI, Bartek J, Hachem R. Challenge of hepatitis C in Egypt and hepatitis B in Mauritania. World J Hepatol 2018;10:549-57. [PMID: 30310533 DOI: 10.4254/wjh.v10.i9.549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
291 Fasano M, Maggi P, Leone A, Volpe A, Fiore JR, Angarano G, Santantonio TA. Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients. Dig Liver Dis 2017;49:530-4. [PMID: 28179096 DOI: 10.1016/j.dld.2017.01.140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
292 Kranidioti H, Manolakopoulos S, Kontos G, Breen MS, Kourikou A, Deutsch M, Quesada-Del-Bosque ME, Martinez-Nunez RT, Naiyer MM, Woelk CH, Sanchez-Elsner T, Hadziyannis E, Papatheodoridis G, Khakoo SI. Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat 2019;26:697-709. [PMID: 30702196 DOI: 10.1111/jvh.13068] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
293 Shen FF, Wang Y, Wang YF, Zheng RD, Xian JC, Shi JP, Qu Y, Dong YW, Xu MY, Lu LG. Prediction of hepatic necroinflammatory activity in patients with chronic hepatitis B by a simple noninvasive model. J Transl Med 2018;16:166. [PMID: 29914513 DOI: 10.1186/s12967-018-1538-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
294 Kuo M, Hu T, Hung C, Wang J, Lu S, Tsai K, Chen C. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther 2019;49:218-28. [DOI: 10.1111/apt.15053] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
295 Park JH, Choi J, Jun DW, Han SW, Yeo YH, Nguyen MH. Low Alanine Aminotransferase Cut-Off for Predicting Liver Outcomes; A Nationwide Population-Based Longitudinal Cohort Study. J Clin Med 2019;8:E1445. [PMID: 31514449 DOI: 10.3390/jcm8091445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
296 Sirilert S, Tongsong T. Hepatitis B Virus Infection in Pregnancy: An Update on Evidence-Based Management. Obstet Gynecol Surv. 2020;75:557-565. [PMID: 32997148 DOI: 10.1097/ogx.0000000000000831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
297 Han K, Cremer J, Elston R, Oliver S, Baptiste-Brown S, Chen S, Gardiner D, Davies M, Saunders J, Hamatake R, Losos J, Leivers M, Hood S, van der Berg F, Paff M, Ritter JM, Theodore D. A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects. Clin Pharmacol Drug Dev. 2019;8:790-801. [PMID: 30861337 DOI: 10.1002/cpdd.670] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
298 Masrour-Roudsari J, Hasanjani-Roushan M, Yahyapour Y, Barari-Savadkoohi R, Bijani A, Sadeghi F, Mohammadnia-Afroozi M. HBS Ag seroclearance and seroconversion time in Patients with chronic hepatitis B Infection. Caspian J Intern Med 2020;11:205-10. [PMID: 32509250 DOI: 10.22088/cjim.11.2.205] [Reference Citation Analysis]
299 Cheung KW, Seto MTY, Kan ASY, Wong D, Kou KO, So PL, Lau WL, Jalal K, Chee YY, Wong RMS, Lee CP, Ng EHY. Immunoprophylaxis Failure of Infants Born to Hepatitis B Carrier Mothers Following Routine Vaccination. Clinical Gastroenterology and Hepatology 2018;16:144-5. [DOI: 10.1016/j.cgh.2017.07.013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
300 Na JH, Kim JH, Choe WH, Kwon SY, Yoo BC. Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients. Korean J Gastroenterol 2021;77:285-93. [PMID: 34158448 DOI: 10.4166/kjg.2021.043] [Reference Citation Analysis]
301 Zhu S, Zhang H, Dong Y, Wang L, Xu Z, Liu W, Gan Y, Tang H, Chen D, Wang F, Zhao P. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study. J Hepatol. 2018;68:1123-1128. [PMID: 29452204 DOI: 10.1016/j.jhep.2018.01.037] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
302 Huynh T, Zhang J, Hu KQ. Hepatitis C Virus Clearance by Direct-acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase Normalization. J Clin Transl Hepatol 2018;6:258-63. [PMID: 30271737 DOI: 10.14218/JCTH.2018.00014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
303 Xu X, Xiang K, Su M, Li Y, Ji W, Li Y, Zhuang H, Li T. HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining. Viruses 2017;9:E199. [PMID: 28749433 DOI: 10.3390/v9080199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
304 Nakano LA, Katayose JT, Abreu RM, Mendes LCA, Martins MC, Pinto VB, Carrilho FJ, Ono SK. Assessment of the prevalence of vertical hepatitis B transmission in two consecutive generations. Rev Assoc Med Bras (1992) 2018;64:154-8. [PMID: 29641674 DOI: 10.1590/1806-9282.64.02.154] [Reference Citation Analysis]
305 Li T, Liang Y, Zhang M, Liu F, Zhang L, Yang B, Wang L. Nucleoside/nucleotide analog consolidation therapy in hepatitis B e-antigen positive chronic hepatitis B patients: Three years should be preferred. Hepatol Res 2021;51:633-40. [PMID: 33772988 DOI: 10.1111/hepr.13641] [Reference Citation Analysis]
306 Cao Z, Li Z, Wang H, Liu Y, Xu Y, Mo R, Ren P, Chen L, Lu J, Li H, Zhuang Y, Liu Y, Wang X, Zhao G, Tang W, Xiang X, Cai W, Liu L, Bao S, Xie Q. Algorithm of Golgi protein 73 and liver stiffness accurately diagnoses significant fibrosis in chronic HBV infection. Liver Int. 2017;37:1612-1621. [PMID: 28772348 DOI: 10.1111/liv.13536] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
307 Seto WK, Sau-Yan Chan T, Hwang YY, Mak LY, Ka-Ho Wong D, Fung J, Sze-Hang Liu K, Cheung KS, Lai CL, Kwong YL, Yuen MF. Monitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV. Clin Gastroenterol Hepatol. 2018;. [PMID: 30243760 DOI: 10.1016/j.cgh.2018.09.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
308 Megahed FAK, Zhou X, Sun P. The Interactions between HBV and the Innate Immunity of Hepatocytes. Viruses 2020;12:E285. [PMID: 32151000 DOI: 10.3390/v12030285] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
309 Pfefferkorn M, Schott T, Böhm S, Deichsel D, Felkel C, Gerlich WH, Glebe D, Wat C, Pavlovic V, Heyne R, Berg T, van Bömmel F. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2021;74:283-92. [PMID: 32931877 DOI: 10.1016/j.jhep.2020.08.039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
310 Sun WC, Tang PL, Chen WC, Tsay FW, Wang HM, Tsai TJ, Kao SS, Cheng JS, Tsai WL. Hepatitis B Virus Screening Before Cancer Chemotherapy in Taiwan: A Nationwide Population-Based Study. Front Med (Lausanne) 2021;8:657109. [PMID: 34336877 DOI: 10.3389/fmed.2021.657109] [Reference Citation Analysis]
311 Burgis JC, Kong D, Salibay C, Zipprich J, Harriman K, So S. Perinatal transmission in infants of mothers with chronic hepatitis B in California. World J Gastroenterol 2017;23:4942-9. [PMID: 28785148 DOI: 10.3748/wjg.v23.i27.4942] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
312 Huang CZ, Zhang J, Zhang L, Yu CH, Mo Y, Mo LY. Serum vitamin D and vitamin-D-binding protein levels in children with chronic hepatitis B. World J Gastroenterol 2021;27:255-66. [PMID: 33519140 DOI: 10.3748/wjg.v27.i3.255] [Reference Citation Analysis]
313 Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf 2021;44:133-65. [PMID: 33141341 DOI: 10.1007/s40264-020-01014-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
314 Linye H, Zijing X, Wei P, Chao H, Chuan L, Tianfu W. Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma: A propensity score matching analysis. Medicine (Baltimore) 2021;100:e25749. [PMID: 34011034 DOI: 10.1097/MD.0000000000025749] [Reference Citation Analysis]
315 Guo R, Xie Y, Yang J, Lu H, Ye P, Jin L, Lin W. Increasing plasma ADAMTS13 activity is associated with HBeAg seroconversion in chronic hepatitis B patients during 5 years of entecavir treatment. Sci Rep 2019;9:5916. [PMID: 30976044 DOI: 10.1038/s41598-019-42421-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
316 Cho H, Chang Y, Lee JH, Cho YY, Nam JY, Lee YB, Lee DH, Cho EJ, Yu SJ, Kim YJ, Lee JM, Yoon JH. Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B. J Clin Gastroenterol 2020;54:633-41. [PMID: 31033805 DOI: 10.1097/MCG.0000000000001217] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
317 Yeh ML, Huang CI, Hsieh MY, Huang CF, Hsieh MH, Huang JF, Dai CY, Lin ZY, Chen SC, Yu ML, Chuang WL. Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study. Kaohsiung J Med Sci 2016;32:559-66. [PMID: 27847098 DOI: 10.1016/j.kjms.2016.08.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
318 Ahmed B, Konje JC. Screening for infections in pregnancy - An overview of where we are today. Eur J Obstet Gynecol Reprod Biol 2021;263:85-93. [PMID: 34171635 DOI: 10.1016/j.ejogrb.2021.06.002] [Reference Citation Analysis]
319 Yıldız Kaya S, Mete B, Kaya A, Balkan II, Saltoglu N, Tabak ÖF. The role of quantitative HBsAg in patients with HBV DNA between 2000-20,000 IU/ml. Wien Klin Wochenschr 2021;133:647-53. [PMID: 33914152 DOI: 10.1007/s00508-021-01854-7] [Reference Citation Analysis]
320 Ma K, Berger D, Reau N. Liver Diseases During Pregnancy. Clin Liver Dis 2019;23:345-61. [PMID: 30947881 DOI: 10.1016/j.cld.2018.12.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
321 Zhang L, Li MH, Cao WH, Qi TL, Lu Y, Wu SL, Hao HX, Shen G, Liu RY, Hu LP, Chang M, Hua WH, Song SJ, Wan G, Xie Y. Negative Correlation of Serum Hepatitis B Surface Antigen and Hepatitis B e Antigen Levels with the Severity of Liver Inflammation in Treatment-naïve Patients with Chronic Hepatitis B Virus Infection. Chin Med J (Engl) 2017;130:2697-702. [PMID: 29133758 DOI: 10.4103/0366-6999.218000] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
322 Lee SK, Song MJ, Kim SH, Lee BS, Lee TH, Kang YW, Kim SB, Song IH, Chae HB, Ko SY, Lee JD. Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis. World J Gastroenterol 2017;23:2396-403. [PMID: 28428719 DOI: 10.3748/wjg.v23.i13.2396] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
323 Guo L, Wang D, Ouyang X, Tang N, Chen X, Zhang Y, Zhu H, Li X. Recent Advances in HBV Reactivation Research. Biomed Res Int. 2018;2018:2931402. [PMID: 30687740 DOI: 10.1155/2018/2931402] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
324 Chuaypen N, Sriprapun M, Praianantathavorn K, Payungporn S, Wisedopas N, Poovorawan Y, Tangkijvanich P. Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. J Med Virol. 2017;89:130-138. [PMID: 27307409 DOI: 10.1002/jmv.24601] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
325 Pfefferkorn M, Böhm S, Schott T, Deichsel D, Bremer CM, Schröder K, Gerlich WH, Glebe D, Berg T, van Bömmel F. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Gut 2018;67:2045-53. [PMID: 28951526 DOI: 10.1136/gutjnl-2017-313811] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
326 Lee HJ, Kim SJ, Kweon YO, Park SY, Heo J, Woo HY, Hwang JS, Chung WJ, Lee CH, Kim BS, Suh JI, Tak WY, Jang BK. Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients. PLoS One 2018;13:e0190581. [PMID: 29329305 DOI: 10.1371/journal.pone.0190581] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
327 Seo KI, Bae SH, Sung PS, Park CH, Lee HL, Kim HY, Kim HJ, Jang BH, Jang JW, Yoon SK, Choi JY, Park IY, Lee J, Lee HS, Kim SJ, Kwon JH, Chang UI, Kim CW, Jo SH, Lee Y, Tekle F, Kim JH. Effect of antiviral therapy in reducing perinatal transmission of hepatitis B virus and maternal outcomes after discontinuing them. Clin Mol Hepatol 2018;24:374-83. [PMID: 29940720 DOI: 10.3350/cmh.2017.0082] [Reference Citation Analysis]
328 Hsu YC, Mo LR, Chang CY, Wu MS, Kao JH, Wang WL, Yang TH, Wang CS, Chiang MF, Chen CC, Fang YJ, Hung HW, Wu CY, Lin JT. Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen-Negative Patients. Clin Gastroenterol Hepatol 2016;14:1490-1498.e3. [PMID: 27018299 DOI: 10.1016/j.cgh.2016.03.024] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
329 Butler EK, Gersch J, McNamara A, Luk KC, Holzmayer V, de Medina M, Schiff E, Kuhns M, Cloherty GA. Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection. Hepatology. 2018;68:2106-2117. [PMID: 29734472 DOI: 10.1002/hep.30082] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 19.3] [Reference Citation Analysis]
330 Seto WK, Asahina Y, Brown TT, Peng CY, Stanciu C, Abdurakhmanov D, Tabak F, Nguyen TT, Chuang WL, Inokuma T, Ikeda F, Santantonio TA, Habersetzer F, Ramji A, Lau AH, Suri V, Flaherty JF, Wang H, Gaggar A, Subramanian GM, Mukewar S, Brunetto MR, Fung S, Chan HL. Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection. Clin Gastroenterol Hepatol. 2018;. [PMID: 29933096 DOI: 10.1016/j.cgh.2018.06.023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
331 Zhang YR, Wang H, Zhang YD, Lin Y, Wu LY, Wei SF, Ma YY, Wang CX. Highly sensitive nucleic acid detection and transaminase level in treatment decisions for Chinese patients with cirrhosis caused by hepatitis. J Int Med Res 2020;48:300060520959217. [PMID: 33050759 DOI: 10.1177/0300060520959217] [Reference Citation Analysis]
332 Lenci I, Milana M, Grassi G, Manzia TM, Gazia C, Tisone G, Angelico R, Baiocchi L. Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger? World J Gastroenterol 2020;26:2166-76. [PMID: 32476783 DOI: 10.3748/wjg.v26.i18.2166] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
333 Schulz TR, Edwards R, Thurnheer MC, Yuen L, Littlejohn M, Revill P, Chu M, Tanyeri F, Wade A, Biggs BA, Sasadeusz J. Hepatitis B among immigrants from Myanmar: Genotypes and their clinical relevance. J Med Virol 2018;90:271-6. [PMID: 28885711 DOI: 10.1002/jmv.24939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
334 Yang H, Chen P. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA. Virus Research 2018;244:304-10. [DOI: 10.1016/j.virusres.2017.06.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
335 Culp LA, Caucci L, Fenlon NE, Lindley MC, Nelson NP, Murphy TV. Assessment of State Perinatal Hepatitis B Prevention Laws. Am J Prev Med 2016;51:e179-85. [PMID: 27866601 DOI: 10.1016/j.amepre.2016.09.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
336 Chevaliez S, Dauvillier C, Dubernet F, Poveda JD, Laperche S, Hézode C, Pawlotsky JM. The New Aptima HBV Quant Real-Time TMA Assay Accurately Quantifies Hepatitis B Virus DNA from Genotypes A to F. J Clin Microbiol 2017;55:1211-9. [PMID: 28202793 DOI: 10.1128/JCM.02219-16] [Cited by in Crossref: 10] [Article Influence: 2.5] [Reference Citation Analysis]
337 Song A, Lin X, Chen X. Functional cure for chronic hepatitis B: accessibility, durability, and prognosis. Virol J 2021;18:114. [PMID: 34082765 DOI: 10.1186/s12985-021-01589-x] [Reference Citation Analysis]
338 Hu Y, Ye YZ, Ye LJ, Wang XH, Yu H. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China. World J Pediatr 2019;15:595-600. [PMID: 31487005 DOI: 10.1007/s12519-019-00303-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
339 Imprialos KP, Stavropoulos K, Doumas M, Skalkou A, Zografou I, Athyros VG. The potential role of statins in treating liver disease. Expert Review of Gastroenterology & Hepatology 2018;12:331-9. [DOI: 10.1080/17474124.2018.1439379] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
340 Hyun MH, Lee YS, Kim JH, Je JH, Yoo YJ, Yeon JE, Byun KS. Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus. Aliment Pharmacol Ther. 2017;45:1493-1505. [PMID: 28436552 DOI: 10.1111/apt.14068] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
341 Lee SH, Jin YJ, Shin JY, Lee JW. Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs. Medicine (Baltimore). 2017;96:e5321. [PMID: 28072684 DOI: 10.1097/md.0000000000005321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
342 Wang ML, Wu DB, Tao YC, Chen LL, Liu CP, Chen EQ, Tang H. The truncated mutant HBsAg expression increases the tumorigenesis of hepatitis B virus by regulating TGF-β/Smad signaling pathway. Virol J 2018;15:61. [PMID: 29609638 DOI: 10.1186/s12985-018-0972-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
343 McMahon BJ. Editorial Commentary: Sliding Down the Cascade of Care for Chronic Hepatitis B Virus Infection. Clin Infect Dis 2016;63:1209-11. [PMID: 27486113 DOI: 10.1093/cid/ciw517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
344 You H, Kong Y, Hou J, Wei L, Zhang Y, Niu J, Han T, Ou X, Dou X, Shang J, Tang H, Xie Q, Ding H, Ren H, Xu X, Xie W, Liu X, Xu Y, Li Y, Li J, Chow SC, Zhuang H, Jia J. Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B. Sci Rep 2016;6:37498. [PMID: 27892487 DOI: 10.1038/srep37498] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
345 Zheng Z, Liao W, Liu L, Cai S, Zhu H, Yin S. Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study. Biomed Pharmacother 2020;122:109698. [PMID: 31918272 DOI: 10.1016/j.biopha.2019.109698] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
346 Liu Z, Liu F, Wang L, Liu Y, Zhang M, Li T. Clinical characteristics and outcomes of patients with recurrent chronic hepatitis B after nucleos(t)ide analog withdrawal with stringent cessation criteria: A prospective cohort study. Hepatol Res 2017;47:1000-7. [PMID: 27917568 DOI: 10.1111/hepr.12836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
347 Chan HLY. Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy. J Gastroenterol Hepatol 2019;34:501-6. [PMID: 30402981 DOI: 10.1111/jgh.14534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
348 Van Hees S, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Michielsen P, Sprengers D, Reynaert H, Henrion J, Negrin Dastis S, Delwaide J, Lasser L, Decaestecker J, Orlent H, Janssens F, Robaeys G, Colle I, Stärkel P, Moreno C, Nevens F, Vanwolleghem T; Belgian NA Stop Study Group. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes. Aliment Pharmacol Ther 2018;47:1170-80. [PMID: 29498078 DOI: 10.1111/apt.14560] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
349 Wu D, Wang P, Han M, Chen Y, Chen X, Xia Q, Yan W, Wan X, Zhu C, Xie Q, Jiang J, Wei L, Tan D, Dou X, Yu Y, Hou J, Luo X, Ning Q. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study. Hepatol Int. 2019;13:573-586. [PMID: 31172415 DOI: 10.1007/s12072-019-09956-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
350 Ou Q, Guo J, Zeng Y, Chen H. Insights for clinical diagnostic indicators of virus and host in chronic hepatitis B infection. J Viral Hepat 2020;27:224-32. [PMID: 31954089 DOI: 10.1111/jvh.13260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
351 Agarwal K, Ahn SH, Elkhashab M, Lau AH, Gaggar A, Bulusu A, Tian X, Cathcart AL, Woo J, Subramanian GM, Andreone P, Kim HJ, Chuang WL, Nguyen MH. Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment. J Viral Hepat. 2018;25:1331-1340. [PMID: 29851204 DOI: 10.1111/jvh.12942] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
352 Papatheodoridis GV, Manolakopoulos S, Su T, Siakavellas S, Liu C, Kourikou A, Yang H, Kao J. Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B: Papatheodoridis et al. Hepatology 2018;68:415-24. [DOI: 10.1002/hep.29497] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
353 Nsokolo B, Kanunga A, Sinkala E, Zyambo K, Kumwenda D, Chama D, Muyinda G, Vinikoor M, Ijaz S, Tedder R, Elmdaah AKA, Jones M, Chiluba C, Mudenda V, Goldin RD, Foster G, Kelly P. Stage of disease in hepatitis B virus infection in Zambian adults is associated with large cell change but not well defined using classic biomarkers. Trans R Soc Trop Med Hyg 2017;111:425-32. [PMID: 29378031 DOI: 10.1093/trstmh/trx077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
354 Allard N, Emery J, Cowie B, Furler J. Knowing and telling: how African-Australians living with chronic hepatitis B understand hepatocellular carcinoma risk and surveillance. Aust J Prim Health 2018;24:141. [DOI: 10.1071/py17099] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
355 Haraguchi M, Miuma S, Yamamoto K, Nakao Y, Ichikawa T, Kanda Y, Sasaki R, Fukushima M, Akazawa Y, Miyaaki H, Nakao K. Geranylgeranylacetone decreases the production of hepatitis B virus-related antigen by comprehensive downregulation of mRNA transcription activity. J Gastroenterol Hepatol 2021;36:1979-87. [PMID: 33393671 DOI: 10.1111/jgh.15394] [Reference Citation Analysis]
356 Fernández G, L Sanchez A, Jerez E, E Anillo L, Freyre F, A Aguiar J, Leon Y, Cinza Z, A Diaz P, Figueroa N, Muzio V, G Nieto G, Lobaina Y, Aguilar A, Penton E, C Aguilar J. Five-year Follow-up of Chronic Hepatitis B Patients Immunized by Nasal Route with the Therapeutic Vaccine HeberNasvac. Euroasian J Hepatogastroenterol 2018;8:133-9. [PMID: 30828555 DOI: 10.5005/jp-journals-10018-1279] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
357 Jindal A, Vyas AK, Kumar D, Kumar G, Sharma MK, Sarin SK. Higher efficacy of pegylated interferon-α2b add-on therapy in hepatitis B envelope antigen-positive chronic hepatitis B patients on tenofovir monotherapy. Hepatol Res 2018;48:451-8. [PMID: 29314573 DOI: 10.1111/hepr.13049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
358 Enomoto M, Nishiguchi S, Tamori A, Kozuka R, Fujii H, Uchida-Kobayashi S, Fukunishi S, Tsuda Y, Higuchi K, Saito M, Enomoto H, Kawada N. Sequential therapy involving an early switch from entecavir to pegylated interferon-α in Japanese patients with chronic hepatitis B. Hepatol Res 2018;48:459-68. [PMID: 29314465 DOI: 10.1111/hepr.13050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
359 Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599. [PMID: 29405329 DOI: 10.1002/hep.29800] [Cited by in Crossref: 1129] [Cited by in F6Publishing: 892] [Article Influence: 376.3] [Reference Citation Analysis]
360 Grossi G, Loglio A, Facchetti F, Borghi M, Soffredini R, Galmozzi E, Lunghi G, Gaggar A, Lampertico P. Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance. J Hepatol. 2017;. [PMID: 28870666 DOI: 10.1016/j.jhep.2017.08.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
361 Lin M, Guo R, Ma C, Zeng D, Su Z. Manganese Breaks the Immune Tolerance of HBs-Ag. Open Forum Infect Dis 2021;8:ofab028. [PMID: 33614817 DOI: 10.1093/ofid/ofab028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
362 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 7.7] [Reference Citation Analysis]
363 Liu K, Choi J, Le A, Yip TC, Wong VW, Chan SL, Chan HL, Nguyen MH, Lim YS, Wong GL. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. Aliment Pharmacol Ther 2019;50:1037-48. [PMID: 31524304 DOI: 10.1111/apt.15499] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
364 Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, Dusheiko G, Feld JJ, Gore C, Griswold MG, Hamid S, Hellard ME, Hou J, Howell J, Jia J, Kravchenko N, Lazarus JV, Lemoine M, Lesi OA, Maistat L, McMahon BJ, Razavi H, Roberts T, Simmons B, Sonderup MW, Spearman CW, Taylor BE, Thomas DL, Waked I, Ward JW, Wiktor SZ; Lancet Gastroenterology & Hepatology Commissioners. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4:135-184. [PMID: 30647010 DOI: 10.1016/s2468-1253(18)30270-x] [Cited by in Crossref: 180] [Cited by in F6Publishing: 68] [Article Influence: 180.0] [Reference Citation Analysis]
365 Brown RS Jr, McMahon BJ, Lok AS, Wong JB, Ahmed AT, Mouchli MA, Wang Z, Prokop LJ, Murad MH, Mohammed K. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology. 2016;63:319-333. [PMID: 26565396 DOI: 10.1002/hep.28302] [Cited by in Crossref: 179] [Cited by in F6Publishing: 159] [Article Influence: 29.8] [Reference Citation Analysis]
366 Loglio A, Iavarone M, Grossi G, Viganò M, Rumi MG, Facchetti F, Lunghi G, Sangiovanni A, Colombo M, Lampertico P. Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. Aliment Pharmacol Ther 2018;48:431-9. [PMID: 29920698 DOI: 10.1111/apt.14848] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
367 Leeper C, Lutzkanin A 3rd. Infections During Pregnancy. Prim Care 2018;45:567-86. [PMID: 30115342 DOI: 10.1016/j.pop.2018.05.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
368 Wang J, Yu Y, Li G, Shen C, Li J, Chen S, Zhang X, Zhu M, Zheng J, Song Z, Wu J, Shao L, Meng Z, Wang X, Huang Y, Zhang J, Qiu C, Zhang W. Natural history of serum HBV-RNA in chronic HBV infection. J Viral Hepat. 2018;25:1038-1047. [PMID: 29633430 DOI: 10.1111/jvh.12908] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
369 Lee SB, Jeong J, Park JH, Jung SW, Jeong ID, Bang SJ, Shin JW, Park BR, Park EJ, Park NH. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir. Clin Mol Hepatol 2020;26:364-75. [PMID: 32466635 DOI: 10.3350/cmh.2020.0012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
370 Kumar R, Teo EK, How CH, Wong TY, Ang TL. A practical clinical approach to liver fibrosis. Singapore Med J 2018;59:628-33. [PMID: 30631885 DOI: 10.11622/smedj.2018145] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
371 Wang YC, Yang SS, Su CW, Wang YJ, Lee KC, Huo TI, Lin HC, Huang YH. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. Sci Rep. 2016;6:29605. [PMID: 27405043 DOI: 10.1038/srep29605] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
372 Thanapirom K, Suksawatamnuay S, Sukeepaisarnjaroen W, Treeprasertsuk S, Tanwandee T, Charatcharoenwitthaya P, Thongsawat S, Leerapun A, Piratvisuth T, Boonsirichan R, Bunchorntavakul C, Pattanasirigool C, Pornthisarn B, Tuntipanichteerakul S, Sripariwuth E, Jeamsripong W, Sanpajit T, Poovorawan Y, Komolmit P. Vitamin D-Binding protein Gene Polymorphism Predicts Pegylated Interferon-Related HBsAg Seroclearance in HBeAg-Negative Thai Chronic Hepatitis B Patients: A Multicentre Study. Asian Pac J Cancer Prev 2019;20:1257-64. [PMID: 31030503 DOI: 10.31557/APJCP.2019.20.4.1257] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
373 Kim M, Paik J, Golabi P, Jeffers T, Mishra A, Younossi ZM. Resource Utilization and Outcomes of Medicare Recipients With Chronic Hepatitis B in the United States. J Clin Gastroenterol 2019;53:e341-7. [PMID: 30106839 DOI: 10.1097/MCG.0000000000001110] [Reference Citation Analysis]
374 Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol 2017;8:229-42. [PMID: 28480063 DOI: 10.21037/jgo.2017.03.14] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 15.0] [Reference Citation Analysis]
375 Singh US, Mulamoottil VA, Chu CK. 2′-Fluoro-6′-methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti-HBV agent, active against drug-resistant HBV mutants. Med Res Rev 2018;38:977-1002. [DOI: 10.1002/med.21490] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
376 Schinazi RF, Asselah T. From HCV To HBV Cure. Liver Int 2017;37 Suppl 1:73-80. [PMID: 28052627 DOI: 10.1111/liv.13324] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
377 Iida-Ueno A, Enomoto M, Kozuka R, Tamori A, Kawada N. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial. J Med Virol 2019;91:1295-300. [PMID: 30815880 DOI: 10.1002/jmv.25442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
378 Zhang K, Lin S, Wang M, Huang J, Zhu Y. The Risk of Acute Kidney Injury in Hepatitis B Virus-Related Acute on Chronic Liver Failure with Tenofovir Treatment. Biomed Res Int 2020;2020:5728359. [PMID: 32596332 DOI: 10.1155/2020/5728359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
379 Chang CY, Aziz N, Poongkunran M, Javaid A, Trinh HN, Lau D, Nguyen MH. Serum Alanine Aminotransferase and Hepatitis B DNA Flares in Pregnant and Postpartum Women with Chronic Hepatitis B. Am J Gastroenterol. 2016;111:1410-1415. [PMID: 27456990 DOI: 10.1038/ajg.2016.296] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
380 Kim DY, Kim JH, Tak WY, Yeon JE, Lee JH, Yoon JH, Lee YJ, Lee BS, Han BH, Lee HC. Baracle® vs Baraclude® for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety. Drug Des Devel Ther 2017;11:3145-52. [PMID: 29184389 DOI: 10.2147/DDDT.S149199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
381 Wigneswaran J, Van Wyck D, Pegues D, Gholam P, Nissenson AR. Hepatitis C virus infection in patients with end-stage renal disease: Hepatitis C in renal patients. Hemodialysis International 2018;22:297-307. [DOI: 10.1111/hdi.12672] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
382 O'Neil CR, Congly SE, Rose MS, Lee SS, Borman MA, Charlton CL, Osiowy C, Swain MG, Burak KW, Coffin CS. Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers. Ann Hepatol 2018;17:232-41. [PMID: 31097238 DOI: 10.5604/01.3001.0010.8640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
383 Gill US, Peppa D, Micco L, Singh HD, Carey I, Foster GR, Maini MK, Kennedy PT. Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo. PLoS Pathog 2016;12:e1005788. [PMID: 27487232 DOI: 10.1371/journal.ppat.1005788] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
384 Chen J, Zhao SS, Liu XX, Huang ZB, Huang Y. Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis. Clin Ther 2017;39:1870-80. [PMID: 28797777 DOI: 10.1016/j.clinthera.2017.07.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
385 Jasmine Bullard A, Cunningham FE, Volpp BD, Lowy E, Beste LA, Heron BB, Geraci M, Hammond JM, LaPlant K, Stave EA, Turner MJ, O'Leary MC, Kelley MJ, Hunt CM. Preventing Hepatitis B Reactivation During Anti-CD20 Antibody Treatment in the Veterans Health Administration. Hepatol Commun 2018;2:1136-46. [PMID: 30202826 DOI: 10.1002/hep4.1238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
386 Ruggeri M, Basile M, Coretti S, Drago C, Cicchetti A. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy. Appl Health Econ Health Policy 2017;15:479-90. [DOI: 10.1007/s40258-017-0311-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
387 Luk A, Jiang Q, Glavini K, Triyatni M, Zhao N, Racek T, Zhu Y, Grippo JF. A Single and Multiple Ascending Dose Study of Toll-Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers. Clin Transl Sci. 2020;13:985-993. [PMID: 32268000 DOI: 10.1111/cts.12791] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
388 Braun P, Delgado R, Drago M, Fanti D, Fleury H, Izopet J, Lombardi A, Marcos M, Sauné K, O'Shea S, Pérez-Rivilla A, Ramble J, Trimoulet P, Vila J, Whittaker D, Artus A, Rhodes D. A European multicientre study on the comparison of HBV viral loads between VERIS HBV assay and Roche COBAS® TAQMAN® HBV test, Abbott RealTime HBV assay, Siemens VERSANT HBV assay, and Qiagen artus HBV RG kit. J Clin Virol 2017;95:76-83. [PMID: 28892764 DOI: 10.1016/j.jcv.2017.08.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
389 Zoulim F, Lebossé F, Levrero M. Current treatments for chronic hepatitis B virus infections. Curr Opin Virol 2016;18:109-16. [PMID: 27318098 DOI: 10.1016/j.coviro.2016.06.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
390 Chevaliez S, Pawlotsky J. New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings. Journal of Hepatology 2018;69:916-26. [DOI: 10.1016/j.jhep.2018.05.017] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 16.0] [Reference Citation Analysis]
391 Wu D, Rao Q, Chen W, Ji F, Xie Z, Huang K, Chen E, Zhao Y, Ouyang X, Zhang S, Jiang Z, Zhang L, Xu L, Gao H, Li L. Development and validation of a novel score for fibrosis staging in patients with chronic hepatitis B. Liver Int 2018;38:1930-9. [DOI: 10.1111/liv.13756] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
392 Ding R, Zheng J, Huang D, Wang Y, Li X, Zhou X, Yan L, Lu W, Yang Z, Zhang Z. INR-to-platelet ratio (INPR) as a novel noninvasive index for predicting liver fibrosis in chronic hepatitis B. Int J Med Sci 2021;18:1159-66. [PMID: 33526976 DOI: 10.7150/ijms.51799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
393 Tacke F, Boeker KHW, Klinker H, Heyne R, Buggisch P, Pathil A, Wiegand J, Cornberg M, Lange C, Berg T, Zeuzem S, Mauss S. Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. Liver Int 2020;40:539-48. [PMID: 31241820 DOI: 10.1111/liv.14186] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
394 Segeral O, Dim B, Durier C, Prak S, Chhim K, Vong C, Pech S, Tiv S, Nem B, Hout K, Nouhin J, Chhun S, Borand L. Hepatitis B e Antigen (HBeAg) Rapid Test and Alanine Aminotransferase Level-Based Algorithm to Identify Pregnant Women at Risk of HBV Mother-to-Child Transmission: The ANRS 12345 TA PROHM Study. Clin Infect Dis 2020;71:e587-93. [PMID: 32188982 DOI: 10.1093/cid/ciaa282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
395 Yao K, Liu J, Wang J, Yan X, Xia J, Yang Y, Wu W, Liu Y, Chen Y, Zhang Z, Li J, Huang R, Wu C. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat 2021;28:1025-33. [PMID: 33797145 DOI: 10.1111/jvh.13511] [Reference Citation Analysis]
396 Zhou K, Terrault N. Immune tolerant HBV and HCC: time to revise our tolerance levels for therapy? AME Med J 2018;3:27. [PMID: 31058256 DOI: 10.21037/amj.2018.02.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
397 Yamauchi R, Takeyama Y, Takata K, Fukunaga A, Sakurai K, Tanaka T, Fukuda H, Fukuda S, Kunimoto H, Umeda K, Morihara D, Yokoyama K, Irie M, Shakado S, Sakisaka S, Hirai F. Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate. Intern Med 2020;59:1163-6. [PMID: 31956202 DOI: 10.2169/internalmedicine.3805-19] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
398 Shirvani-Dastgerdi E, Winer BY, Celià-Terrassa T, Kang Y, Tabernero D, Yagmur E, Rodríguez-Frías F, Gregori J, Luedde T, Trautwein C, Ploss A, Tacke F. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. J Hepatol 2017;67:246-54. [PMID: 28392234 DOI: 10.1016/j.jhep.2017.03.027] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
399 Squires JE, McKiernan P, Squires RH. Acute Liver Failure: An Update. Clin Liver Dis 2018;22:773-805. [PMID: 30266162 DOI: 10.1016/j.cld.2018.06.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
400 Zhou SN, Zhang N, Liu HH, Xia P, Zhang C, Song JW, Fan X, Shi M, Jin L, Zhang JY, Wang FS. Skewed CD39/CD73/adenosine pathway contributes to B-cell hyperactivation and disease progression in patients with chronic hepatitis B. Gastroenterol Rep (Oxf) 2021;9:49-58. [PMID: 33747526 DOI: 10.1093/gastro/goaa048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
401 Höner Zu Siederdissen C, Hui AJ, Sukeepaisarnjaroen W, Tangkijvanich P, Su WW, Nieto GEG, Gineste P, Nitcheu J, Crabé S, Stepien S, Manns MP, Trépo C, Wedemeyer H, Cornberg M. Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients. J Infect Dis 2018;218:1480-4. [PMID: 29893893 DOI: 10.1093/infdis/jiy350] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
402 Matsumoto A. Hepatitis B core-related antigen: a strong indicator for cessation of nucleos(t)ide analog therapy in patients with chronic hepatitis B. J Gastroenterol 2017;52:127-8. [DOI: 10.1007/s00535-016-1259-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
403 Xue X, Cai S, Ou H, Zheng C, Wu X. Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment. Patient Prefer Adherence 2017;11:85-93. [PMID: 28138226 DOI: 10.2147/PPA.S127139] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
404 Chen ZX, Zhuang X, Zhu XH, Hao YL, Gu GF, Cai MZ, Qin G. Comparative Effectiveness of Prophylactic Strategies for Perinatal Transmission of Hepatitis B Virus: A Network Meta-analysis of Randomized Controlled Trials. Open Forum Infect Dis. 2017;4:ofx225. [PMID: 29181424 DOI: 10.1093/ofid/ofx225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
405 An P, Xu J, Yu Y, Winkler CA. Host and Viral Genetic Variation in HBV-Related Hepatocellular Carcinoma. Front Genet 2018;9:261. [PMID: 30073017 DOI: 10.3389/fgene.2018.00261] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 15.0] [Reference Citation Analysis]
406 Li Q, Lu C, Li W, Huang Y, Chen L. Globulin–platelet model predicts significant fibrosis and cirrhosis in CHB patients with high HBV DNA and mildly elevated alanine transaminase levels. Clin Exp Med 2018;18:71-8. [DOI: 10.1007/s10238-017-0472-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
407 Sinn DH. [Natural History and Treatment Indications of Chronic Hepatitis B]. Korean J Gastroenterol 2019;74:245-50. [PMID: 31765552 DOI: 10.4166/kjg.2019.74.5.245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
408 Caballero A, Tabernero D, Buti M, Rodriguez-Frias F. Hepatitis B virus: The challenge of an ancient virus with multiple faces and a remarkable replication strategy. Antiviral Res 2018;158:34-44. [PMID: 30059722 DOI: 10.1016/j.antiviral.2018.07.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
409 Wu X, Cai B, Su Z, Li Y, Xu J, Deng R, Wang L. Aspartate transaminase to platelet ratio index and gamma-glutamyl transpeptidase-to-platelet ratio outweigh fibrosis index based on four factors and red cell distribution width-platelet ratio in diagnosing liver fibrosis and inflammation in chronic hepatitis B. J Clin Lab Anal. 2018;32:e22341. [PMID: 29251384 DOI: 10.1002/jcla.22341] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
410 Al-Qahtani AA, Al-Anazi MR, Nazir N, Abdo AA, Sanai FM, Al-Hamoudi WK, Alswat KA, Al-Ashgar HI, Khan MQ, Albenmousa A, El-Shamy A, Alanazi SK, Dela Cruz D, Bohol MFF, Al-Ahdal MN. The Correlation Between Hepatitis B Virus Precore/Core Mutations and the Progression of Severe Liver Disease. Front Cell Infect Microbiol. 2018;8:355. [PMID: 30406036 DOI: 10.3389/fcimb.2018.00355] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
411 Wu D, Ning Q. Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome. J Infect Dis. 2017;216:S771-S777. [PMID: 29156046 DOI: 10.1093/infdis/jix355] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
412 Chen XF, Fan YN, Si CW, Yu YY, Shang J, Yu ZJ, Mao Q, Xie Q, Zhao W, Li J, Gao ZL, Wu SM, Tang H, Cheng J, Chen XY, Zhang WH, Wang H, Xu ZN, Wang L, Dai J, Xu JH. Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks. World J Clin Cases 2021;9:4690-9. [PMID: 34222435 DOI: 10.12998/wjcc.v9.i18.4690] [Reference Citation Analysis]
413 Cao J, Chi H, Yu T, Li Z, Hansen BE, Zhang X, Zhong C, Sun J, Hou J, Janssen HLA. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study. J Infect Dis. 2017;215:581-589. [PMID: 28329347 DOI: 10.1093/infdis/jix025] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 8.5] [Reference Citation Analysis]
414 Komatsu H, Inui A, Fujisawa T. Pediatric hepatitis B treatment. Ann Transl Med 2017;5:37. [PMID: 28251116 DOI: 10.21037/atm.2016.11.52] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
415 Sarpel D, Baichoo E, Dieterich DT. Chronic hepatitis B and C infection in the United States: a review of current guidelines, disease burden and cost effectiveness of screening. Expert Review of Anti-infective Therapy 2016;14:511-21. [DOI: 10.1586/14787210.2016.1174066] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
416 Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C, Salvadori N, Cressey TR, Sirirungsi W, Achalapong J, Yuthavisuthi P, Kanjanavikai P, Na Ayudhaya OP, Siriwachirachai T, Prommas S, Sabsanong P, Limtrakul A, Varadisai S, Putiyanun C, Suriyachai P, Liampongsabuddhi P, Sangsawang S, Matanasarawut W, Buranabanjasatean S, Puernngooluerm P, Bowonwatanuwong C, Puthanakit T, Klinbuayaem V, Thongsawat S, Thanprasertsuk S, Siberry GK, Watts DH, Chakhtoura N, Murphy TV, Nelson NP, Chung RT, Pol S, Chotivanich N. Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. N Engl J Med 2018;378:911-23. [PMID: 29514030 DOI: 10.1056/NEJMoa1708131] [Cited by in Crossref: 148] [Cited by in F6Publishing: 54] [Article Influence: 49.3] [Reference Citation Analysis]
417 Lembo T, Saffioti F, Chiofalo B, Granese R, Filomia R, Grasso R, Triolo O, Raimondo G. Low prevalence of hepatitis B and hepatitis C virus serum markers in a cohort of pregnant women from Southern Italy. Dig Liver Dis. 2017;49:1368-1372. [PMID: 28818677 DOI: 10.1016/j.dld.2017.07.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
418 Ma T, Lee LY, Aw MM, Lee GH. Cost-effectiveness analysis of antiviral treatment for pregnant women with high viral load to prevent hepatitis B virus vertical transmission. Singapore Med J 2020;61:24-7. [PMID: 31388686 DOI: 10.11622/smedj.2019092] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
419 Chen L, Zhu C, Li F, Wang Y, Bao R, Cao Z, Xiang X, Yan L, Lin L, Zhao G, Xie Q, Bao S, Wang H. Correlation between hepatic human males absent on the first (hMOF) and viral persistence in chronic hepatitis B patients. Cell Biosci 2018;8:14. [PMID: 29484170 DOI: 10.1186/s13578-018-0215-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
420 Li H, Zhang L, Ren H, Hu P. Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B. Infect Drug Resist 2018;11:671-80. [PMID: 29765238 DOI: 10.2147/IDR.S163765] [Reference Citation Analysis]
421 Yao X, Huang S, Zhou H, Tang S, Qin J. Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt. WJG 2021;27:5088-99. [DOI: 10.3748/wjg.v27.i30.5088] [Reference Citation Analysis]
422 Wang J, Jia J, Chen R, Ding S, Xu Q, Zhang T, Chen X, Liu S, Lu F. RFX1 participates in doxorubicin-induced hepatitis B virus reactivation. Cancer Med 2018;7:2021-33. [PMID: 29601674 DOI: 10.1002/cam4.1468] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
423 Jeng WJ, Chen YC, Chien RN, Sheen IS, Liaw YF. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2018;68:425-434. [PMID: 29108132 DOI: 10.1002/hep.29640] [Cited by in Crossref: 100] [Cited by in F6Publishing: 77] [Article Influence: 33.3] [Reference Citation Analysis]
424 Liu Y, Maya S, Ploss A. Animal Models of Hepatitis B Virus Infection-Success, Challenges, and Future Directions. Viruses 2021;13:777. [PMID: 33924793 DOI: 10.3390/v13050777] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
425 Zhou K, Terrault N. Management of hepatitis B in special populations. Best Pract Res Clin Gastroenterol. 2017;31:311-320. [PMID: 28774413 DOI: 10.1016/j.bpg.2017.06.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
426 Parikh P, Ryan JD, Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Ann Transl Med. 2017;5:40. [PMID: 28251119 DOI: 10.21037/atm.2017.01.28] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
427 Auriti C, De Rose DU, Santisi A, Martini L, Piersigilli F, Bersani I, Ronchetti MP, Caforio L. Pregnancy and viral infections: Mechanisms of fetal damage, diagnosis and prevention of neonatal adverse outcomes from cytomegalovirus to SARS-CoV-2 and Zika virus. Biochim Biophys Acta Mol Basis Dis 2021;1867:166198. [PMID: 34118406 DOI: 10.1016/j.bbadis.2021.166198] [Reference Citation Analysis]
428 Janssen HLA, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen AH, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Yoshida EM, Ahn SH, Tsai NCS, Fung S, Gane EJ. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. J Hepatol. 2018;68:431-440. [PMID: 29104121 DOI: 10.1016/j.jhep.2017.10.027] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 19.0] [Reference Citation Analysis]
429 Wu Y, Wang X, Lin X, Shen C, Chen X. Quantitative of serum hepatitis B core antibody is a potential predictor of recurrence after interferon-induced hepatitis B surface antigen clearance. J Microbiol Immunol Infect 2021;54:238-44. [PMID: 31784245 DOI: 10.1016/j.jmii.2019.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
430 Biset Ayalew M, Adugna Horsa B. Hepatitis B Vaccination Status among Health Care Workers in a Tertiary Hospital in Ethiopia. Hepat Res Treat 2017;2017:6470658. [PMID: 28751988 DOI: 10.1155/2017/6470658] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
431 Atasoy HI, Sirmatel P, Sirmatel F. Pegylated interferon therapy during early pregnancy for hepatitis B infection: does it prevent vertical transmission? J Matern Fetal Neonatal Med 2017;30:745-7. [PMID: 27125766 DOI: 10.1080/14767058.2016.1183639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
432 Li XK, Zhang MX, Shao FZ, Zhou DQ, Xue JD, Liu TJ, Chi XL, Lu BJ, Wang XB, Li Q, Li J, Mao DW, Yang HS, Yang HZ, Zhao WX, Li Y, Zhang GL, Zhao YM, Zou JD, Liu MY, Zhang KK, Yang XZ, Gan DN, Li Y, Zhang P, Li ZG, Li S, Ye YA. Adefovir Dipivoxil plus Chinese Medicine in HBeAg-Positive Chronic Hepatitis B Patients: A Randomized Controlled 48-Week Trial. Chin J Integr Med 2020;26:330-8. [PMID: 31919749 DOI: 10.1007/s11655-020-3250-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
433 Kim YA, Estevez J, Le A, Israelski D, Baatarkhuu O, Sarantuya T, Narantsetseg S, Nymadawa P, H Le R, Yuen MF, Dusheiko G, Rizzetto M, Nguyen MH. Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia. BMJ Open Gastroenterol 2016;3:e000119. [PMID: 27933202 DOI: 10.1136/bmjgast-2016-000119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
434 Yin GQ, Li J, Zhong B, Yang YF, Wang MR. New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage. World J Gastroenterol 2021;27:666-76. [PMID: 33716446 DOI: 10.3748/wjg.v27.i8.666] [Reference Citation Analysis]
435 Li FC, Li YK, Fan YC. Biomarkers for hepatitis B virus replication: an overview and a look to the future. Expert Rev Gastroenterol Hepatol 2020;14:1131-9. [PMID: 32887529 DOI: 10.1080/17474124.2020.1815530] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
436 Martin P. Immune-Tolerant Hepatitis B: Maybe a Misnomer but Still Hard to Treat. Hepatology 2019;69:2315-7. [PMID: 30964209 DOI: 10.1002/hep.30654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
437 Hardtstock F, Sbarigia U, Kocaata Z, Wilke T, Sylvester SV. Preferences of Patients with Chronic Hepatitis B - A Discrete Choice Experiment on the Acceptability of Functional Cure. Patient Prefer Adherence 2020;14:613-24. [PMID: 32256052 DOI: 10.2147/PPA.S238833] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
438 Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, Jiang J, Xie Q, Dou X, Sun Y, Li Y, Liu Y, Liu G, Mao D, Chi X, Tang H, Li X, Xie Y, Chen X, Jiang J, Zhao P, Hou J, Gao Z, Fan H, Ding J, Zhang D, Ren H. HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. J Clin Transl Hepatol 2018;6:25-34. [PMID: 29577029 DOI: 10.14218/JCTH.2017.00072] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 9.7] [Reference Citation Analysis]
439 Xun Z, Liu C, Yu QQ, Lin JP, Huang JL, Yang TW, Wu WN, Wu SH, Ou QS. Albumin-bilirubin score is associated with response to pegylated interferon and nucleos(t)ide analogues in chronic hepatitis B patients. Clin Chim Acta 2020;502:120-7. [PMID: 31891671 DOI: 10.1016/j.cca.2019.12.020] [Reference Citation Analysis]
440 Zhang P, Du H, Tong G, Li X, Sun X, Chi X, Xing Y, Zhou Z, Li Q, Chen B, Wang H, Wang L, Jin H, Mao D, Wang X, Wu Q, Li F, Hu X, Lu B, Yang Z, Zhang M, Shi W, He Q, Li Y, Jiang K, Xue J, Li X, Jiang J, Lu W, Tian G, Hu Z, Guo J, Li C, Deng X, Luo X, Li F, Zhang X, Zheng Y, Zhao G, Wang L, Wu J, Guo H, Mi Y, Gong Z, Wang C, Jiang F, Guo P, Yang X, Shi W, Yang H, Zhou Y, Sun N, Jiao Y, Gao Y, Zhou D, Ye Y. Serum hepatitis B surface antigen correlates with fibrosis and necroinflammation: A multicentre perspective in China. J Viral Hepat 2018;25:1017-25. [DOI: 10.1111/jvh.12903] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
441 Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. The Lancet Gastroenterology & Hepatology 2017;2:123-34. [DOI: 10.1016/s2468-1253(16)30076-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 3] [Article Influence: 5.3] [Reference Citation Analysis]
442 Shimakawa Y, Vernoux L, Gabassi A, Mercier-Delarue S, Vincent JP, Simon F, Maylin S. Analytical validation of hepatitis B core-related antigen (HBcrAg) using dried blood spots (DBS). J Viral Hepat 2021;28:837-43. [PMID: 33599049 DOI: 10.1111/jvh.13489] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
443 Arora A, Anand AC, Kumar A, Singh SP, Aggarwal R, Dhiman RK, Aggarwal S, Alam S, Bhaumik P, Dixit VK, Goel A, Goswami B, Kumar A, Kumar M, Madan K, Murugan N, Nagral A, Puri AS, Rao PN, Saraf N, Saraswat VA, Sehgal S, Sharma P, Shenoy KT, Wadhawan M; Members of the INASL taskforce on Hepatitis B. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids. J Clin Exp Hepatol 2018;8:403-31. [PMID: 30568345 DOI: 10.1016/j.jceh.2018.06.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
444 Nguyen VH, Le AK, Trinh HN, Chung M, Johnson T, Wong C, Wong C, Zhang J, Li J, Levitt BS, Nguyen HA, Nguyen KK, Henry L, Cheung R, Nguyen MH. Poor Adherence to Guidelines for Treatment of Chronic Hepatitis B Virus Infection at Primary Care and Referral Practices. Clinical Gastroenterology and Hepatology 2019;17:957-967.e7. [DOI: 10.1016/j.cgh.2018.10.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
445 Chen L, Cao Z, Yan L, Ding Y, Shen X, Liu K, Xiang X, Xie Q, Zhu C, Bao S, Wang H. Circulating Receptor-Interacting Protein Kinase 3 Are Increased in HBV Patients With Acute-on-Chronic Liver Failure and Are Associated With Clinical Outcome. Front Physiol 2020;11:526. [PMID: 32655398 DOI: 10.3389/fphys.2020.00526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
446 Freeland C, Farrell S, Kumar P, Kamischke M, Jackson M, Bodor S, Block TM, Frasso R, Cohen C. Common concerns, barriers to care, and the lived experience of individuals with hepatitis B: a qualitative study. BMC Public Health 2021;21:1004. [PMID: 34044808 DOI: 10.1186/s12889-021-11093-0] [Reference Citation Analysis]
447 Lee HW, Park SY, Lee M, Lee EJ, Lee J, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia. Liver Int. 2020;40:1736-1743. [PMID: 32239602 DOI: 10.1111/liv.14451] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
448 Cho EJ, Yu SJ, Kwon SY, Kim JH, Kim DY, Kim W, Lee JS, Lee JW, Lee YJ, Chae HB, Yoon JH. Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial. Drug Des Devel Ther 2018;12:3767-74. [PMID: 30464407 DOI: 10.2147/DDDT.S181561] [Reference Citation Analysis]
449 Gu Y, Chen L, Lian Y, Gu L, Chen Y, Bi Y, Huang Z, Huang Y, Hu B, Huang Y. Serum HBV pregenomic RNA is correlated with Th1/Th2 immunity in treatment-naïve chronic hepatitis B patients. J Med Virol 2020;92:317-28. [PMID: 31642539 DOI: 10.1002/jmv.25612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
450 Jing W, Liu J, Liu M. Eliminating mother-to-child transmission of HBV: progress and challenges in China. Front Med 2020;14:21-9. [PMID: 31974872 DOI: 10.1007/s11684-020-0744-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
451 Yao M, Wang L, You H, Wang J, Liao H, Yang D, Liu S, Xu Q, Chen X, Jia J, Zhao J, Lu F. Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B. Clin Chim Acta 2019;493:92-7. [PMID: 30796901 DOI: 10.1016/j.cca.2019.02.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
452 Price H, Dunn D, Zachary T, Vudriko T, Chirara M, Kityo C, Munderi P, Spyer M, Hakim J, Gilks C, Kaleebu P, Pillay D, Gilson R; DART Virology Group. Hepatitis B serological markers and plasma DNA concentrations. AIDS 2017;31:1109-17. [PMID: 28328795 DOI: 10.1097/QAD.0000000000001454] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
453 Zhang TY, Guo XR, Wu YT, Kang XZ, Zheng QB, Qi RY, Chen BB, Lan Y, Wei M, Wang SJ, Xiong HL, Cao JL, Zhang BH, Qiao XY, Huang XF, Wang YB, Fang MJ, Zhang YL, Cheng T, Chen YX, Zhao QJ, Li SW, Ge SX, Chen PJ, Zhang J, Yuan Q, Xia NS. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut 2020;69:343-54. [PMID: 30926653 DOI: 10.1136/gutjnl-2018-317725] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
454 Jung WJ, Jang JY, Park WY, Jeong SW, Lee HJ, Park SJ, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Park S, Baymbajav B. Effect of tenofovir on renal function in patients with chronic hepatitis B. Medicine (Baltimore) 2018;97:e9756. [PMID: 29443737 DOI: 10.1097/MD.0000000000009756] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 4.7] [Reference Citation Analysis]
455 Choi J, Yoo S, Lim YS. Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance. Hepatology 2021;73:2155-66. [PMID: 33131063 DOI: 10.1002/hep.31610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
456 Chen W, Lin C, Gong L, Chen J, Liang Y, Zeng P, Diao H. Comprehensive Analysis of the mRNA-lncRNA Co-expression Profile and ceRNA Networks Patterns in Chronic Hepatitis B. Curr Genomics 2019;20:231-45. [PMID: 32030083 DOI: 10.2174/1389202920666190820122126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
457 Cao Z, Li J, Wang Y, Bao R, Liu Y, Xiang X, Lin L, Ye F, Lu J, Xie Q, Bao S, Wang H. Serum hepatocyte apoptosis biomarker predicts the presence of significant histological lesion in chronic hepatitis B virus infection. Digestive and Liver Disease 2016;48:1463-70. [DOI: 10.1016/j.dld.2016.07.037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
458 Seo HY, Lee HA, Ko SY, Wang JH, Kim JH, Choe WH, Kwon SY. Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B. Clin Mol Hepatol 2017;23:154-9. [PMID: 28479588 DOI: 10.3350/cmh.2016.0067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
459 Liu S, Zhou B, Valdes JD, Sun J, Guo H. Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection. Hepatology 2019;69:1816-27. [PMID: 30362148 DOI: 10.1002/hep.30325] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 28.0] [Reference Citation Analysis]
460 Oliveri F, Surace L, Cavallone D, Colombatto P, Ricco G, Salvati N, Coco B, Romagnoli V, Gattai R, Salvati A. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance. Liver Int. 2017;37:1622-1631. [PMID: 28296013 DOI: 10.1111/liv.13416] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
461 Kho-herman SGR, Chan HL. Stopping nucleos(t)ide analog treatment in chronic hepatitis B — Who and when? Liver Research 2017;1:135-9. [DOI: 10.1016/j.livres.2017.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
462 Chen C, Hsu Y, Lu S, Hung C, Wang J, Lee C, Hu T. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients. J Viral Hepat 2018;25:590-7. [DOI: 10.1111/jvh.12851] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
463 Trivella JP, Martin P, Carrion AF. Novel targeted therapies for the management of liver fibrosis. Expert Opinion on Emerging Drugs 2020;25:59-70. [DOI: 10.1080/14728214.2020.1735350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
464 Anderson RT, Choi HSJ, Lenz O, Peters MG, Janssen HLA, Mishra P, Donaldson E, Westman G, Buchholz S, Miller V, Hansen BE. Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021;19:463-72. [PMID: 32473348 DOI: 10.1016/j.cgh.2020.05.041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
465 Chamroonkul N, Piratvisuth T. Hepatitis B During Pregnancy in Endemic Areas: Screening, Treatment, and Prevention of Mother-to-Child Transmission. Paediatr Drugs 2017;19:173-81. [PMID: 28434087 DOI: 10.1007/s40272-017-0229-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
466 Shiels MS, Engels EA, Yanik EL, McGlynn KA, Pfeiffer RM, O'Brien TR. Incidence of hepatocellular carcinoma among older Americans attributable to hepatitis C and hepatitis B: 2001 through 2013. Cancer 2019;125:2621-30. [PMID: 30980394 DOI: 10.1002/cncr.32129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
467 Liu J, Wang J, Yan T, Du D, Qi C, Cao F, Yao N, Yang Y, He Y, Tian Z, Ren D, Zhu L, Chen T, Zhao Y. Efficacy and safety of telbivudine and tenofovir disoproxil fumarate in preventing hepatitis B vertical transmission: A real-life practice. J Viral Hepat 2019;26:1170-7. [PMID: 31177596 DOI: 10.1111/jvh.13156] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
468 Yip TC, Chan HL, Wong VW, Tse Y, Lam KL, Wong GL. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Journal of Hepatology 2017;67:902-8. [DOI: 10.1016/j.jhep.2017.06.019] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 18.8] [Reference Citation Analysis]
469 Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease. Clin Liver Dis. 2016;20:607-628. [PMID: 27742003 DOI: 10.1016/j.cld.2016.06.006] [Cited by in Crossref: 115] [Cited by in F6Publishing: 87] [Article Influence: 38.3] [Reference Citation Analysis]
470 Borgia G, Maraolo AE, Gentile I. Hepatitis B mother-to-child transmission and infants immunization: we have not come to the end of the story yet. Infect Dis (Lond). 2017;49:584-587. [PMID: 28316268 DOI: 10.1080/23744235.2017.1303746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
471 Okada M, Enomoto M, Kawada N, Nguyen MH. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Expert Rev Gastroenterol Hepatol. 2017;11:1095-1104. [PMID: 28752768 DOI: 10.1080/17474124.2017.1361822] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
472 Heo NY. Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign? Clin Mol Hepatol 2017;23:125-7. [PMID: 28669139 DOI: 10.3350/cmh.2017.0106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
473 Du Y, Han X, Ding YB, Yin JH, Cao GW. Prediction and prophylaxis of hepatocellular carcinoma occurrence and postoperative recurrence in chronic hepatitis B virus-infected subjects. World J Gastroenterol 2016;22:6565-72. [PMID: 27547000 DOI: 10.3748/wjg.v22.i29.6565] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
474 Li Q, Li W, Huang Y, Chen L. The gamma-glutamyl transpeptidase-to-platelet ratio predicts liver fibrosis and cirrhosis in HBeAg-positive chronic HBV infection patients with high HBV DNA and normal or mildly elevated alanine transaminase levels in China. J Viral Hepat. 2016;23:912-919. [PMID: 27375134 DOI: 10.1111/jvh.12563] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
475 Chang CY, Aziz N, Poongkunran M, Javaid A, Trinh HN, Lau DT, Nguyen MH. Serum Aminotransferase Flares in Pregnant and Postpartum Women With Current or Prior Treatment for Chronic Hepatitis B. Journal of Clinical Gastroenterology 2018;52:255-61. [DOI: 10.1097/mcg.0000000000000822] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
476 Ray G. Current Scenario of Hepatitis B and Its Treatment in India. J Clin Transl Hepatol 2017;5:277-96. [PMID: 28936409 DOI: 10.14218/JCTH.2017.00024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
477 Teschke R, Danan G. Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue? Expert Opin Drug Metab Toxicol. 2017;13:425-438. [PMID: 27822971 DOI: 10.1080/17425255.2017.1252749] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
478 Wu R, Zhang Y, Xiang Y, Tang Y, Cui F, Cao J, Zhou L, You Y, Duan L. Association between serum S100A9 levels and liver necroinflammation in chronic hepatitis B. J Transl Med 2018;16:83. [PMID: 29615081 DOI: 10.1186/s12967-018-1462-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
479 Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA, Singh S, Mohamed EA, Abu Dabrh AM, Prokop LJ, Wang Z, Murad MH, Mohammed K. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. 2016;63:284-306. [PMID: 26566246 DOI: 10.1002/hep.28280] [Cited by in Crossref: 239] [Cited by in F6Publishing: 207] [Article Influence: 39.8] [Reference Citation Analysis]
480 Hu Y, Yu H. Prevention strategies of mother-to-child transmission of hepatitis B virus (HBV) infection. Pediatr Investig 2020;4:133-7. [PMID: 32851357 DOI: 10.1002/ped4.12205] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
481 Merriman RB, Tran TT. AASLD practice guidelines: The past, the present, and the future. Hepatology. 2016;63:31-34. [PMID: 26565582 DOI: 10.1002/hep.28345] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
482 Garcia-Garcia S, Cortese MF, Rodríguez-Algarra F, Tabernero D, Rando-Segura A, Quer J, Buti M, Rodríguez-Frías F. Next-generation sequencing for the diagnosis of hepatitis B: current status and future prospects. Expert Rev Mol Diagn 2021;21:381-96. [PMID: 33880971 DOI: 10.1080/14737159.2021.1913055] [Reference Citation Analysis]
483 Lee I, Yang S, Lee C, Su C, Wang Y, Lan K, Lin H, Hou M, Peng C, Huang Y. Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-Negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study. The Journal of Infectious Diseases 2018;218:1075-84. [DOI: 10.1093/infdis/jiy272] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
484 Shen Z, Gao Z, Gu C, Wu J, Wang J, Zhang J, Xie Y, Liu J. Prior transient exposure to interleukin-21 delivered by recombinant adeno-associated virus vector protects mice from hepatitis B virus persistence. Antiviral Res 2021;190:105076. [PMID: 33865876 DOI: 10.1016/j.antiviral.2021.105076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
485 Hsu WF, Chen CF, Lai HC, Su WP, Lin CH, Chuang PH, Chen SH, Chen CH, Wang HW, Huang GT, Peng CY. Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy. Liver Int 2018;38:627-35. [PMID: 28857411 DOI: 10.1111/liv.13564] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
486 Liao Y, Gong J, Zhou W, Dong H, Liang J, Luo M, Hu B. Serum liver fibrosis markers discriminate significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase. J Med Virol 2019;91:642-9. [PMID: 30537157 DOI: 10.1002/jmv.25364] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
487 Chen JZ, Liao ZW, Huang FL, Su RK, Wang WB, Cheng XY, Chen JQ, Liu JQ, Huang Z. Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load. Sci Rep 2017;7:4132. [PMID: 28646142 DOI: 10.1038/s41598-017-04479-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
488 Dessordi R, Santana RC, Navarro AM. Influence of antiretroviral therapy on bone metabolism of patients with chronic hepatitis B: a review. Rev Soc Bras Med Trop 2019;52:e20180441. [PMID: 31596347 DOI: 10.1590/0037-8682-0441-2018] [Reference Citation Analysis]
489 Lee LY, Chan SM, Ong C, M Aw M, Wong F, Saw S, Lee GH, Thoon KC, Phua KB. Comparing monovalent and combination hepatitis B vaccine outcomes in children delivered by mothers with chronic hepatitis B. J Paediatr Child Health 2019;55:327-32. [PMID: 30161273 DOI: 10.1111/jpc.14194] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
490 Lazear HM, Schoggins JW, Diamond MS. Shared and Distinct Functions of Type I and Type III Interferons. Immunity 2019;50:907-23. [PMID: 30995506 DOI: 10.1016/j.immuni.2019.03.025] [Cited by in Crossref: 267] [Cited by in F6Publishing: 213] [Article Influence: 133.5] [Reference Citation Analysis]
491 Wu I, Hu T, Hung C, Lu S, Wang J, Lee C, Chen C. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study. Clinical Microbiology and Infection 2017;23:464-9. [DOI: 10.1016/j.cmi.2017.02.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
492 Yu JH, Lee JI. Current role of transient elastography in the management of chronic hepatitis B patients. Ultrasonography. 2017;36:86-94. [PMID: 27956732 DOI: 10.14366/usg.16023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
493 Hsu Y, Jun T, Huang Y, Yeh M, Lee C, Ogawa S, Cho S, Lin J, Yu M, Nguyen MH, Tanaka Y. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B. Aliment Pharmacol Ther 2018;48:1128-37. [DOI: 10.1111/apt.15006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
494 Wu W, Zhu Y, Yu C, Yang S, Ruan B, Chen Y, Li L. Clinical features of treatment-naive patients with hepatitis B virus infection: A community-based survey from high- and intermediate-hepatitis B endemicity regions in Southeast China. Medicine (Baltimore) 2017;96:e6660. [PMID: 28422873 DOI: 10.1097/MD.0000000000006660] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
495 Yamagiwa Y, Masaki N. Factors improving the utility of antiviral therapy for chronic hepatitis B: A nationwide multicenter study in Japan. Hepatol Res 2018;48:1069-80. [PMID: 29934990 DOI: 10.1111/hepr.13221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
496 Moore MS, Ivanina E, Bornschlegel K, Qiao B, Schymura MJ, Laraque F. Hepatocellular Carcinoma and Viral Hepatitis in New York City. Clin Infect Dis 2016;63:1577-83. [PMID: 27585801 DOI: 10.1093/cid/ciw605] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
497 Zampino R, Capoluongo N, Boemio A, Macera M, Vitrone M, Adinolfi LE, Filippini P, Sagnelli E, Sagnelli C, Durante-Mangoni E, Coppola N. Effect of a Cooperation Strategy between Primary Care Physicians and Hospital Liver Units on HBV Care in Campania, Italy. Can J Gastroenterol Hepatol 2018;2018:5670374. [PMID: 30148123 DOI: 10.1155/2018/5670374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
498 King H, Xing J, Dean HD, Holtzman D. Trends in Prevalence of Protective Levels of Hepatitis B Surface Antibody Among Adults Aged 18-49 Years With Risk Factors for Hepatitis B Virus Infection-United States, 2003-2014. Clin Infect Dis 2020;70:1907-15. [PMID: 31228240 DOI: 10.1093/cid/ciz537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
499 Rajbhandari R, Chung RT. Treatment of Hepatitis B: A Concise Review. Clin Transl Gastroenterol 2016;7:e190. [PMID: 27628420 DOI: 10.1038/ctg.2016.46] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
500 Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833-51. [PMID: 34297329 DOI: 10.1007/s12072-021-10223-5] [Reference Citation Analysis]
501 Pan CQ, Li MH, Yi W, Zhang L, Lu Y, Hao HX, Wan G, Cao WH, Wang XY, Ran CP, Shen G, Wu SL, Chang M, Gao YJ, Xie Y. Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens. Liver Int 2021;41:1498-508. [PMID: 33486874 DOI: 10.1111/liv.14801] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
502 Cai S, Li Z, Yu T, Xia M, Peng J. Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs. Infect Drug Resist 2018;11:469-77. [PMID: 29662321 DOI: 10.2147/IDR.S163038] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
503 Safadi R, Khoury T, Saed N, Hakim M, Jamalia J, Nijim Y, Farah N, Nuser T, Natur N, Mahamid M, Amer J, Roppert PL, Gerlich WH, Glebe D. Efficacy of Birth Dose Vaccination in Preventing Mother-to-Child Transmission of Hepatitis B: A Randomized Controlled Trial Comparing Engerix-B and Sci-B-Vac. Vaccines (Basel) 2021;9:331. [PMID: 33915943 DOI: 10.3390/vaccines9040331] [Reference Citation Analysis]
504 Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: From discovery to regulatory approval. Hepatology. 2017;66:1296-1313. [PMID: 28762522 DOI: 10.1002/hep.29323] [Cited by in Crossref: 129] [Cited by in F6Publishing: 118] [Article Influence: 32.3] [Reference Citation Analysis]
505 Jacobson IM, Washington MK, Buti M, Thompson A, Afdhal N, Flisiak R, Akarca US, Tchernev KG, Flaherty JF, Aguilar Schall R, Myers RP, Subramanian GM, Mchutchison JG, Younossi Z, Marcellin P, Patel K. Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. Clinical Gastroenterology and Hepatology 2017;15:1087-1094.e2. [DOI: 10.1016/j.cgh.2017.01.032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
506 van Bömmel F, Berg T. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B. Liver Int 2018;38 Suppl 1:90-6. [PMID: 29427489 DOI: 10.1111/liv.13654] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
507 Wan YM, Li YH, Xu ZY, Wu HM, Xu Y, Wu XN, Yang JH. Tenofovir Versus Entecavir for the Treatment of Acute-on-Chronic Liver Failure due to Reactivation of Chronic Hepatitis B With Genotypes B and C. J Clin Gastroenterol 2019;53:e171-7. [PMID: 29659382 DOI: 10.1097/MCG.0000000000001038] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
508 Zhang ZQ, Wang YB, Lu W, Liu DP, Shi BS, Zhang XN, Huang D, Li XF, Zhou XL, Ding RR. Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis. Ann Lab Med 2019;39:67-75. [PMID: 30215232 DOI: 10.3343/alm.2019.39.1.67] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
509 McGowan DC, Herschke F, Pauwels F, Stoops B, Smyej I, Last S, Pieters S, Embrechts W, Khamlichi MD, Thoné T, Van Schoubroeck B, Mostmans W, Wuyts D, Verstappen D, Scholliers A, De Pooter D, Dhuyvetter D, Borghys H, Tuefferd M, Arnoult E, Hong J, Fanning G, Bollekens J, Urmaliya V, Teisman A, Horton H, Jonckers THM, Raboisson P. Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B. J Med Chem 2017;60:6137-51. [PMID: 28671847 DOI: 10.1021/acs.jmedchem.7b00365] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
510 Wu YL, Shen CL, Chen XY. Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis. World J Clin Cases 2019;7:1784-94. [PMID: 31417924 DOI: 10.12998/wjcc.v7.i14.1784] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
511 Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. WJH 2020;12:210-9. [DOI: 10.4254/wjh.v12.i5.210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
512 van Campenhout MJH, Brouwer WP, Xie Q, Guo S, Chi H, Qi X, Tabak F, Streinu-Cercel A, Wang JY, Zhang NP, Idilman R, Reesink HW, Diculescu M, Simon K, Akdogan M, Mazur W, de Knegt RJ, Verhey E, Hansen BE, Janssen HLA; ARES Study Group. Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up. J Viral Hepat 2019;26:109-17. [PMID: 30187612 DOI: 10.1111/jvh.12997] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
513 Cao Z, Li Z, Wang Y, Liu Y, Mo R, Ren P, Chen L, Lu J, Li H, Zhuang Y, Liu Y, Wang X, Zhao G, Tang W, Xiang X, Wang H, Cai W, Liu L, Zhu C, Bao S, Xie Q. Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection. J Viral Hepat. 2017;24 Suppl 1:57-65. [PMID: 29082644 DOI: 10.1111/jvh.12786] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
514 Spearman CW, Afihene M, Ally R, Apica B, Awuku Y, Cunha L, Dusheiko G, Gogela N, Kassianides C, Kew M, Lam P, Lesi O, Lohouès-Kouacou MJ, Mbaye PS, Musabeyezu E, Musau B, Ojo O, Rwegasha J, Scholz B, Shewaye AB, Tzeuton C, Sonderup MW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. Lancet Gastroenterol Hepatol 2017;2:900-9. [PMID: 29132759 DOI: 10.1016/S2468-1253(17)30295-9] [Cited by in Crossref: 98] [Cited by in F6Publishing: 57] [Article Influence: 32.7] [Reference Citation Analysis]
515 Boudewijns R, Ma J, Neyts J, Dallmeier K. A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice. JHEP Rep 2021;3:100295. [PMID: 34159304 DOI: 10.1016/j.jhepr.2021.100295] [Reference Citation Analysis]
516 Suzuki F, Hosaka T, Suzuki Y, Sezaki H, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan. J Gastroenterol 2019;54:182-93. [PMID: 30136216 DOI: 10.1007/s00535-018-1502-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
517 Yenilmez E, Çetinkaya RA, Tural E. Diagnostic Dilemma for Low Viremia with Significant Fibrosis; is Hepatitis B Virus DNA Threshold Level a Good Indicator for Predicting Liver Damage? Balkan Med J 2018;35:326-32. [PMID: 29726399 DOI: 10.4274/balkanmedj.2017.0888] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
518 Zhou J, Song L, Zhao H, Yan L, Ma A, Xie S, Zhang X, Zhang D, Xie Q, Zhang G, Shang J, Cheng J, Zhao W, Zou Z, Zhang M, Xia N, Wang G. Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase. Sci Rep 2017;7:2747. [PMID: 28584279 DOI: 10.1038/s41598-017-03102-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
519 Sbarigia U, Vincken T, Wigfield P, Hashim M, Heeg B, Postma M. A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients. J Comp Eff Res 2020;9:1051-65. [PMID: 32945178 DOI: 10.2217/cer-2020-0068] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
520 Yip TC, Wong GL, Wong VW, Tse Y, Lui GC, Lam KL, Chan HL. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. Journal of Hepatology 2018;68:63-72. [DOI: 10.1016/j.jhep.2017.09.018] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 14.7] [Reference Citation Analysis]
521 Na HG, Imran A, Kim K, Han HS, Lee YJ, Kim MJ, Yun CS, Jung YS, Lee JY, Han SB. Discovery of a New Sulfonamide Hepatitis B Capsid Assembly Modulator. ACS Med Chem Lett 2020;11:166-71. [PMID: 32071684 DOI: 10.1021/acsmedchemlett.9b00550] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
522 Park J, Cho H, Choi SJ, Lee GD, Sin SH, Ryu JH, Park HS, Lee H, Kim Y, Oh EJ. Performance Evaluation of the Beckman Coulter DxN VERIS Hepatitis B Virus (HBV) Assay in Comparison With the Abbott RealTime HBV Assay. Ann Lab Med 2019;39:86-90. [PMID: 30215235 DOI: 10.3343/alm.2019.39.1.86] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
523 Ormaechea MS, Hassan M, Onghanseng N, Park JH, Mahajan S, Al-Kirwi KY, Uludag G, Halim MS, Schlaen A, Sepah YJ, Do DV, Nguyen QD. Safety of systemic therapy for noninfectious uveitis. Expert Opin Drug Saf 2019;18:1219-35. [PMID: 31801415 DOI: 10.1080/14740338.2019.1692810] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
524 Kim JH, Sinn DH, Gwak G, Kang W, Paik Y, Choi MS, Lee JH, Koh KC, Paik SW. Insulin resistance and the risk of hepatocellular carcinoma in chronic hepatitis B patients: Insulin resistance and hepatitis B. Journal of Gastroenterology and Hepatology 2017;32:1100-6. [DOI: 10.1111/jgh.13647] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
525 Childs-Kean LM, Egelund EF, Jourjy J. Tenofovir Alafenamide for the Treatment of Chronic Hepatitis B Monoinfection. Pharmacotherapy 2018;38:1051-7. [PMID: 30120841 DOI: 10.1002/phar.2174] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
526 Dusséaux M, Masse-Ranson G, Darche S, Ahodantin J, Li Y, Fiquet O, Beaumont E, Moreau P, Rivière L, Neuveut C, Soussan P, Roingeard P, Kremsdorf D, Di Santo JP, Strick-Marchand H. Viral Load Affects the Immune Response to HBV in Mice With Humanized Immune System and Liver. Gastroenterology 2017;153:1647-1661.e9. [PMID: 28851562 DOI: 10.1053/j.gastro.2017.08.034] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
527 Aslam S, Grossi P, Schlendorf KH, Holm AM, Woolley AE, Blumberg E, Mehra MR; working group members. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement. J Heart Lung Transplant 2020;39:418-32. [PMID: 32362393 DOI: 10.1016/j.healun.2020.03.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
528 Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020;48:7-17. [PMID: 31347138 DOI: 10.1007/s15010-019-01345-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 17.5] [Reference Citation Analysis]
529 Liou IW, Nguyen MH. The Cascade of Care in Chronic Hepatitis B. Curr Hepatology Rep 2016;15:209-19. [DOI: 10.1007/s11901-016-0316-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
530 Pan HY, Pan HY, Song WY, Zheng W, Tong YX, Yang DH, Dai YN, Chen MJ, Wang MS, Huang YC, Zhang JJ, Huang HJ. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis. J Viral Hepat 2017;24 Suppl 1:29-35. [PMID: 29082652 DOI: 10.1111/jvh.12794] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
531 Holt SG, Locarnini S, Sasadeusz J. Hepatitis B related dilemmas in the renal unit. Nephrology (Carlton) 2021;26:287-93. [PMID: 33155307 DOI: 10.1111/nep.13815] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
532 Meng C, Belino C, Pereira L, Pinho A, Sampaio S, Tavares I, Bustorff M, Sarmento A, Pestana M. Reactivation of Hepatitis B virus in kidney transplant recipients with previous clinically resolved infection: A single-center experience. Nefrologia (Engl Ed) 2018;38:545-50. [PMID: 29709320 DOI: 10.1016/j.nefro.2018.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
533 Fujita K, Mimura S, Iwama H, Nakahara M, Oura K, Tadokoro T, Nomura T, Tani J, Yoneyama H, Morishita A, Oryu M, Himoto T, Nishitsuji H, Shimotohno K, Omata M, Masaki T. Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients. Int J Mol Sci 2018;19:E1940. [PMID: 30004437 DOI: 10.3390/ijms19071940] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
534 Zhang K, Liu Y, Chen R, Li Q, Xu Z, Si L, Cheng Y, Yang Y, Chen J, Xu D, Lin S. Antigenicity reduction contributes mostly to poor detectability of HBsAg by hepatitis B virus (HBV) S-gene mutants isolated from individuals with occult HBV infection. J Med Virol. 2018;90:263-270. [PMID: 28876463 DOI: 10.1002/jmv.24936] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
535 Siyahian A, Malik SU, Mushtaq A, Howe CL, Majeed A, Zangeneh T, Iftikhar S, Habib S, Zahid U, Riaz IB, Warraich Z, Faridi W, Anwer F. Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant 2018;24:1483-9. [PMID: 29545185 DOI: 10.1016/j.bbmt.2018.02.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
536 Block TM, Alter H, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten TF, Guo JT, Hoshida Y, Kowdley KV, Li W, Lok AS, McMahon B, Mehta A, Perrillo R, Rice CM, Rinaudo J, Schinazi RF, Shetty K. Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop. Antiviral Res 2018;150:93-100. [PMID: 29248746 DOI: 10.1016/j.antiviral.2017.12.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
537 Abreu RM, Bassit LC, Tao S, Jiang Y, Ferreira AS, Hori PC, Ganova-Raeva LM, Khudyakov Y, Schinazi RF, Carrilho FJ, Ono SK. Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic HBV study. Antivir Ther 2019;24:567-79. [PMID: 31799942 DOI: 10.3851/IMP3338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
538 Huang M, Lin G, Shi H, Wu Y, Jie Y, Zhu Z, Chong Y. TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China. Biomed Res Int 2017;2017:2463197. [PMID: 28656138 DOI: 10.1155/2017/2463197] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
539 Toy M, Hutton D, Harris AM, Nelson N, Salomon JA, So S. Cost-Effectiveness of One-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States. Clin Infect Dis 2021:ciab405. [PMID: 33956937 DOI: 10.1093/cid/ciab405] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
540 Barritt AS, Jhaveri R. Treatment of Hepatitis C during Pregnancy-Weighing the Risks and Benefits in Contrast to HIV. Curr HIV/AIDS Rep 2018;15:155-61. [DOI: 10.1007/s11904-018-0386-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
541 El-Khayat H, Yakoot M, El-Shabrawi M, Fouad Y, Attia D, Kamal EM. Treatment of Chronic Hepatitis C in Adolescent Patients With Positive HBsAg or With Occult Hepatitis B: Is the Risk of Hepatitis B Reactivation Significant? Pediatr Infect Dis J 2021;40:11-5. [PMID: 32925546 DOI: 10.1097/INF.0000000000002894] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
542 Chen Y, Xie C, Zhang Y, Li Y, Ehrhardt S, Thio CL, Nelson KE, Chen Y, Lin CS. Knowledge regarding hepatitis B mother-to-child transmission among healthcare workers in South China. J Viral Hepat 2018;25:561-70. [PMID: 29194878 DOI: 10.1111/jvh.12839] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
543 Yuen MF, Gane EJ, Kim DJ, Weilert F, Yuen Chan HL, Lalezari J, Hwang SG, Nguyen T, Flores O, Hartman G, Liaw S, Lenz O, Kakuda TN, Talloen W, Schwabe C, Klumpp K, Brown N. Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. Gastroenterology 2019; 156: 1392-1403. e7. [PMID: 30625297 DOI: 10.1053/j.gastro.2018.12.023] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 25.0] [Reference Citation Analysis]
544 Yip TC, Wong GL, Chan HL, Tse Y, Lam KL, Lui GC, Wong VW. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. Journal of Hepatology 2019;70:361-70. [DOI: 10.1016/j.jhep.2018.10.014] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 32.0] [Reference Citation Analysis]
545 Sou FM, Hu TH, Hung CH, Lai HC, Wang JH, Lu SN, Peng CY, Chen CH. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients. Hepatol Int. 2020;14:513-520. [PMID: 32319045 DOI: 10.1007/s12072-020-10031-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
546 Ormeci A, Aydın Y, Sumnu A, Baran B, Soyer OM, Pınarbasi B, Gokturk S, Gulluoglu M, Onel D, Badur S, Akyuz F, Karaca C, Demir K, Besisik F, Kaymakoglu S. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels. Int J Infect Dis 2016;52:68-73. [PMID: 27619844 DOI: 10.1016/j.ijid.2016.09.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
547 Al Ashgar H, Peedikayil MC, Al Quaiz M, Al Sohaibani F, Al Fadda A, Khan MQ, Thoralsson E, Al Thawadi S, Al Jedai A, Al Kahtani K. HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study. Saudi J Gastroenterol 2017;23:190-8. [PMID: 28611343 DOI: 10.4103/sjg.SJG_541_16] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
548 Ozaras R, Uraz S, Demirel A, Mete B, Tabak F. Resolved hepatitis B virus infection: an unresolved issue of terminology. Eur J Gastroenterol Hepatol 2018;30:1389. [PMID: 30252716 DOI: 10.1097/MEG.0000000000001209] [Reference Citation Analysis]
549 Wu S, Tu R, Liang X. Patchy echogenicity of the liver in patients with chronic hepatitis B does not indicate poorer elasticity. Ultrasonography 2019;38:327-35. [PMID: 31302950 DOI: 10.14366/usg.18071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
550 Qiu K, Liu B, Li S, Li H, Chen Z, Luo A, Peng M, Ren H, Hu P. Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance. Aliment Pharmacol Ther 2018;47:1340-8. [DOI: 10.1111/apt.14629] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 8.7] [Reference Citation Analysis]
551 Joshita S, Ichikawa Y, Umemura T, Usami Y, Sugiura A, Shibata S, Yamazaki T, Fujimori N, Komatsu M, Matsumoto A, Igarashi K, Ota M, Tanaka E. Serum autotaxin is a useful liver fibrosis marker in patients with chronic hepatitis B virus infection. Hepatol Res 2018;48:275-85. [PMID: 29114991 DOI: 10.1111/hepr.12997] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
552 Sasagawa Y, Yamada H, Morizane M, Deguchi M, Shirakawa T, Morioka I, Tanimura K. Hepatitis B virus infection: Prevention of mother-to-child transmission and exacerbation during pregnancy. J Infect Chemother 2019;25:621-5. [PMID: 30982723 DOI: 10.1016/j.jiac.2019.03.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
553 Chen M, Zhuang J, Zhou D, Xu Y, Zhao Y, Wang S, Zhang W, Duan M, Zhu T, Li J, Cai H, Cao X, Han B. Outcome of anti-thymocyte immunoglobulin plus cyclosporine A for severe aplastic anaemia with chronic hepatitis B virus infection. Ann Hematol 2017;96:581-7. [PMID: 28084534 DOI: 10.1007/s00277-017-2918-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
554 Terrault N. Is Low Level Viremia Acceptable During Antiviral Therapy of Patients With HBV Infection and Decompensated Cirrhosis? Clinical Gastroenterology and Hepatology 2018;16:1876-8. [DOI: 10.1016/j.cgh.2018.09.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
555 Zhou L, Li X, Huang X, Chen L, Gu L, Huang Y. Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B. J Viral Hepat. 2019;26:795-802. [PMID: 30578715 DOI: 10.1111/jvh.13055] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
556 Shimakawa Y, Njie R, Ndow G, Vray M, Mbaye PS, Bonnard P, Sombié R, Nana J, Leroy V, Bottero J, Ingiliz P, Post G, Sanneh B, Baldeh I, Suso P, Ceesay A, Jeng A, Njai HF, Nayagam S, D'Alessandro U, Chemin I, Mendy M, Thursz M, Lemoine M. Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa. J Hepatol 2018;69:776-84. [PMID: 30104154 DOI: 10.1016/j.jhep.2018.05.024] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
557 Tsuge M, Uchida T, Hiraga N, Kan H, Makokha GN, Abe-Chayama H, Miki D, Imamura M, Ochi H, Hayes CN, Shimozono R, Iwamura T, Narumi H, Suzuki T, Kainoh M, Taniguchi T, Chayama K. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus. Antimicrob Agents Chemother. 2017;61. [PMID: 28373196 DOI: 10.1128/aac.00183-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
558 Xiong F, Bao X, Gu N, Guo J, Wang J, Ma Y, Yu L, Gao Y, Tan B, Lu J. The combination therapy of Peginterferonα and entecavir for HBeAg-positive chronic hepatitis B with high HCC risk. Infect Genet Evol 2020;78:104101. [PMID: 31689542 DOI: 10.1016/j.meegid.2019.104101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
559 Yu XQ, Wang MJ, Yu DM, Chen PZ, Zhu MY, Huang W, Han Y, Gong QM, Zhang XX. Comparison of Serum Hepatitis B Virus RNA Levels and Quasispecies Evolution Patterns between Entecavir and Pegylated-Interferon Mono-treatment in Chronic Hepatitis B Patients. J Clin Microbiol 2020;58:e00075-20. [PMID: 32554476 DOI: 10.1128/JCM.00075-20] [Reference Citation Analysis]
560 Byrne R, Carey I, Agarwal K. Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. Therap Adv Gastroenterol 2018;11:1756284818786108. [PMID: 30034532 DOI: 10.1177/1756284818786108] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
561 Qin C, Gao Y, Li J, Huang C, He S. Predictive effects of preoperative serum CA125 and AFP levels on post-hepatectomy survival in patients with hepatitis B-related hepatocellular carcinoma. Oncol Lett 2021;21:487. [PMID: 33968203 DOI: 10.3892/ol.2021.12748] [Reference Citation Analysis]
562 Lim YS. Management of Antiviral Resistance in Chronic Hepatitis B. Gut Liver 2017;11:189-95. [PMID: 28183162 DOI: 10.5009/gnl15562] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
563 Feld JJ, Terrault NA, Lin HS, Belle SH, Chung RT, Tsai N, Khalili M, Perrillo R, Cooper SL, Ghany MG, Janssen HLA, Lok AS; Hepatitis B Research Network. Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection. Hepatology 2019;69:2338-48. [PMID: 30549279 DOI: 10.1002/hep.30417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
564 Chi X, Xiao H, Shi M, Cai G, Xie Y, Jiang J, Tian G, Wu S, Zhang C, Zhao P, Chen J. Histological improvement in chronic hepatitis B patients treated with bicyclol: real world experience. BMC Gastroenterol 2019;19:88. [PMID: 31196030 DOI: 10.1186/s12876-019-1005-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
565 Lyu J, Wang S, He Q, Pan C, Tang AS. Hep B Moms: A cross-sectional study of mother-to-child transmission risk among pregnant Asian American women with chronic hepatitis B in New York City, 2007-2017. J Viral Hepat 2020;27:168-75. [PMID: 31638292 DOI: 10.1111/jvh.13221] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
566 Singh S, Muir AJ, Dieterich DT, Falck-Ytter YT. American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. Gastroenterology 2017;152:1544-77. [PMID: 28442120 DOI: 10.1053/j.gastro.2017.03.016] [Cited by in Crossref: 135] [Cited by in F6Publishing: 116] [Article Influence: 33.8] [Reference Citation Analysis]
567 Federico A, Brancaccio G, Dallio M, Iodice P, Fabozzi A, Del Prete S, Ciardiello F, Loguercio C, Gaeta GB. Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? Dig Liver Dis 2017;49:197-201. [PMID: 27899262 DOI: 10.1016/j.dld.2016.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
568 Cai S, Cao J, Yu T, Xia M, Peng J. Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine. Medicine (Baltimore) 2017;96:e7021. [PMID: 28562554 DOI: 10.1097/MD.0000000000007021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
569 Höner Zu Siederdissen C, Maasoumy B, Cornberg M. New viral biomarkers for Hepatitis B: Are we able to change practice? J Viral Hepat 2018;25:1226-35. [PMID: 30187603 DOI: 10.1111/jvh.12993] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
570 Yao X, Li Z, Gong X, Fu X, Xiao X, He M, Huang B, Xu Z. Total saponins extracted from Abrus cantoniensis Hance suppress hepatitis B virus replication in vitro and in rAAV8-1.3HBV transfected mice. J Ethnopharmacol 2020;249:112366. [PMID: 31678415 DOI: 10.1016/j.jep.2019.112366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
571 Wang B, Agarwal K, Joshi D. Management of chronic hepatitis B before and after liver transplantation. Frontline Gastroenterol 2018;9:79-84. [PMID: 29484165 DOI: 10.1136/flgastro-2016-100768] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
572 Cai M, Hao Y, Zhong J, Yao W, Cao X, Gu G, Qin G. Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective Study. Can J Gastroenterol Hepatol 2019;2019:9046260. [PMID: 31380321 DOI: 10.1155/2019/9046260] [Reference Citation Analysis]
573 Nam JY, Chang Y, Cho H, Kang SH, Cho YY, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B. J Viral Hepat 2018;25:552-60. [PMID: 29194870 DOI: 10.1111/jvh.12838] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
574 Vittal A, Ghany MG. WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV: A US Perspective. Clin Liver Dis. 2019;23:417-432. [PMID: 31266617 DOI: 10.1016/j.cld.2019.04.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
575 Chan HLY, Chan FWS, Hui AJ, Li MKK, Chan KH, Wong GLH, Loo CK, Chim AML, Tse CH, Wong VWS. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study. J Viral Hepat 2019;26:126-35. [DOI: 10.1111/jvh.13000] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
576 Chung TL, Chen NC, Chen CL. Severe hypophosphatemia induced by denosumab in a patient with osteomalacia and tenofovir disoproxil fumarate-related acquired Fanconi syndrome. Osteoporos Int 2019;30:519-23. [PMID: 30171299 DOI: 10.1007/s00198-018-4679-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
577 Castillo E, Murphy K, van Schalkwyk J. N° 342-L'hépatite B et la grossesse. Journal of Obstetrics and Gynaecology Canada 2017;39:191-201. [DOI: 10.1016/j.jogc.2017.01.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
578 Mysore KR, Leung DH. Hepatitis B and C. Clin Liver Dis. 2018;22:703-722. [PMID: 30266158 DOI: 10.1016/j.cld.2018.06.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 5.7] [Reference Citation Analysis]
579 Ahn SH, Kim W, Jung YK, Yang JM, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Um SH, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Yim HJ, Lee KS, Lim YS, Lee WS, Park NH, Jin SY, Kim KH, Choi W, Han KH. Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol 2019; 17: 1850-1859. e4. [PMID: 30448598 DOI: 10.1016/j.cgh.2018.11.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
580 Chen S, Huang H, Huang W. A noninvasive model to predict liver histology for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase < 2 upper limit of normal. BMC Gastroenterol 2021;21:4. [PMID: 33407146 DOI: 10.1186/s12876-020-01576-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
581 Lin TF, Hsu PI, Lin KH, Tsay FW, Tsai TJ, Chen YH, Yu HC. Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy. Gastroenterol Res Pract 2017;2017:4192169. [PMID: 28757867 DOI: 10.1155/2017/4192169] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
582 Yeo D, Hossain I, Lim ST, Farid M, Tao M, Quek R, Tang T, Chan A. A response to the letter to the editor on "Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study". J Oncol Pharm Pract 2018;24:478-9. [PMID: 29925294 DOI: 10.1177/1078155218782614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
583 Yoshioka N, Okumura A, Yamamoto Y, Yamaguchi K, Kaga A, Yamada K, Hirosaki T, Ishikawa D, Kunii S, Watanabe K, Utsunomiya S, Hayashi K, Ishigami M, Goto H, Hirooka Y. Promoting notification and linkage of HBs antigen and anti-HCV antibody-positive patients through hospital alert system. BMC Infect Dis 2017;17:330. [PMID: 28482818 DOI: 10.1186/s12879-017-2438-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
584 Paik N, Sinn DH, Lee JH, Oh IS, Kim JH, Kang W, Gwak G, Paik Y, Choi MS, Lee JH, Koh KC, Paik SW. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia. Liver Int 2018;38:68-75. [DOI: 10.1111/liv.13489] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
585 Belperio PS, Shahoumian TA, Mole LA, Backus LI. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology. 2017;66:27-36. [PMID: 28240789 DOI: 10.1002/hep.29135] [Cited by in Crossref: 84] [Cited by in F6Publishing: 67] [Article Influence: 21.0] [Reference Citation Analysis]
586 Cai D, Pan C, Yu W, Dang S, Li J, Wu S, Jiang N, Wang M, Zhang Z, Lin F, Xin S, Yang Y, Shen B, Ren H. Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B: A large, multicentre, randomized controlled trials. Medicine (Baltimore) 2019;98:e13983. [PMID: 30608440 DOI: 10.1097/MD.0000000000013983] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
587 Zhang Z, Wang C, Liu Z, Zou G, Li J, Lu M. Host Genetic Determinants of Hepatitis B Virus Infection. Front Genet. 2019;10:696. [PMID: 31475028 DOI: 10.3389/fgene.2019.00696] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
588 Lee YB, Lee JH. Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus? Clin Mol Hepatol 2017;23:219-21. [PMID: 28942622 DOI: 10.3350/cmh.2017.0045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
589 Zhou Y, Yan R, Ru GQ, Yu LL, Yao J, Wang H. Pegylated-interferon consolidation treatment versus nucleos(t)ide analogue consolidation treatment in non-cirrhotic hepatitis B patients with hepatitis B e antigen seroconversion: an open-label pilot trial. Hepatol Int. 2019;13:422-430. [PMID: 31172416 DOI: 10.1007/s12072-019-09957-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
590 Gu Y, Li X, Gu L, Lian Y, Wang K, Chen Y, Lai J, Mei Y, Liu J, Huang Z, Zhang M, Chen L, Huang Y. An Immuno-Clinic score model for evaluating T cell immunity and predicting early antiviral therapy effectiveness in chronic hepatitis B. Aging (Albany NY) 2020;12:26063-79. [PMID: 33401245 DOI: 10.18632/aging.202274] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
591 Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: From discovery to regulatory approval. J Hepatol. 2017;67:847-861. [PMID: 28778687 DOI: 10.1016/j.jhep.2017.05.008] [Cited by in Crossref: 102] [Cited by in F6Publishing: 89] [Article Influence: 25.5] [Reference Citation Analysis]
592 Abdulaziz S, Halabi H, Omair MA, Attar S, Alghamdi A, Shabrawishi M, Neyazi A, Alnazzawi H, Meraiani N, Almoallim H. Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series. Eur J Rheumatol 2017;4:194-9. [PMID: 29164002 DOI: 10.5152/eurjrheum.2017.17003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
593 Wu X, Su Z, Cai B, Yan L, Li Y, Feng W, Wang L. Increased Circulating Follicular Regulatory T-Like Cells May Play a Critical Role in Chronic Hepatitis B Virus Infection and Disease Progression. Viral Immunology 2018;31:379-88. [DOI: 10.1089/vim.2017.0171] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
594 Doyle J, Raggatt M, Slavin M, Mclachlan S, Strasser SI, Sasadeusz JJ, Howell J, Hajkowicz K, Nandurkar H, Johnston A, Bak N, Thompson AJ. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement. Medical Journal of Australia 2019;210:462-8. [DOI: 10.5694/mja2.50160] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
595 Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology. Clin Liver Dis 2019;23:487-92. [PMID: 31266622 DOI: 10.1016/j.cld.2019.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
596 Carey I, Byrne R, Childs K, Horner M, Bruce M, Wang B, Dusheiko G, Agarwal K. Serum NGAL can act as an early renal safety biomarker during long-term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B. J Viral Hepat 2018;25:1139-50. [PMID: 29660209 DOI: 10.1111/jvh.12916] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
597 Kim SS, Cho HJ, Kim HJ, Kang DR, Berry JR, Kim JH, Yang MJ, Lim SG, Kim S, Cheong JY, Cho SW. Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. Dig Liver Dis. 2018;50:370-377. [PMID: 29398414 DOI: 10.1016/j.dld.2017.12.018] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
598 Talla C, Itanyi IU, Tsuyuki K, Stadnick N, Ogidi AG, Olakunde BO, Patel D, Oko JO, Aarons G, Onoka CA, Ezeanolue EE. Hepatitis B infection and risk factors among pregnant women and their male partners in the Baby Shower Programme in Nigeria: a cross-sectional study. Trop Med Int Health 2021;26:316-26. [PMID: 33247862 DOI: 10.1111/tmi.13531] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
599 Castillo E, Murphy K, van Schalkwyk J. No. 342-Hepatitis B and Pregnancy. Journal of Obstetrics and Gynaecology Canada 2017;39:181-90. [DOI: 10.1016/j.jogc.2016.11.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
600 Li G, Lin J, Jiang C, Feng Q, Wen L. Trends in chronic hepatitis B treatment-related research from 1973 to 2018: a bibliometric and visual analysis. J Int Med Res 2020;48:300060519893234. [PMID: 31878813 DOI: 10.1177/0300060519893234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
601 Xiao Y, Howell J, van Gemert C, Thompson AJ, Seaman CP, McCulloch K, Scott N, Hellard ME. Enhancing the hepatitis B care cascade in Australia: A cost-effectiveness model. J Viral Hepat 2020;27:526-36. [PMID: 31856377 DOI: 10.1111/jvh.13252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
602 Chen HL, Wen WH, Chang MH. Management of Pregnant Women and Children: Focusing on Preventing Mother-to-Infant Transmission. J Infect Dis. 2017;216:S785-S791. [PMID: 29156049 DOI: 10.1093/infdis/jix429] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
603 Liu YY, Liang XS. Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA. World J Hepatol 2018;10:603-11. [PMID: 30310538 DOI: 10.4254/wjh.v10.i9.603] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
604 Ogawa E, Furusyo N, Nguyen MH. Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. Drug Des Devel Ther 2017;11:3197-204. [PMID: 29158666 DOI: 10.2147/DDDT.S126742] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
605 Jeon MY, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Han K, Ahn SH, Kim SU. Entecavir and tenofovir on renal function in patients with hepatitis B virus‐related hepatocellular carcinoma. J Viral Hepat 2020;27:932-40. [DOI: 10.1111/jvh.13313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
606 Tu T, Budzinska MA, Shackel NA, Urban S. HBV DNA Integration: Molecular Mechanisms and Clinical Implications. Viruses. 2017;9. [PMID: 28394272 DOI: 10.3390/v9040075] [Cited by in Crossref: 140] [Cited by in F6Publishing: 122] [Article Influence: 35.0] [Reference Citation Analysis]
607 Matsumoto A, Imaizumi M, Tanaka Y, Nishiguchi S, Yatsuhashi H, Ishida T, Moriyama K, Aoyagi K, Tanaka E. Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody. J Gastroenterol 2017;52:376-84. [DOI: 10.1007/s00535-016-1244-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
608 Sun Y, Zhou J, Wang L, Wu X, Chen Y, Piao H, Lu L, Jiang W, Xu Y, Feng B, Nan Y, Xie W, Chen G, Zheng H, Li H, Ding H, Liu H, Lv F, Shao C, Wang T, Ou X, Wang B, Chen S, Wee A, Theise ND, You H, Jia J. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. Hepatology. 2017;65:1438-1450. [PMID: 28027574 DOI: 10.1002/hep.29009] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 15.8] [Reference Citation Analysis]
609 Liem KS, van Campenhout MJH, Xie Q, Brouwer WP, Chi H, Qi X, Chen L, Tabak F, Hansen BE, Janssen HLA. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2019;49:448-456. [PMID: 30689258 DOI: 10.1111/apt.15098] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
610 Xing YF, Zhou DQ, He JS, Wei CS, Zhong WC, Han ZY, Peng DT, Shao MM, Sham TT, Mok DK, Chan CO, Tong GD. Clinical and histopathological features of chronic hepatitis B virus infected patients with high HBV-DNA viral load and normal alanine aminotransferase level: A multicentre-based study in China. PLoS One. 2018;13:e0203220. [PMID: 30180183 DOI: 10.1371/journal.pone.0203220] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
611 Kim YM, Shin HP, Lee JI, Joo KR, Cha JM, Jeon JW, Yoon JY, Kwak MS. Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B. Saudi J Gastroenterol 2018;24:326-35. [PMID: 30004042 DOI: 10.4103/sjg.SJG_49_18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
612 Xu M, Zhou Z, Xu R, Zhang H, Lin N, Zhong Y. Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis. World J Surg Oncol 2019;17:45. [PMID: 30823932 DOI: 10.1186/s12957-019-1577-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
613 Höner zu Siederdissen C, Maasoumy B, Cornberg M. What is new on HBsAg and other diagnostic markers in HBV infection? Best Practice & Research Clinical Gastroenterology 2017;31:281-9. [DOI: 10.1016/j.bpg.2017.04.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
614 Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. Liver Int. 2019;39:1624-1630. [PMID: 31050379 DOI: 10.1111/liv.14129] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
615 Silva MJ, Valente J, Capela T, Russo P, Calinas F. Epidemiology of hepatitis B in Portugal. Eur J Gastroenterol Hepatol 2017;29:249-58. [PMID: 27861252 DOI: 10.1097/MEG.0000000000000792] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
616 Cloherty G, Butler E, Kuhns M. Serum Hepatitis B Virus RNA as a Potential Diagnostic Biomarker During Chronic Hepatitis B Virus Infection. Clin Liver Dis (Hoboken) 2019;13:90-2. [PMID: 30988945 DOI: 10.1002/cld.774] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
617 Wang J, Wu W, Yan X, Wei J, Yao K, Yang Y, Xiong Y, Xia J, Liu Y, Chen Y, Jia B, Zhang Z, Ding W, Huang R, Wu C. HBeAg Negativity Is Associated With More Advanced Liver Fibrosis in Patients With Chronic Hepatitis B: A Propensity Score-Matching Analysis. J Clin Gastroenterol 2020;54:826-31. [PMID: 31789771 DOI: 10.1097/MCG.0000000000001291] [Reference Citation Analysis]
618 Cheuk-fung Yip T, Wai-sun Wong V, Lik-yuen Chan H, Tse Y, Pik-shan Kong A, Long-yan Lam K, Chung-yan Lui G, Lai-hung Wong G. Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. Clinical Gastroenterology and Hepatology 2018;16:765-773.e2. [DOI: 10.1016/j.cgh.2017.12.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
619 Safaie P, Razeghi S, Rouster SD, Privitera I, Sherman KE. Hepatitis D diagnostics:Utilization and testing in the United States. Virus Res. 2018;250:114-117. [PMID: 29596839 DOI: 10.1016/j.virusres.2018.03.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
620 Mostafa A, Elsisi GH. A cost-effectiveness analysis of the use of safety-engineered syringes in reducing HBV, HCV, and HIV burden in Egypt. Expert Rev Med Devices 2019;16:155-63. [PMID: 30571154 DOI: 10.1080/17434440.2019.1561267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
621 Duvoux C, Belli LS, Fung J, Angelico M, Buti M, Coilly A, Cortesi P, Durand F, Féray C, Fondevila C, Lebray P, Martini S, Nevens F, Polak WG, Rizzetto M, Volpes R, Zoulim F, Samuel D, Berenguer M. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. Aliment Pharmacol Ther 2021;54:583-605. [PMID: 34287994 DOI: 10.1111/apt.16374] [Reference Citation Analysis]
622 Buti M, Riveiro-Barciela M, Esteban R. Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int. 2018;38 Suppl 1:84-89. [PMID: 29427500 DOI: 10.1111/liv.13641] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
623 Odagiri N, Matsubara T, Sato-Matsubara M, Fujii H, Enomoto M, Kawada N. Anti-fibrotic treatments for chronic liver diseases: The present and the future. Clin Mol Hepatol 2021;27:413-24. [PMID: 33317250 DOI: 10.3350/cmh.2020.0187] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
624 Gu Y, Lian Y, Zheng Q, Huang Z, Gu L, Bi Y, Li J, Huang Y, Wu Y, Chen L, Huang Y. Association among cytokine profiles of innate and adaptive immune responses and clinical-virological features in untreated patients with chronic hepatitis B. BMC Infect Dis 2020;20:509. [PMID: 32664850 DOI: 10.1186/s12879-020-05233-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
625 Kwok RM, Tran TT. Hepatitis B and Risk of Non-Hepatocellular Carcinoma Malignancy. Clin Liver Dis 2016;20:693-702. [PMID: 27742008 DOI: 10.1016/j.cld.2016.06.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
626 Wu T, Kwok RM, Tran TT. Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues. Am J Gastroenterol 2017;112:1780-8. [PMID: 29087395 DOI: 10.1038/ajg.2017.397] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
627 Karlas T, Petroff D, Sasso M, Fan J, Mi Y, de Lédinghen V, Kumar M, Lupsor-platon M, Han K, Cardoso AC, Ferraioli G, Chan W, Wong VW, Myers RP, Chayama K, Friedrich-rust M, Beaugrand M, Shen F, Hiriart J, Sarin SK, Badea R, Jung KS, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. Journal of Hepatology 2017;66:1022-30. [DOI: 10.1016/j.jhep.2016.12.022] [Cited by in Crossref: 342] [Cited by in F6Publishing: 265] [Article Influence: 85.5] [Reference Citation Analysis]
628 Sheng Q, Ding Y, Li B, Han C, Li Y, Zhang C, Bai H, Wang J, Zhao L, Xia T, An Z, Zhang M, Dou X. Efficacy and safety of nucleos(t)ide analogues to prevent hepatitis B virus mother-to-child transmission in pregnant women with high viremia: real life practice from China. Int J Med Sci. 2018;15:796-801. [PMID: 30008589 DOI: 10.7150/ijms.25047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
629 Laing N, Tufton H, Ochola E, P'Kingston OG, Maini MK, Easom N. Hepatitis B assessment without hepatitis B virus DNA quantification: a prospective cohort study in Uganda. Trans R Soc Trop Med Hyg 2019;113:11-7. [PMID: 30452730 DOI: 10.1093/trstmh/try117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
630 Gil-García AI, Madejón A, Francisco-Recuero I, López-López A, Villafranca E, Romero M, García A, Olveira A, Mena R, Larrubia JR, García-Samaniego J. Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment. World J Gastroenterol 2019;25:5883-96. [PMID: 31636479 DOI: 10.3748/wjg.v25.i38.5883] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
631 Zhang Q, Li G, Yu Y, Qiu C, Zheng J, Zhang H, Zhang M, Song Z, Yang Y, Du X, Hong J, Lu J, Li N, Tang Q, Xu L, Wang X, Huang Y, Zhang J, Chen Z, Zhang W. Histological response to combination therapy with nucleos(t)ide analogs and peginterferon alpha in treatment-naïve chronic hepatitis B patients. J Viral Hepat 2019;26 Suppl 1:59-68. [PMID: 31380588 DOI: 10.1111/jvh.13153] [Reference Citation Analysis]
632 Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. World J Hepatol 2020;12:220-9. [PMID: 32547689 DOI: 10.4254/wjh.v12.i5.220] [Reference Citation Analysis]
633 Law MF, Ho R, Cheung CK, Tam LH, Ma K, So KC, Ip B, So J, Lai J, Ng J, Tam TH. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol. 2016;22:6484-6500. [PMID: 27605883 DOI: 10.3748/wjg.v22.i28.6484] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 32] [Article Influence: 10.5] [Reference Citation Analysis]
634 Li X, Zhang L, Qiu M, Huang Y, Xiao H, Lu B, Jiang Y, Long F, Lin H, He J, Wu Q, Zhang M, Wang L, Zhu X, Gong M, Sun X, Sun J, Sun F, Lu W, Xu W, Chen G, Li Z, Gan D, Yang X, Du H, Ye Y. Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China. Trials 2020;21:708. [PMID: 32787905 DOI: 10.1186/s13063-020-04417-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
635 Chen YH, Lu SN, Wang JH, Hung CH, Hu TH, Chen CH. Pre-S/Surface and Core Promoter/Precore Mutations in Chronic Hepatitis B Patients with Severe Acute Exacerbation. Dig Dis Sci 2019;64:2563-9. [PMID: 30835025 DOI: 10.1007/s10620-019-05571-0] [Reference Citation Analysis]
636 Wu QJ, Lv WL, Li JM, Zhang TT, Zhou WH, Zhang Q, Wang JC, Wang QN, Zhang RX, Zhao X, Chen ST, Liu S, Li GH, Cao ZM, Xu L, Chen J. Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial. Trials 2020;21:482. [PMID: 32503608 DOI: 10.1186/s13063-020-04395-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
637 Zeng Q, Xu G, Wang B, Li Z, Yu Z. Prophylactic antiviral therapy for the prevention of mother‐to‐child transmission of hepatitis B virus can be stopped at delivery. J Viral Hepat 2018;25:612-3. [DOI: 10.1111/jvh.12848] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
638 Zhang W, Zhang D, Dou X, Xie Q, Jiang J, Chen X, Ren H. Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2018;6:1-10. [PMID: 29577026 DOI: 10.14218/JCTH.2017.00073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
639 Yip TC, Lee HW, Wong VW, Wong GL, Tse YK, Lui GC, Ahn SH, Chan HL. Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. J Gastroenterol Hepatol 2020;35:1610-8. [PMID: 32032974 DOI: 10.1111/jgh.15007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
640 Xie L, Liao G, Chen H, Xia M, Huang X, Fan R, Peng J, Zhang X, Liu H. Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B. BMC Infect Dis 2019;19:640. [PMID: 31324231 DOI: 10.1186/s12879-019-4261-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
641 Wang D, Yan X, Zhang M, Ren C, Wang L, Ma J, Guo L. Association between liver cirrhosis and estimated glomerular filtration rates in patients with chronic HBV infection. Medicine (Baltimore) 2020;99:e21387. [PMID: 32871988 DOI: 10.1097/MD.0000000000021387] [Reference Citation Analysis]
642 Marciano S, Gadano A. Why not to stop antiviral treatment in patients with chronic hepatitis B. Liver Int. 2018;38 Suppl 1:97-101. [PMID: 29427480 DOI: 10.1111/liv.13627] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
643 Yu JH, Jin Y, Lee J, Lee D. Remaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir/tenofovir in South Korea: HCC risk in CHB patients. Hepatol Res 2018;48:862-71. [DOI: 10.1111/hepr.13194] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
644 Toy M, Hutton DW, So S. Population Health And Economic Impacts Of Reaching Chronic Hepatitis B Diagnosis And Treatment Targets In The US. Health Aff (Millwood) 2018;37:1033-40. [PMID: 29985701 DOI: 10.1377/hlthaff.2018.0035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
645 Simon TG, Duberg AS, Aleman S, Hagstrom H, Nguyen LH, Khalili H, Chung RT, Ludvigsson JF. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Ann Intern Med 2019;171:318-27. [PMID: 31426090 DOI: 10.7326/M18-2753] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 15.0] [Reference Citation Analysis]
646 Zhou P, Dong M, Wang J, Li F, Zhang J, Gu J. Baseline serum miR-125b levels predict virologic response to nucleos(t)ide analogue treatment in patients with HBeAg-positive chronic hepatitis B. Exp Ther Med 2018;16:3805-12. [PMID: 30344656 DOI: 10.3892/etm.2018.6685] [Reference Citation Analysis]
647 Viganò M, Loglio A, Grossi G, Lampertico P. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? Expert Review of Anti-infective Therapy 2018;16:153-61. [DOI: 10.1080/14787210.2018.1428561] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
648 Giard JM, Terrault NA. Women with Cirrhosis: Prevalence, Natural History, and Management. Gastroenterol Clin North Am. 2016;45:345-358. [PMID: 27261903 DOI: 10.1016/j.gtc.2016.02.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
649 Fang J, Zhuge L, Rao H, Huang S, Jin L, Li J. Increased Levels of miR-155 are Related to Higher T-Cell Activation in the Peripheral Blood of Patients with Chronic Hepatitis B. Genet Test Mol Biomarkers 2019;23:118-23. [PMID: 30735455 DOI: 10.1089/gtmb.2018.0092] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
650 Wong WWL, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, Saeed Y, Phoon A, Tadrous M, Younis M, Rayad NZ, Rac V, Janssen HLA, Krahn MD. Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Syst Rev 2019;8:207. [PMID: 31426837 DOI: 10.1186/s13643-019-1126-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
651 Fourati S, Challine D, Poveda JD, Laperche S, Rallier S, Pawlotsky JM, Chevaliez S. Evaluation of a new random-access HBV DNA molecular assay: The VERIS HBV assay. J Clin Virol 2017;92:69-74. [PMID: 28549336 DOI: 10.1016/j.jcv.2017.05.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
652 Li Q, Ren X, Lu C, Li W, Huang Y, Chen L. Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT ≤ 2 ULN: A retrospective cohort study. Medicine (Baltimore) 2017;96:e6336. [PMID: 28328813 DOI: 10.1097/MD.0000000000006336] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
653 Koutsianas C, Thomas K, Vassilopoulos D. Hepatitis B Reactivation in Rheumatic Diseases: Screening and Prevention. Rheum Dis Clin North Am 2017;43:133-49. [PMID: 27890170 DOI: 10.1016/j.rdc.2016.09.012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
654 Sirilert S, Tongsong T. Hepatitis B Virus Infection in Pregnancy: Immunological Response, Natural Course and Pregnancy Outcomes. J Clin Med 2021;10:2926. [PMID: 34210105 DOI: 10.3390/jcm10132926] [Reference Citation Analysis]
655 Teschke R, Danan G. Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease. Drug Saf. 2016;39:729-744. [PMID: 27091053 DOI: 10.1007/s40264-016-0423-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
656 Xu N, Xie Q, Li J, Gao Y, Li X. Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease. J Int Med Res 2020;48:300060520903667. [PMID: 32070159 DOI: 10.1177/0300060520903667] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
657 Cho YY, Chang Y, Nam JY, Cho H, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B. Gut Liver 2020;14:225-31. [PMID: 31060115 DOI: 10.5009/gnl18474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
658 Chu C, Liaw Y. Prognosis of immune-tolerant phase chronic hepatitis B. Gut 2018;67:988.1-988. [DOI: 10.1136/gutjnl-2017-315603] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
659 Mohsen W, Levy MT. Hepatitis A to E: what's new? Intern Med J 2017;47:380-9. [PMID: 28401719 DOI: 10.1111/imj.13386] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
660 Wang H, Wang J, Huang R, Xia J, Zuo L, Yan X, Yang Y, Wu C. Red blood cell distribution width for predicting significant liver inflammation in patients with autoimmune hepatitis. Eur J Gastroenterol Hepatol 2019;31:1527-32. [PMID: 31107736 DOI: 10.1097/MEG.0000000000001447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
661 Ahn SB, Choi J, Jun DW, Oh H, Yoon EL, Kim HS, Jeong SW, Kim SE, Shim JJ, Cho YK, Lee HY, Han SW, Nguyen MH; SAINT cohort. Twelve-month post-treatment parameters are superior in predicting hepatocellular carcinoma in patients with chronic hepatitis B. Liver Int 2021;41:1652-61. [PMID: 33550661 DOI: 10.1111/liv.14820] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
662 McCulloch K, Romero N, MacLachlan J, Allard N, Cowie B. Modeling Progress Toward Elimination of Hepatitis B in Australia. Hepatology 2020;71:1170-81. [PMID: 31419332 DOI: 10.1002/hep.30899] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
663 Xu Y, Liu Y, Zhao M, Chen Y, Xie C, Gong M, Deng H, Li X, Sun J, Hou J, Wu H, Wang Z. Dynamic Perturbations of CD4 and CD8 T Cell Receptor Repertoires in Chronic Hepatitis B Patients upon Oral Antiviral Therapy. Front Immunol 2017;8:1142. [PMID: 28959264 DOI: 10.3389/fimmu.2017.01142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
664 Zhang M, Wang D, Liu H, Li H. Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection. Infect Agent Cancer 2018;13:19. [PMID: 29977330 DOI: 10.1186/s13027-018-0191-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
665 Sagnelli C, Pisaturo M, Calò F, Martini S, Sagnelli E, Coppola N. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention. World J Gastroenterol 2019;25:3299-312. [PMID: 31341357 DOI: 10.3748/wjg.v25.i26.3299] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
666 Allard N, Dev A, Dwyer J, Srivatsa G, Thompson A, Cowie B. Factors associated with poor adherence to antiviral treatment for hepatitis B. J Viral Hepat 2017;24:53-8. [PMID: 27502689 DOI: 10.1111/jvh.12582] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
667 Bonacci M, Lens S, Mariño Z, Londoño MC, Rodríguez-Tajes S, Mas A, García-López M, Pérez-Del-Pulgar S, Sánchez-Tapias JM, Forns X. Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone. Aliment Pharmacol Ther 2018;47:1397-408. [PMID: 29577350 DOI: 10.1111/apt.14613] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 5.7] [Reference Citation Analysis]
668 Cheung KW, Seto MTY, So PL, Wong D, Mak ASL, Lau WL, Wang W, Kan ASY, Lee CP, Ng EHY. The effect of rupture of membranes and labour on the risk of hepatitis B vertical transmission: Prospective multicentre observational study. Eur J Obstet Gynecol Reprod Biol 2019;232:97-100. [PMID: 30504033 DOI: 10.1016/j.ejogrb.2018.11.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
669 Shiani A, Narayanan S, Pena L, Friedman M. The Role of Diagnosis and Treatment of Underlying Liver Disease for the Prognosis of Primary Liver Cancer. Cancer Control 2017;24:1073274817729240. [PMID: 28975833 DOI: 10.1177/1073274817729240] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
670 Xiao L, Tang S, Zhang L, Ma S, Zhao Y, Zhang F, Xie Z, Li L. Serum CXCL1 Is a Prognostic Factor for Patients With Hepatitis B Virus-Related Acute-On-Chronic Liver Failure. Front Med (Lausanne) 2021;8:657076. [PMID: 34395462 DOI: 10.3389/fmed.2021.657076] [Reference Citation Analysis]
671 Park ES, Lee AR, Kim DH, Lee JH, Yoo JJ, Ahn SH, Sim H, Park S, Kang HS, Won J, Ha YN, Shin GC, Kwon SY, Park YK, Choi BS, Lee YB, Jeong N, An Y, Ju YS, Yu SJ, Chae HB, Yu KS, Kim YJ, Yoon JH, Zoulim F, Kim KH. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol. 2019;70:1093-1102. [PMID: 30794889 DOI: 10.1016/j.jhep.2019.02.006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 46] [Article Influence: 32.5] [Reference Citation Analysis]
672 Sun Y, Zhang Y, Xu Y, Shu M, Bonroy K, Qiu H, Cai W. Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B. Epidemiol Infect 2019;147:e193. [PMID: 31364558 DOI: 10.1017/S0950268819000815] [Reference Citation Analysis]
673 Lau KCK, Shaheen AA, Aspinall AA, Ricento Ba T, Qureshi Mba K, Congly SE, Borman MA, Jayakumar S, Eksteen B, Lee SS, Stinton L, Swain MG, Burak KW, Coffin CS. Hepatitis B virus testing and linkage to care in a Canadian urban tertiary referral centre: a retrospective cohort study. CMAJ Open 2017;5:E431-6. [PMID: 28596186 DOI: 10.9778/cmajo.20170002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
674 Hwan YJ, Shin J, Jin YJ, Lee JW. Comparison of clinical manifestations and outcomes of noncirrhotic and cirrhotic hepatocellular carcinoma patients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2020;32:66-73. [PMID: 31268949 DOI: 10.1097/MEG.0000000000001478] [Reference Citation Analysis]
675 Chen H, He G, Chen Y, Zhang X. Hepatitis B Virus Might Be Sensed by STING-Dependent DNA Sensors and Attenuates the Response of STING-Dependent DNA Sensing Pathway in Humans with Acute and Chronic Hepatitis B Virus Infection. Viral Immunol 2020;33:642-51. [PMID: 33170089 DOI: 10.1089/vim.2020.0096] [Reference Citation Analysis]
676 Su M, Liao L, Xing H, Wang S, Li Y, Lu W, He L, Deng J, Shao Y, Li T, Zhuang H. Characteristics of HBV infection in 705 HIV-infected patients under lamivudine-based antiretroviral treatment from three regions in China. Infect Drug Resist 2018;11:1635-44. [PMID: 30323633 DOI: 10.2147/IDR.S173757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
677 Li Z, Shen C, Wang Y, Wang W, Zhao Q, Liu Z, Wang Y, Zhao C. Circulating kidney injury molecule-1 is a novel diagnostic biomarker for renal dysfunction during long-term adefovir therapy in chronic hepatitis B. Medicine (Baltimore) 2016;95:e5264. [PMID: 27858892 DOI: 10.1097/MD.0000000000005264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
678 Choi R, Oh Y, Park S, Lee SG, Lee EH. Understanding the patient population and test utilization for hepatitis B virus testing. J Clin Lab Anal 2019;33:e22987. [PMID: 31568619 DOI: 10.1002/jcla.22987] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
679 Chen YM, Chen HH, Huang WN, Chen YH, Hsieh TY, Yang SS, Lan JL, Chen DY. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation. Int J Rheum Dis 2019;22:1145-51. [PMID: 31117160 DOI: 10.1111/1756-185X.13582] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
680 Chen WL, Lin CH, Huang CC, Tsai CI. Chinese herbal medicine reduces acute hepatitis exacerbation in patients with hepatitis B virus infection: A case-control study in Taiwan. Complement Ther Med 2019;42:248-54. [PMID: 30670249 DOI: 10.1016/j.ctim.2018.11.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
681 Park HS, Choe WH, Han HS, Yu MH, Kim YJ, Jung SI, Kim JH, Kwon SY. Assessing significant fibrosis using imaging-based elastography in chronic hepatitis B patients: Pilot study. World J Gastroenterol 2019;25:3256-67. [PMID: 31333316 DOI: 10.3748/wjg.v25.i25.3256] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [